Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models
Identifieur interne : 001C36 ( Istex/Corpus ); précédent : 001C35; suivant : 001C37Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models
Auteurs : Xaioqin Huang ; Liaosa Xu ; Xiaomin Luo ; Kangnian Fan ; Ruyun Ji ; Gang Pei ; Kaixian Chen ; Hualiang JiangSource :
- Journal of Medicinal Chemistry [ 0022-2623 ] ; 2001.
Abstract
The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR). The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite interaction, and hydrogen bonding. The data of geometrical parameters (τ1, τ2, and τ3 listed in Table ) and root mean square deviation values as compared with the known inhibitor, kni272, show that both kinds of inhibitors interact with HIVPR in a very similar way. The r2 value of 0.860 indicates that the calculated binding free energies correlate well with the inhibitory activities. The structural and energetic differences in inhibitory potencies of AHPBAs were reasonably explored. Using the binding conformations of AHPBAs, consistent and highly predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR analyses. The reasonable rcorss2 values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA, and HQSAR models, respectively. The predictive ability of these models was validated by kni272 and a set of nine compounds that were not included in the training set. Mapping these models back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA−HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide clear guidelines and accurate activity predictions for novel HIVPR inhibitors.
Url:
DOI: 10.1021/jm0102710
Links to Exploration step
ISTEX:7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models</title>
<author><name sortKey="Huang, Xaioqin" sort="Huang, Xaioqin" uniqKey="Huang X" first="Xaioqin" last="Huang">Xaioqin Huang</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Xu, Liaosa" sort="Xu, Liaosa" uniqKey="Xu L" first="Liaosa" last="Xu">Liaosa Xu</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Fudan University.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Luo, Xiaomin" sort="Luo, Xiaomin" uniqKey="Luo X" first="Xiaomin" last="Luo">Xiaomin Luo</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Fan, Kangnian" sort="Fan, Kangnian" uniqKey="Fan K" first="Kangnian" last="Fan">Kangnian Fan</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Fudan University.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Ji, Ruyun" sort="Ji, Ruyun" uniqKey="Ji R" first="Ruyun" last="Ji">Ruyun Ji</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pei, Gang" sort="Pei, Gang" uniqKey="Pei G" first="Gang" last="Pei">Gang Pei</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Kaixian" sort="Chen, Kaixian" uniqKey="Chen K" first="Kaixian" last="Chen">Kaixian Chen</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jiang, Hualiang" sort="Jiang, Hualiang" uniqKey="Jiang H" first="Hualiang" last="Jiang">Hualiang Jiang</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041B</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1021/jm0102710</idno>
<idno type="url">https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C36</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C36</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease
and Building Predictive 3D-QSAR Models</title>
<author><name sortKey="Huang, Xaioqin" sort="Huang, Xaioqin" uniqKey="Huang X" first="Xaioqin" last="Huang">Xaioqin Huang</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Xu, Liaosa" sort="Xu, Liaosa" uniqKey="Xu L" first="Liaosa" last="Xu">Liaosa Xu</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Fudan University.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Luo, Xiaomin" sort="Luo, Xiaomin" uniqKey="Luo X" first="Xiaomin" last="Luo">Xiaomin Luo</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Fan, Kangnian" sort="Fan, Kangnian" uniqKey="Fan K" first="Kangnian" last="Fan">Kangnian Fan</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Fudan University.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Ji, Ruyun" sort="Ji, Ruyun" uniqKey="Ji R" first="Ruyun" last="Ji">Ruyun Ji</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pei, Gang" sort="Pei, Gang" uniqKey="Pei G" first="Gang" last="Pei">Gang Pei</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Kaixian" sort="Chen, Kaixian" uniqKey="Chen K" first="Kaixian" last="Chen">Kaixian Chen</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jiang, Hualiang" sort="Jiang, Hualiang" uniqKey="Jiang H" first="Hualiang" last="Jiang">Hualiang Jiang</name>
<affiliation><mods:affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Medicinal Chemistry</title>
<title level="j" type="abbrev">J. Med. Chem.</title>
<idno type="ISSN">0022-2623</idno>
<idno type="eISSN">1520-4804</idno>
<imprint><publisher>American Chemical Society</publisher>
<date type="e-published">2001</date>
<date type="published">2002</date>
<biblScope unit="vol">45</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="333">333</biblScope>
<biblScope unit="page" to="343">343</biblScope>
</imprint>
<idno type="ISSN">0022-2623</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0022-2623</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR). The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite interaction, and hydrogen bonding. The data of geometrical parameters (τ1, τ2, and τ3 listed in Table ) and root mean square deviation values as compared with the known inhibitor, kni272, show that both kinds of inhibitors interact with HIVPR in a very similar way. The r2 value of 0.860 indicates that the calculated binding free energies correlate well with the inhibitory activities. The structural and energetic differences in inhibitory potencies of AHPBAs were reasonably explored. Using the binding conformations of AHPBAs, consistent and highly predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR analyses. The reasonable rcorss2 values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA, and HQSAR models, respectively. The predictive ability of these models was validated by kni272 and a set of nine compounds that were not included in the training set. Mapping these models back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA−HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide clear guidelines and accurate activity predictions for novel HIVPR inhibitors.</div>
</front>
</TEI>
<istex><corpusName>acs</corpusName>
<keywords><teeft><json:string>hivpr</json:string>
<json:string>ahpbas</json:string>
<json:string>chem</json:string>
<json:string>ahpba</json:string>
<json:string>comfa</json:string>
<json:string>inhibitory potency</json:string>
<json:string>binding free energy</json:string>
<json:string>hqsar</json:string>
<json:string>docking</json:string>
<json:string>comsia</json:string>
<json:string>protease</json:string>
<json:string>inhibitor</json:string>
<json:string>shanghai</json:string>
<json:string>steric</json:string>
<json:string>side chain</json:string>
<json:string>subsite</json:string>
<json:string>medicinal chemistry</json:string>
<json:string>binding affinity</json:string>
<json:string>inhibitory</json:string>
<json:string>aromatic ring</json:string>
<json:string>shanghai institute</json:string>
<json:string>molecular docking</json:string>
<json:string>binding conformation</json:string>
<json:string>tripos</json:string>
<json:string>hydroxyl</json:string>
<json:string>hydroxyl group</json:string>
<json:string>crystal structure</json:string>
<json:string>autodock</json:string>
<json:string>meta</json:string>
<json:string>substituents</json:string>
<json:string>grid</json:string>
<json:string>alkane</json:string>
<json:string>hydrogen bond</json:string>
<json:string>binding pocket</json:string>
<json:string>medicinal</json:string>
<json:string>hqsar model</json:string>
<json:string>protease inhibitor</json:string>
<json:string>active site</json:string>
<json:string>torsion angle</json:string>
<json:string>binding site</json:string>
<json:string>hydrophobic</json:string>
<json:string>conformation</json:string>
<json:string>geometrical parameter</json:string>
<json:string>predictive model</json:string>
<json:string>probe atom</json:string>
<json:string>inhibitory activity</json:string>
<json:string>biological science</json:string>
<json:string>chinese academy</json:string>
<json:string>derivative</json:string>
<json:string>datum</json:string>
<json:string>algorithm</json:string>
<json:string>geometrical</json:string>
<json:string>hydrophobic interaction</json:string>
<json:string>structural modification</json:string>
<json:string>binding mode</json:string>
<json:string>tripos force field</json:string>
<json:string>lamarckian genetic algorithm</json:string>
<json:string>probable binding conformation</json:string>
<json:string>physicochemical property</json:string>
<json:string>experimental inhibitory potency</json:string>
<json:string>total binding free energy</json:string>
<json:string>tertiary butyl group</json:string>
<json:string>predictive ability</json:string>
<json:string>electrostatic interaction</json:string>
<json:string>grid point</json:string>
<json:string>ahpba molecule</json:string>
<json:string>binding free energy prediction</json:string>
<json:string>hydrophobic effect</json:string>
<json:string>interaction energy</json:string>
<json:string>score function</json:string>
<json:string>binding energy</json:string>
<json:string>aromatic</json:string>
<json:string>binding</json:string>
<json:string>potency</json:string>
<json:string>predictive</json:string>
<json:string>conformational</json:string>
<json:string>ahpba derivative figure</json:string>
<json:string>conformational change</json:string>
<json:string>hydrophobic field</json:string>
<json:string>similarity index</json:string>
<json:string>final model</json:string>
<json:string>molecular fingerprint</json:string>
<json:string>conformational comparison</json:string>
<json:string>rmsd value</json:string>
<json:string>structural model</json:string>
<json:string>hydrogen atom</json:string>
<json:string>amino acid</json:string>
<json:string>butyl group</json:string>
<json:string>small hydrophobic pocket</json:string>
<json:string>hivpr inhibitor</json:string>
<json:string>better understanding</json:string>
<json:string>other inhibitor</json:string>
<json:string>amber force field</json:string>
<json:string>methyl carbon</json:string>
<json:string>subsite interaction</json:string>
<json:string>intramolecular interaction</json:string>
<json:string>fudan university</json:string>
<json:string>cell biology</json:string>
<json:string>oxygen atom</json:string>
<json:string>other hand</json:string>
<json:string>experimental activity</json:string>
<json:string>water molecule</json:string>
<json:string>atomic charge</json:string>
<json:string>materia medica</json:string>
<json:string>statistical index</json:string>
<json:string>sybyl theory manual</json:string>
<json:string>catalytic site</json:string>
<json:string>ortho position</json:string>
<json:string>meta position</json:string>
<json:string>para position</json:string>
<json:string>binding energetics</json:string>
<json:string>structural stability</json:string>
<json:string>energetic explanation</json:string>
<json:string>same level</json:string>
<json:string>free energy perturbation</json:string>
<json:string>protease system</json:string>
<json:string>molecular dynamic simulation</json:string>
<json:string>potential hivpr inhibitor</json:string>
<json:string>comsia model</json:string>
<json:string>field property</json:string>
<json:string>structural topology</json:string>
<json:string>comfa contour</json:string>
<json:string>colored polyhedras</json:string>
<json:string>green contour</json:string>
<json:string>biological activity</json:string>
<json:string>methyl group</json:string>
<json:string>drug discovery</json:string>
<json:string>potent protease inhibitor</json:string>
<json:string>inhibitor binding</json:string>
<json:string>ahpba derivative</json:string>
<json:string>molecular modeling</json:string>
<json:string>free energy calculation</json:string>
<json:string>substitution</json:string>
</teeft>
</keywords>
<author><json:item><name>HUANG Xaioqin</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</json:string>
<json:string>Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</json:string>
</affiliations>
</json:item>
<json:item><name>XU Liaosa</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Fudan University.</json:string>
</affiliations>
</json:item>
<json:item><name>LUO Xiaomin</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</json:string>
</affiliations>
</json:item>
<json:item><name>FAN Kangnian</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Fudan University.</json:string>
</affiliations>
</json:item>
<json:item><name>JI Ruyun</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</json:string>
</affiliations>
</json:item>
<json:item><name>PEI Gang</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</json:string>
<json:string>To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</json:string>
</affiliations>
</json:item>
<json:item><name>CHEN Kaixian</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</json:string>
</affiliations>
</json:item>
<json:item><name>JIANG Hualiang</name>
<affiliations><json:string>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</json:string>
<json:string>Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</json:string>
<json:string>To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</json:string>
</affiliations>
</json:item>
</author>
<arkIstex>ark:/67375/TPS-51T68V2C-W</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>research-article</json:string>
</originalGenre>
<abstract>The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR). The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite interaction, and hydrogen bonding. The data of geometrical parameters (τ1, τ2, and τ3 listed in Table ) and root mean square deviation values as compared with the known inhibitor, kni272, show that both kinds of inhibitors interact with HIVPR in a very similar way. The r2 value of 0.860 indicates that the calculated binding free energies correlate well with the inhibitory activities. The structural and energetic differences in inhibitory potencies of AHPBAs were reasonably explored. Using the binding conformations of AHPBAs, consistent and highly predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR analyses. The reasonable rcorss2 values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA, and HQSAR models, respectively. The predictive ability of these models was validated by kni272 and a set of nine compounds that were not included in the training set. Mapping these models back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA−HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide clear guidelines and accurate activity predictions for novel HIVPR inhibitors.</abstract>
<qualityIndicators><score>9.556</score>
<pdfWordCount>7576</pdfWordCount>
<pdfCharCount>48827</pdfCharCount>
<pdfVersion>1.2</pdfVersion>
<pdfPageCount>11</pdfPageCount>
<pdfPageSize>612 x 792 pts (letter)</pdfPageSize>
<pdfWordsPerPage>689</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>true</refBibsNative>
<abstractWordCount>213</abstractWordCount>
<abstractCharCount>1442</abstractCharCount>
<keywordCount>0</keywordCount>
</qualityIndicators>
<title>Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models</title>
<genre><json:string>research-article</json:string>
</genre>
<host><title>Journal of Medicinal Chemistry</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>0022-2623</json:string>
</issn>
<eissn><json:string>1520-4804</json:string>
</eissn>
<volume>45</volume>
<issue>2</issue>
<pages><first>333</first>
<last>343</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<ark><json:string>ark:/67375/TPS-51T68V2C-W</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - chemistry, medicinal</json:string>
</wos>
<scienceMetrix><json:string>1 - natural sciences</json:string>
<json:string>2 - chemistry</json:string>
<json:string>3 - medicinal & biomolecular chemistry</json:string>
</scienceMetrix>
<scopus><json:string>1 - Life Sciences</json:string>
<json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string>
<json:string>3 - Drug Discovery</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>3 - Molecular Medicine</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>2002</publicationDate>
<copyrightDate>2002</copyrightDate>
<doi><json:string>10.1021/jm0102710</json:string>
</doi>
<id>7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041B</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/bundle.zip</uri>
</json:item>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/fulltext.txt</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease
and Building Predictive 3D-QSAR Models</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>American Chemical Society</publisher>
<availability><licence>Copyright © 2002 American Chemical Society</licence>
<p>American Chemical Society</p>
</availability>
<date type="published">2002</date>
<date type="Copyright" when="2002">2002</date>
</publicationStmt>
<notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease
and Building Predictive 3D-QSAR Models</title>
<author xml:id="author-0000"><persName><surname>Huang</surname>
<forename type="first">Xaioqin</forename>
</persName>
<note place="foot" n="jm0102710AF2"><ref>†</ref>
<p>
Shanghai Institute of Materia Medica, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences.</p>
</note>
<note place="foot" n="jm0102710AF3"><ref>‡</ref>
<p>
Shanghai Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, Chinese Academy of Sciences.</p>
</note>
</author>
<author xml:id="author-0001"><persName><surname>Xu</surname>
<forename type="first">Liaosa</forename>
</persName>
<affiliation><orgName type="institution">Center for Drug Design and Discovery</orgName>
<orgName type="laboratory">State Key Laboratory of Drug Research</orgName>
<orgName type="institution">Shanghai Institute of Materia Medica</orgName>
<orgName type="institution">Shanghai Institutes for Biological Sciences</orgName>
<orgName type="institution">Chinese Academy of Sciences</orgName>
<address><addrLine>294 Taiyuan Road</addrLine>
<addrLine>Shanghai 200031</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>Shanghai Institute of Biochemistry and Cell Biology</addrLine>
<addrLine>Shanghai Institutes for Biological Sciences</addrLine>
<addrLine>Chinese Academy of Sciences</addrLine>
<addrLine>320 Yueyang Road</addrLine>
<addrLine>Shanghai 200032</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>and Department of Chemistry</addrLine>
<addrLine>Fudan University</addrLine>
<addrLine>Shanghai 2000437</addrLine>
<addrLine>People's Republic of China</addrLine>
</address>
</affiliation>
<note place="foot" n="jm0102710AF4"><ref>§</ref>
<p>
Fudan University.</p>
</note>
</author>
<author xml:id="author-0002"><persName><surname>Luo</surname>
<forename type="first">Xiaomin</forename>
</persName>
<affiliation><orgName type="institution">Center for Drug Design and Discovery</orgName>
<orgName type="laboratory">State Key Laboratory of Drug Research</orgName>
<orgName type="institution">Shanghai Institute of Materia Medica</orgName>
<orgName type="institution">Shanghai Institutes for Biological Sciences</orgName>
<orgName type="institution">Chinese Academy of Sciences</orgName>
<address><addrLine>294 Taiyuan Road</addrLine>
<addrLine>Shanghai 200031</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>Shanghai Institute of Biochemistry and Cell Biology</addrLine>
<addrLine>Shanghai Institutes for Biological Sciences</addrLine>
<addrLine>Chinese Academy of Sciences</addrLine>
<addrLine>320 Yueyang Road</addrLine>
<addrLine>Shanghai 200032</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>and Department of Chemistry</addrLine>
<addrLine>Fudan University</addrLine>
<addrLine>Shanghai 2000437</addrLine>
<addrLine>People's Republic of China</addrLine>
</address>
</affiliation>
<note place="foot" n="jm0102710AF2"><ref>†</ref>
<p>
Shanghai Institute of Materia Medica, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences.</p>
</note>
</author>
<author xml:id="author-0003"><persName><surname>Fan</surname>
<forename type="first">Kangnian</forename>
</persName>
<affiliation><orgName type="institution">Center for Drug Design and Discovery</orgName>
<orgName type="laboratory">State Key Laboratory of Drug Research</orgName>
<orgName type="institution">Shanghai Institute of Materia Medica</orgName>
<orgName type="institution">Shanghai Institutes for Biological Sciences</orgName>
<orgName type="institution">Chinese Academy of Sciences</orgName>
<address><addrLine>294 Taiyuan Road</addrLine>
<addrLine>Shanghai 200031</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>Shanghai Institute of Biochemistry and Cell Biology</addrLine>
<addrLine>Shanghai Institutes for Biological Sciences</addrLine>
<addrLine>Chinese Academy of Sciences</addrLine>
<addrLine>320 Yueyang Road</addrLine>
<addrLine>Shanghai 200032</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>and Department of Chemistry</addrLine>
<addrLine>Fudan University</addrLine>
<addrLine>Shanghai 2000437</addrLine>
<addrLine>People's Republic of China</addrLine>
</address>
</affiliation>
<note place="foot" n="jm0102710AF4"><ref>§</ref>
<p>
Fudan University.</p>
</note>
</author>
<author xml:id="author-0004"><persName><surname>Ji</surname>
<forename type="first">Ruyun</forename>
</persName>
<affiliation><orgName type="institution">Center for Drug Design and Discovery</orgName>
<orgName type="laboratory">State Key Laboratory of Drug Research</orgName>
<orgName type="institution">Shanghai Institute of Materia Medica</orgName>
<orgName type="institution">Shanghai Institutes for Biological Sciences</orgName>
<orgName type="institution">Chinese Academy of Sciences</orgName>
<address><addrLine>294 Taiyuan Road</addrLine>
<addrLine>Shanghai 200031</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>Shanghai Institute of Biochemistry and Cell Biology</addrLine>
<addrLine>Shanghai Institutes for Biological Sciences</addrLine>
<addrLine>Chinese Academy of Sciences</addrLine>
<addrLine>320 Yueyang Road</addrLine>
<addrLine>Shanghai 200032</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>and Department of Chemistry</addrLine>
<addrLine>Fudan University</addrLine>
<addrLine>Shanghai 2000437</addrLine>
<addrLine>People's Republic of China</addrLine>
</address>
</affiliation>
<note place="foot" n="jm0102710AF2"><ref>†</ref>
<p>
Shanghai Institute of Materia Medica, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences.</p>
</note>
</author>
<author xml:id="author-0005" role="corresp"><persName><surname>Pei</surname>
<forename type="first">Gang</forename>
</persName>
<note place="foot" n="jm0102710AF3"><ref>‡</ref>
<p>
Shanghai Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, Chinese Academy of Sciences.</p>
</note>
<affiliation role="corresp"> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@ mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</affiliation>
</author>
<author xml:id="author-0006"><persName><surname>Chen</surname>
<forename type="first">Kaixian</forename>
</persName>
<affiliation><orgName type="institution">Center for Drug Design and Discovery</orgName>
<orgName type="laboratory">State Key Laboratory of Drug Research</orgName>
<orgName type="institution">Shanghai Institute of Materia Medica</orgName>
<orgName type="institution">Shanghai Institutes for Biological Sciences</orgName>
<orgName type="institution">Chinese Academy of Sciences</orgName>
<address><addrLine>294 Taiyuan Road</addrLine>
<addrLine>Shanghai 200031</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>Shanghai Institute of Biochemistry and Cell Biology</addrLine>
<addrLine>Shanghai Institutes for Biological Sciences</addrLine>
<addrLine>Chinese Academy of Sciences</addrLine>
<addrLine>320 Yueyang Road</addrLine>
<addrLine>Shanghai 200032</addrLine>
<addrLine>People's Republic of China</addrLine>
<addrLine>and Department of Chemistry</addrLine>
<addrLine>Fudan University</addrLine>
<addrLine>Shanghai 2000437</addrLine>
<addrLine>People's Republic of China</addrLine>
</address>
</affiliation>
<note place="foot" n="jm0102710AF2"><ref>†</ref>
<p>
Shanghai Institute of Materia Medica, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences.</p>
</note>
</author>
<author xml:id="author-0007" role="corresp"><persName><surname>Jiang</surname>
<forename type="first">Hualiang</forename>
</persName>
<note place="foot" n="jm0102710AF2"><ref>†</ref>
<p>
Shanghai Institute of Materia Medica, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences.</p>
</note>
<affiliation role="corresp"> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@ mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</affiliation>
</author>
<idno type="istex">7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041B</idno>
<idno type="ark">ark:/67375/TPS-51T68V2C-W</idno>
<idno type="DOI">10.1021/jm0102710</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Medicinal Chemistry</title>
<title level="j" type="abbrev">J. Med. Chem.</title>
<idno type="acspubs">jm</idno>
<idno type="coden">jmcmar</idno>
<idno type="pISSN">0022-2623</idno>
<idno type="eISSN">1520-4804</idno>
<imprint><publisher>American Chemical Society</publisher>
<date type="e-published">2001</date>
<date type="published">2002</date>
<biblScope unit="vol">45</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="333">333</biblScope>
<biblScope unit="page" to="343">343</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.41" when="2020-04-06"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract><p><graphic url="jm0102710n00001.tif"></graphic>
</p>
<p>The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(<hi rend="italic">S</hi>
)-amino-2(<hi rend="italic">S</hi>
)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR).
The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite
interaction, and hydrogen bonding. The data of geometrical parameters (τ<hi rend="subscript">1</hi>
, τ<hi rend="subscript">2</hi>
, and τ<hi rend="subscript">3</hi>
listed in
Table <ref type="bib" target="#jm0102710t00002"></ref>
) and root mean square deviation values as compared with the known inhibitor, kni272,<ref type="bibr" target="#jm0102710b00028"></ref>
show that both kinds of inhibitors interact with HIVPR in a very similar way. The <hi rend="italic">r</hi>
<hi rend="superscript">2</hi>
value of
0.860 indicates that the calculated binding free energies correlate well with the inhibitory
activities. The structural and energetic differences in inhibitory potencies of AHPBAs were
reasonably explored. Using the binding conformations of AHPBAs, consistent and highly
predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR
analyses. The reasonable <hi rend="italic">r</hi>
<hi rend="subscript">corss</hi>
<hi rend="superscript">2</hi>
values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA, and
HQSAR models, respectively. The predictive ability of these models was validated by kni272
and a set of nine compounds that were not included in the training set. Mapping these models
back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA−HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide
clear guidelines and accurate activity predictions for novel HIVPR inhibitors.
</p>
</abstract>
<textClass ana="subject"><keywords scheme="document-type-name"><term>Article</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2020-04-06" who="#istex" xml:id="pub2tei">formatting</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus acs not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration>
<istex:document><article article-type="research-article" specific-use="acs2jats-1.1.23" dtd-version="1.1d1"><front><journal-meta><journal-id journal-id-type="acspubs">jm</journal-id>
<journal-id journal-id-type="coden">jmcmar</journal-id>
<journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title>
<abbrev-journal-title>J. Med. Chem.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-2623</issn>
<issn pub-type="epub">1520-4804</issn>
<publisher><publisher-name>American Chemical Society</publisher-name>
</publisher>
<self-uri>pubs.acs.org/jmc</self-uri>
</journal-meta>
<article-meta><article-id pub-id-type="doi">10.1021/jm0102710</article-id>
<article-categories><subj-group subj-group-type="document-type-name"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease
and Building Predictive 3D-QSAR Models</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname>
<given-names>Xaioqin</given-names>
</name>
<xref rid="jm0102710AF2"><sup>†</sup>
</xref>
<xref rid="jm0102710AF3"><sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name name-style="western"><surname>Xu</surname>
<given-names>Liaosa</given-names>
</name>
<xref rid="jm0102710AF4"><sup>§</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name name-style="western"><surname>Luo</surname>
<given-names>Xiaomin</given-names>
</name>
<xref rid="jm0102710AF2"><sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name name-style="western"><surname>Fan</surname>
<given-names>Kangnian</given-names>
</name>
<xref rid="jm0102710AF4"><sup>§</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name name-style="western"><surname>Ji</surname>
<given-names>Ruyun</given-names>
</name>
<xref rid="jm0102710AF2"><sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pei</surname>
<given-names>Gang</given-names>
</name>
<xref rid="jm0102710AF1">*</xref>
<xref rid="jm0102710AF3"><sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name name-style="western"><surname>Chen</surname>
<given-names>Kaixian</given-names>
</name>
<xref rid="jm0102710AF2"><sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jiang</surname>
<given-names>Hualiang</given-names>
</name>
<xref rid="jm0102710AF1">*</xref>
<xref rid="jm0102710AF2"><sup>†</sup>
</xref>
</contrib>
<aff>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute of
Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,
Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, and
Department of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China
</aff>
</contrib-group>
<author-notes><fn id="jm0102710AF2"><label>†</label>
<p>
Shanghai Institute of Materia Medica, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences.</p>
</fn>
<fn id="jm0102710AF3"><label>‡</label>
<p>
Shanghai Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, Chinese Academy of Sciences.</p>
</fn>
<fn id="jm0102710AF4"><label>§</label>
<p>
Fudan University.</p>
</fn>
<corresp id="jm0102710AF1">
To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@
mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</corresp>
</author-notes>
<pub-date pub-type="epub"><day>8</day>
<month>12</month>
<year>2001</year>
</pub-date>
<pub-date pub-type="ppub"><day>17</day>
<month>01</month>
<year>2002</year>
</pub-date>
<volume>45</volume>
<issue>2</issue>
<fpage>333</fpage>
<lpage>343</lpage>
<history><date date-type="received"><day>18</day>
<month>06</month>
<year>2001</year>
</date>
<date date-type="asap"><day>8</day>
<month>12</month>
<year>2001</year>
</date>
<date date-type="issue-pub"><day>17</day>
<month>01</month>
<year>2002</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2002 American Chemical Society</copyright-statement>
<copyright-year>2002</copyright-year>
<copyright-holder>American Chemical Society</copyright-holder>
</permissions>
<abstract><graphic content-type="abstract-graphic" xlink:href="jm0102710n00001.tif" orientation="portrait" position="float"></graphic>
<p>The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(<italic toggle="yes">S</italic>
)-amino-2(<italic toggle="yes">S</italic>
)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR).
The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite
interaction, and hydrogen bonding. The data of geometrical parameters (τ<sub>1</sub>
, τ<sub>2</sub>
, and τ<sub>3</sub>
listed in
Table <xref rid="jm0102710t00002"></xref>
) and root mean square deviation values as compared with the known inhibitor, kni272,<xref rid="jm0102710b00028" ref-type="bibr"></xref>
show that both kinds of inhibitors interact with HIVPR in a very similar way. The <italic toggle="yes">r</italic>
<sup>2</sup>
value of
0.860 indicates that the calculated binding free energies correlate well with the inhibitory
activities. The structural and energetic differences in inhibitory potencies of AHPBAs were
reasonably explored. Using the binding conformations of AHPBAs, consistent and highly
predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR
analyses. The reasonable <italic toggle="yes">r</italic>
<sub>corss</sub>
<sup>2</sup>
values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA, and
HQSAR models, respectively. The predictive ability of these models was validated by kni272
and a set of nine compounds that were not included in the training set. Mapping these models
back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA−HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide
clear guidelines and accurate activity predictions for novel HIVPR inhibitors.
</p>
</abstract>
<custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name>
<meta-value>jm0102710</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body><sec id="d7e235"><title>Introduction</title>
<p>Acquired immunodeficiency syndrome (AIDS) is the
first major epidemic caused by human immunodeficiency virus type (HIV), a member of the retroviruses
family.<xref rid="jm0102710b00001" ref-type="bibr"></xref>
Analysis of the nucleotide sequence of HIV-1
genome leads to the discovery that the virus encodes
an aspartic protease.<named-content content-type="bibref-group"><xref rid="jm0102710b00002" ref-type="bibr"></xref>
,<xref rid="jm0102710b00003" ref-type="bibr"></xref>
</named-content>
Interaction of the HIV-1 protease
(HIVPR) by either mutation or chemical inhibition
results in the production of immature, noninfectious
viral particles; thus, the function of this enzyme is
shown to be essential for proper virion assembly and
maturation.<named-content content-type="bibref-group"><xref rid="jm0102710b00004" ref-type="bibr"></xref>
−<xref rid="jm0102710b00005" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00006" ref-type="bibr"></xref>
</named-content>
It is not surprising that HIVPR is
identified as the prime target for structure-based drug
design,<named-content content-type="bibref-group"><xref rid="jm0102710b00007" ref-type="bibr"></xref>
,<xref rid="jm0102710b00008" ref-type="bibr"></xref>
</named-content>
and the importance of HIVPR inhibitors in the
treatment of AIDS has been well-established.<xref rid="jm0102710b00009" ref-type="bibr"></xref>
More
recent advances in inhibitor design have focused on
structural modification to improve their inhibitory
potency and oral bioavailability and to circumvent drug
resistances.<named-content content-type="bibref-group"><xref rid="jm0102710b00010" ref-type="bibr"></xref>
−<xref rid="jm0102710b00011" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00012" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00013" ref-type="bibr"></xref>
</named-content>
Despite these successes, it is nearly
impossible to treat all of the growing worldwide AIDS
population based on currently available drugs, so the
need for inexpensive and widely available HIVPR
inhibitors still exists.
</p>
<p>AHPBA (3(<italic toggle="yes">S</italic>
)-amino-2(<italic toggle="yes">S</italic>
)-hydroxyl-4-phenylbutanoic
acid) and its derivatives (AHPBAs), which are the
transition state mimics of HIVPR substrates,<xref rid="jm0102710b00014" ref-type="bibr"></xref>
are
totally new lead compounds as inhibitors to HIVPR and
have been shown potent inhibitory activity against
HIVPR.<named-content content-type="bibref-group"><xref rid="jm0102710b00015" ref-type="bibr"></xref>
−<xref rid="jm0102710b00016" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00017" ref-type="bibr"></xref>
</named-content>
Some of them also have high anti-HIV
activities; compound <bold>20</bold>
(Table <xref rid="jm0102710t00001"></xref>
) is the most potent
(IC<sub>50</sub>
is 0.8 nM and IC<sub>90</sub>
CEM/HIV-1 IIIB is 27nM) and
has demonstrated good pharmacokinetics in rats.<xref rid="jm0102710b00017" ref-type="bibr"></xref>
Structure−activity relationships of AHPBAs show that
these compounds possess strong potency and good
enzyme selectivity.<xref rid="jm0102710b00016" ref-type="bibr"></xref>
The lipophilic aromatic ring system, which fits into the S<sub>1</sub>
hydrophobic pocket of HIVPR,
is demonstrated to be very important.<xref rid="jm0102710b00018" ref-type="bibr"></xref>
The X-ray
structure determination together with the molecular
dynamic simulations<named-content content-type="bibref-group"><xref rid="jm0102710b00013" ref-type="bibr"></xref>
,<xref rid="jm0102710b00019" ref-type="bibr"></xref>
</named-content>
revealed the atomic details of
inhibitor-induced conformational changes and also the
essential role of structural subunits for the catalytic
activity of HIVPR. These structure-based approaches
are approved to be valuable for dynamic optimization
of inhibitors against HIVPR but could not lead to
predictive models for structural modification or new
inhibitor designing. Some meaningful clues from QSAR
studies on cyclic cyanoguanidines<xref rid="jm0102710b00020" ref-type="bibr"></xref>
were obtained for
the selection of positional substituents according to their
physical chemistry properties. Without the investigation
about conformation space of inhibitors and their binding
mechanism with HIVPR, it remains speculative whether
these semiempirical models could be used as practical
tools for designing better analogues with superior
pharmacokinetic and efficacy profiles. Developing 3D-QSAR models under the guide of information from the
catalytic site of enzymes<xref rid="jm0102710b00021" ref-type="bibr"></xref>
has been proven as one of
the more rational methodologies for binding affinity
prediction of new inhibitors.
<table-wrap id="jm0102710t00001" position="float" orientation="portrait"><label>1</label>
<caption><p>Compounds and Their HIVPR Inhibitory Activity</p>
</caption>
<oasis:table colsep="2" rowsep="2"><oasis:tgroup cols="1"><oasis:colspec colnum="1" colname="1"></oasis:colspec>
<oasis:tbody><oasis:row><oasis:entry colname="1"><graphic xlink:href="jm0102710u00001a.tif" position="float" orientation="portrait"></graphic>
</oasis:entry>
</oasis:row>
</oasis:tbody>
</oasis:tgroup>
</oasis:table>
<table-wrap-foot><p>* Compounds that were not included in the construction of 3D-QSAR models.</p>
</table-wrap-foot>
</table-wrap>
</p>
<p>Taking account of the pioneering works in the field
of designing and synthesis of HIVPR inhibitors, it
becomes fascinating for us to study the inhibitory
mechanism of AHPBAs against HIVPR and investigate
the three-dimensional quantitative structure−activity
relationships (3D-QSAR) of AHPBAs. To the best of our
knowledge, there has been no previous effort carried out
to seek new insight into the relationship between the
structure information and the inhibitory potency of
AHPBAs at the level of binding free energy prediction,
especially by theoretical methods, such as automated
molecular docking, comparative molecular field analysis
(CoMFA),<xref rid="jm0102710b00022" ref-type="bibr"></xref>
comparative molecular similarity analysis
(CoMSIA),<xref rid="jm0102710b00023" ref-type="bibr"></xref>
and hologram quantitative structure−activity relationship (HQSAR)<xref rid="jm0102710b00024" ref-type="bibr"></xref>
approaches.
</p>
<p>The aim of the present research is to demonstrate the
common binding mode of AHPBAs with HIVPR and to
predict the binding free energies relative to the inhibitory potencies of these compounds. The further important goal is to obtain not only stable and predictive but
also fast and convenient QSAR models, which are
located at the 3D level about the main intermolecular
interactions involved in the HIVPR inhibition.
</p>
</sec>
<sec id="d7e351"><title>Computational Details</title>
<p>To test the reliability of the Tripos force field encoded
in the Sybyl 6.5 software package,<xref rid="jm0102710b00025" ref-type="bibr"></xref>
the geometry of the
AHPBA structural template (Formula 1) was optimized
by an ab initio Hartree−Fock self-consistent field
method along with the standard polarized double-ζ
bases set (6-31G**).<xref rid="jm0102710b00026" ref-type="bibr"></xref>
The Tripos force field optimized
structure of AHPBAs fit well with the structure derived
from the ab initio method. Thus, the initial structures
of the 27 AHPBA compounds (Table <xref rid="jm0102710t00001"></xref>
) were built based
on the skeleton of Formula 1 and then subjected to
minimization using Tripos force field and Gasteiger−Hückel charges;<xref rid="jm0102710b00027" ref-type="bibr"></xref>
a nonbond cutoff of 8 Å was adopted
to consider the intramolecular interaction. All of the
calculations were performed on a Silicon Graphics
Indigo XZR 10 000 workstation.
<fig id="jm0102710f1" position="float" orientation="portrait"><label></label>
<graphic xlink:href="jm0102710f1.tif" position="float" orientation="portrait"></graphic>
</fig>
</p>
<p><bold>1. Molecular Docking.</bold>
The crystal structure of
HIVPR in complex with its inhibitor (kni272) was
recovered from Brookhaven Protein Database (entry
code <ext-link ext-link-type="pdb" xlink:href="1HPX">1HPX</ext-link>
).<xref rid="jm0102710b00028" ref-type="bibr"></xref>
Missing side chains of the HIVPR 3D
structure were added using the fragment library of the
Biopolymer module in Sybyl 6.5.<xref rid="jm0102710b00025" ref-type="bibr"></xref>
The potential of the
HIVPR 3D structure was assigned according to Amber
4.0 force field with Kollman-all-atom charges, and it was
further checked by the Procheck function in Insight II<xref rid="jm0102710b00029" ref-type="bibr"></xref>
to correct some unfavorable φ and ψ values of the amino
acids.
</p>
<p>For the reason of tackling the interacting mode of
AHPBAs with HIVPR, the advanced docking program
AutoDock 3.0<xref rid="jm0102710b00030" ref-type="bibr"></xref>
was used to perform the automated
molecular docking. The Lamarckian genetic algorithm
(LGA)<sup>30</sup>
was applied to deal with the AHPBA−HIVPR
interactions. Briefly, the LGA described the relationship
between AHPBA and HIVPR by the translation, orientation, and conformation of AHPBA. These so-called
“state variables” were the AHPBA's genotype, and the
resulting atomic coordinates together with the interaction and the intramolecular energies were the AHPBA's
phenotype. The environmental adaptation of AHPBA's
phenotype was reverse-transcribed into its genotype and
became heritable traits. Each docking cycle, or generation, consisted of a regimen of fitness evaluation,
crossover, mutation, and selection. A Solis and Wets
local search<xref rid="jm0102710b00031" ref-type="bibr"></xref>
performed the energy minimization on a
user-specified proportion of the population. The docked
structures of AHPBAs were generated after a reasonable number of evaluations. The whole docking operation could be stated as follows.
</p>
<p>First, the HIVPR molecule was checked for polar
hydrogens and partial atomic charges, the PDBQs
format file was created, and the atomic solvation
parameters were also assigned for this macromolecule.
In the meanwhile, all of the torsion angles of AHPBAs
were defined in order to be explored during molecular
docking. This allowed the conformational search of
AHPBA during the process of docking.
</p>
<p>Second, the 3D grid was created by the AutoGrid
algorithm<sup>30</sup>
to evaluate the interacting energy between
the AHPBAs and the HIVPR. In this stage, the HIVPR
was embedded in the 3D grid and a probe atom was
placed at each grid point. The affinity and electrostatic
potential grid were calculated for each type of atom in
AHPBA molecules. The energetics of a particular AHPBA configuration was found by trilinear interpolation
of affinity values and electrostatic interaction of the
eight grid points surrounding each of the atoms in
AHPBA.
</p>
<p>Third, a series of the docking parameters were set on.
Not only the atom types but also the generations and
the number of runs for the LGA algorithm were edited
and properly assigned according to the requirement of
the Amber force field. The number of generation, energy
evaluation, and docking runs was set to 370 000,
1 500 000, and 10, respectively. The kinds of atomic
charges were taken as Kollman-all-atom<xref rid="jm0102710b00032" ref-type="bibr"></xref>
for HIVPR
and Gasteiger−Hückel<sup>27</sup>
for AHPBAs.
</p>
<p>Finally, the docked complexes of AHPBAs−HIVPR
were selected according to the criteria of interacting
energy combined with geometrical matching quality.
These complexes were used as the starting conformation
for further energetic minimization and geometrical
optimization before the final models were achieved.
</p>
<p><bold>2. Binding Free Energy Prediction.</bold>
Typically,
three binding energy terms used in the previous versions of AutoDock<xref rid="jm0102710b00033" ref-type="bibr"></xref>
were included in the score function: the van der Waals interaction represented as a
Lennard−Jones 12−6 dispersion/repulsion term, the
hydrogen bonding represented as a directional 12−10
term, and the Coulombic electrostatic potential. So, the
binding energy of AHPBAs with HIVPR could be simply
described as the electrostatic, van der Waals, and
hydrogen bonding interaction energy, respectively.
</p>
<p>On the basis of the traditional molecular force field
model of interaction energy, a new score function at the
level of binding free energy was derived and adopted in
the version of AutoDock 3.0.<xref rid="jm0102710b00030" ref-type="bibr"></xref>
Not only the restriction
of internal rotors, the global rotation, and translation
were modeled depending on the number of torsion
angles of the ligand but also the desolvation upon
binding and the hydrophobic effect (solvent entropy
changes at solute−solvent interfaces) were calculated.
The total binding free energy was empirically calibrated
based on the above-stated terms and a set of coefficient
factors.<xref rid="jm0102710b00030" ref-type="bibr"></xref>
Thus, the new score function was sufficient
to rank the inhibitors in the different levels of binding
affinities.
</p>
<p>The same rationale was applied to the system of
AHPBAs−HIVPR in order to evaluate the binding
properties more precisely than the traditional molecular
mechanics method did, and the total binding free energy
between AHPBAs and HIVPR was calculated according
to the algorithm in the AuotDock 3.0 program.<xref rid="jm0102710b00030" ref-type="bibr"></xref>
</p>
<p><bold>3. 3D-QSAR Studies.</bold>
To more fully explore the
specific contributions of electrostatic, steric, and hydrophobic effects in the binding of AHPBAs to HIVPR and
to build predictive QSAR models, CoMFA,<xref rid="jm0102710b00022" ref-type="bibr"></xref>
CoMSIA,<xref rid="jm0102710b00023" ref-type="bibr"></xref>
and HQSAR<sup>24</sup>
studies were performed by using the
conformations and their alignment at the binding site
of the HIVPR, which resulted from the molecular
docking.
</p>
<p><bold>3.1. CoMFA.</bold>
Usually, steric and electrostatic field
energies were probed using an sp<sup>3</sup>
carbon atom and a
+1 net charge atom, respectively. Steric and electrostatic interactions were calculated using a Tripos force
field with a distance-dependent dielectric constant at
all intersections in a regularly spaced (2 Å) grid. The
minimum-σ (column filtering) was set to 2.0 kcal/mol
to improve the signal-to-noise ratio by omitting those
lattice points whose energy variation was below this
threshold. A cutoff of 30 kcal/mol was adopted, and the
regression analysis was carried out using the partial
least-squares (PLS) method. The final model was developed with the optimum number of components equal
to that yielding the highest <italic toggle="yes">r</italic>
<sub>cv</sub>
<sup>2</sup>
.
</p>
<p><bold>3.2. CoMSIA.</bold>
Three physicochemical properties,
steric, electrostatic, and hydrophobic fields, have been
evaluated. The steric contribution was reflected by the
third power of the atomic radii of the atoms. Electrostatic properties were introduced as atomic charges that
resulted from molecular docking. An atom-based hydrophobicity was assigned according to the parametrization developed by Viswanadhan et al.<xref rid="jm0102710b00034" ref-type="bibr"></xref>
The lattice
dimensions were selected with a sufficiently large margin
(>4 Å) to enclose all aligned molecules. Any singularities
were avoided at atomic positions in CoMSIA fields
because a Gaussian type distance dependence of the
physicochemical properties was adopted; thus, no arbitrary cutoffs were required. In general, similarity
indices (<italic toggle="yes">A</italic>
<sub>F,K</sub>
) between the compounds of interest and a
probe atom placed at the intersections of the lattice
could be calculated with eq 1<xref rid="jm0102710e00001"></xref>
<disp-formula content-type="pre-labeled" id="jm0102710e00001"><!--%@md;sys;6q@%%@ital@%A%@rsf@%%@sb@%F,K%@sbx@%%@ital@%%@ex@%q%@rsf@%%@exx@%%@fn;(;vis;full;auto@%%@ital@%j%@rsf@%%@fnx;);vis;full@% = − %@mspx;50@%%@sm@%%@lu@%%@ital@%i%@rsf@%=1%@bu@%%@ital@%n%@rsf@%%@lux@%%@smx@% %@ital@%w%@rsf@%%@sb@%probe,k%@sbx@%%@ital@% w%@rsf@%%@sb@%ik %@sbx@%e%@ex@%$-$%@ital@%ar%@rsf@%%@sb@%%@ital@%iq%@rsf@%%@sbx@%%@ex@%2%@exx@%%@exx@%%@id;reqid;1@%%@mx@%[S_EL2;quad]
--><graphic xlink:href="jm0102710e00001.gif" position="anchor" orientation="portrait"></graphic>
</disp-formula>
where <italic toggle="yes">q</italic>
represents a grid point; <italic toggle="yes">i</italic>
is the summation
index over all atoms of the molecule <italic toggle="yes">j</italic>
under computation; <italic toggle="yes">w</italic>
<sub>ik</sub>
is the actual value of the physicochemical
property <italic toggle="yes">k</italic>
of atom <italic toggle="yes">i</italic>
; and <italic toggle="yes">w</italic>
<sub>prob,k</sub>
is the value of the probe
atom. In the present study, similarity indices were
computed using a probe atom (<italic toggle="yes">w</italic>
<sub>prob,k</sub>
) with a charge of
+1, a radius of 1 Å, a hydrophobicity of +1, and an
attenuation factor α 0.3 for the Gaussian type distance.
The statistical evaluation for the CoMSIA analyses was
performed in the same way as described in CoMFA.
</p>
<p><bold>3.3. HQSAR.</bold>
The construction of a molecular hologram containing the HQSAR descriptors was completed
as following this procedure: at first, the molecule was
hashed to a molecular fingerprint that encoded the
frequency of occurrence of various molecular fragment
types using a predefined set of rules. Then, the molecular fingerprint was cut into strings at a fixed interval
as specified by a hologram length (HL) parameter, and
at last, all of the generated strings were hashed into a
fixed length array. The Sybyl line notation for each
string was mapped to a unique integer in the range of
0−2<sup>31</sup>
using a cyclic redundancy check algorithm. The
numerical representation of molecules was exploited by
a subsequent correlation analysis; typically, a PLS
QSAR model was constructed. The optimal HQSAR
model was constructed by screening the 12 default HL
values, which were a set of prime numbers ranging from
53 to 401.
</p>
</sec>
<sec id="d7e531"><title>Results and Discussion</title>
<p><bold>1. Interacting Mode with HIVPR. 1.1. Inhibitor's
Conformation.</bold>
Figure <xref rid="jm0102710f00001"></xref>
illustrates the probable binding conformations for the 27 AHPBAs extracted from
AHPBA−HIVPR complexes. Figure <xref rid="jm0102710f00002"></xref>
A shows the 3D
model of the AHPBAs−HIVPR complex, and Figure <xref rid="jm0102710f00002"></xref>
B
is the conformational comparison for the most potent
inhibitors, compound <bold>12 </bold>
(Table <xref rid="jm0102710t00001"></xref>
) and compound
kni272.<xref rid="jm0102710b00028" ref-type="bibr"></xref>
The main conformational difference between
the AHPBAs and the kni272 could be represented as
the three torsion angles (τ<sub>1</sub>
, τ<sub>2</sub>
, and τ<sub>3</sub>
in Formula 1) and
the root mean square deviation (RMSD) values based
on the parts of similar structure including the Ar<sub>2</sub>
group.
These data are summarized in Table <xref rid="jm0102710t00002"></xref>
and shown in
Figure <xref rid="jm0102710f00002"></xref>
C. Figure <xref rid="jm0102710f00003"></xref>
generally represents the interacting
mode of AHPBAs with HIVPR. Just like the inhibitor
kni272<sup>28</sup>
and most of the other transition state mimic
inhibitors cocrystallized with HIVPR,<named-content content-type="bibref-group"><xref rid="jm0102710b00035" ref-type="bibr"></xref>
,<xref rid="jm0102710b00036" ref-type="bibr"></xref>
</named-content>
AHPBAs locate in the center of the typical binding pocket of HIVPR
and share some common binding features for each other.
All of the AHPBAs are bound in the active site of HIVPR
in an extended conformation (Figures <xref rid="jm0102710f00001"></xref>
and <xref rid="jm0102710f00002"></xref>
A), and
the binding conformations of AHPBAs could be aligned
quite well overall. Following a similar binding pattern
with compound kni272,<xref rid="jm0102710b00028" ref-type="bibr"></xref>
the Ar<sub>2</sub>
group (Table <xref rid="jm0102710t00001"></xref>
) of all
of the 27 AHPBAs is situated at the S<sub>1</sub>
subsite of the
binding pocket, and the Ar1−CONH group occupies the
S<sub>2</sub>
subsite. Meanwhile, the NH−tertiary butyl group
interacts with the S<sub>2</sub>
‘ subsite, and the proline−CO part
is in match with the S<sub>1</sub>
‘ subsite.
<fig id="jm0102710f00001" position="float" orientation="portrait"><label>1</label>
<caption><p>Probable binding conformations of AHPBAs and their alignment in the binding site of HIVPR.</p>
</caption>
<graphic xlink:href="jm0102710f00001.tif" position="float" orientation="portrait"></graphic>
</fig>
<fig id="jm0102710f00002" position="float" orientation="portrait"><label>2</label>
<caption><p>3D-model of the AHPBA−HIVPR complex. (A) Cartoon representation of the AHPBA−HIVPR structural model. (B) The conformational comparison for one of the potential inhibitors, compound<bold>12</bold>
, and kni272 in the crystal
structure;<xref rid="jm0102710b00028" ref-type="bibr"></xref>
all of the molecules are shown in stick style, and
the hydrogen atoms are hidden. (C) The geometrical parameters (τ<sub>1</sub>
, τ<sub>2</sub>
, and τ<sub>3</sub>
) and RMSD values of AHPBAs as compared
with kni272; red-colored points are of the testing set. (A) and
(B) are reproduced from the POV-Ray<sup>39</sup>
program.</p>
</caption>
<graphic xlink:href="jm0102710f00002.tif" position="float" orientation="portrait"></graphic>
</fig>
<fig id="jm0102710f00003" position="float" orientation="portrait"><label>3</label>
<caption><p>2D representative for the general interacting mode of AHPBAs (compound<bold>20</bold>
as a representative) with HIVPR;
it is drawn by LIGPLOT.<xref rid="jm0102710b00040" ref-type="bibr"></xref>
</p>
</caption>
<graphic xlink:href="jm0102710f00003.tif" position="float" orientation="portrait"></graphic>
</fig>
<table-wrap id="jm0102710t00002" position="float" orientation="portrait"><label>2</label>
<caption><p>Geometrical Parameters of AHPBAs Binding Conformations and RMSD Values as Compared with kni272 from Crystal Structure 1HPX<sup>28</sup>
</p>
</caption>
<oasis:table colsep="2" rowsep="2"><oasis:tgroup cols="5"><oasis:colspec colnum="1" colname="1"></oasis:colspec>
<oasis:colspec colnum="2" colname="2"></oasis:colspec>
<oasis:colspec colnum="3" colname="3"></oasis:colspec>
<oasis:colspec colnum="4" colname="4"></oasis:colspec>
<oasis:colspec colnum="5" colname="5"></oasis:colspec>
<oasis:tbody><oasis:row><oasis:entry namest="1" nameend="1">compd</oasis:entry>
<oasis:entry namest="2" nameend="2">τ<sub>1</sub>
<sub> </sub>
(°)</oasis:entry>
<oasis:entry namest="3" nameend="3">τ<sub>2</sub>
<sub> </sub>
(°)</oasis:entry>
<oasis:entry namest="4" nameend="4">τ<sub>3</sub>
<sub> </sub>
(°)</oasis:entry>
<oasis:entry namest="5" nameend="5">RMSD
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>1</bold>
</oasis:entry>
<oasis:entry colname="2">−170.9
</oasis:entry>
<oasis:entry colname="3">−85.2
</oasis:entry>
<oasis:entry colname="4">42.5
</oasis:entry>
<oasis:entry colname="5">0.173
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>2</bold>
</oasis:entry>
<oasis:entry colname="2">−168.8
</oasis:entry>
<oasis:entry colname="3">−85.6
</oasis:entry>
<oasis:entry colname="4">42.7
</oasis:entry>
<oasis:entry colname="5">0.185
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>3</bold>
</oasis:entry>
<oasis:entry colname="2">−163.7
</oasis:entry>
<oasis:entry colname="3">−89.5
</oasis:entry>
<oasis:entry colname="4">42.7
</oasis:entry>
<oasis:entry colname="5">0.182
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>4</bold>
</oasis:entry>
<oasis:entry colname="2">−163.9
</oasis:entry>
<oasis:entry colname="3">−92.3
</oasis:entry>
<oasis:entry colname="4">51.1
</oasis:entry>
<oasis:entry colname="5">0.192
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>5</bold>
</oasis:entry>
<oasis:entry colname="2">−164.3
</oasis:entry>
<oasis:entry colname="3">−88.4
</oasis:entry>
<oasis:entry colname="4">45.3
</oasis:entry>
<oasis:entry colname="5">0.171
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>6</bold>
</oasis:entry>
<oasis:entry colname="2">−161.7
</oasis:entry>
<oasis:entry colname="3">−91.2
</oasis:entry>
<oasis:entry colname="4">43.5
</oasis:entry>
<oasis:entry colname="5">0.176
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>7</bold>
</oasis:entry>
<oasis:entry colname="2">−161.7
</oasis:entry>
<oasis:entry colname="3">−89.9
</oasis:entry>
<oasis:entry colname="4">44.2
</oasis:entry>
<oasis:entry colname="5">0.166
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>8</bold>
</oasis:entry>
<oasis:entry colname="2">−166.0
</oasis:entry>
<oasis:entry colname="3">−92.1
</oasis:entry>
<oasis:entry colname="4">52.9
</oasis:entry>
<oasis:entry colname="5">0.163
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>9</bold>
</oasis:entry>
<oasis:entry colname="2">−149.6
</oasis:entry>
<oasis:entry colname="3">−95.8
</oasis:entry>
<oasis:entry colname="4">45.4
</oasis:entry>
<oasis:entry colname="5">0.170
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>10</bold>
</oasis:entry>
<oasis:entry colname="2">−153.4
</oasis:entry>
<oasis:entry colname="3">−95.5
</oasis:entry>
<oasis:entry colname="4">53.4
</oasis:entry>
<oasis:entry colname="5">0.170
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>11</bold>
</oasis:entry>
<oasis:entry colname="2">−167.3
</oasis:entry>
<oasis:entry colname="3">−91.8
</oasis:entry>
<oasis:entry colname="4">45.6
</oasis:entry>
<oasis:entry colname="5">0.174
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>12</bold>
</oasis:entry>
<oasis:entry colname="2">−165.0
</oasis:entry>
<oasis:entry colname="3">−90.7
</oasis:entry>
<oasis:entry colname="4">43.4
</oasis:entry>
<oasis:entry colname="5">0.178
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>13</bold>
</oasis:entry>
<oasis:entry colname="2">−173.7
</oasis:entry>
<oasis:entry colname="3">−80.6
</oasis:entry>
<oasis:entry colname="4">34.4
</oasis:entry>
<oasis:entry colname="5">0.179
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>14</bold>
</oasis:entry>
<oasis:entry colname="2">−156.9
</oasis:entry>
<oasis:entry colname="3">−92.9
</oasis:entry>
<oasis:entry colname="4">43.8
</oasis:entry>
<oasis:entry colname="5">0.168
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>15</bold>
</oasis:entry>
<oasis:entry colname="2">−160.5
</oasis:entry>
<oasis:entry colname="3">−92.6
</oasis:entry>
<oasis:entry colname="4">51.4
</oasis:entry>
<oasis:entry colname="5">0.181
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>16</bold>
</oasis:entry>
<oasis:entry colname="2">−148.5
</oasis:entry>
<oasis:entry colname="3">−92.8
</oasis:entry>
<oasis:entry colname="4">44.7
</oasis:entry>
<oasis:entry colname="5">0.179
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>17</bold>
</oasis:entry>
<oasis:entry colname="2">−171.8
</oasis:entry>
<oasis:entry colname="3">−88.7
</oasis:entry>
<oasis:entry colname="4">59.3
</oasis:entry>
<oasis:entry colname="5">0.185
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>18</bold>
</oasis:entry>
<oasis:entry colname="2">−164.6
</oasis:entry>
<oasis:entry colname="3">−90.5
</oasis:entry>
<oasis:entry colname="4">43.1
</oasis:entry>
<oasis:entry colname="5">0.177
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>19</bold>
</oasis:entry>
<oasis:entry colname="2">−163.8
</oasis:entry>
<oasis:entry colname="3">−91.3
</oasis:entry>
<oasis:entry colname="4">43.5
</oasis:entry>
<oasis:entry colname="5">0.167
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>20</bold>
</oasis:entry>
<oasis:entry colname="2">−161.3
</oasis:entry>
<oasis:entry colname="3">−89.7
</oasis:entry>
<oasis:entry colname="4">41.8
</oasis:entry>
<oasis:entry colname="5">0.170
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>21</bold>
</oasis:entry>
<oasis:entry colname="2">−164.7
</oasis:entry>
<oasis:entry colname="3">−92.6
</oasis:entry>
<oasis:entry colname="4">48.5
</oasis:entry>
<oasis:entry colname="5">0.169
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>22</bold>
</oasis:entry>
<oasis:entry colname="2">−161.1
</oasis:entry>
<oasis:entry colname="3">−89.7
</oasis:entry>
<oasis:entry colname="4">40.8
</oasis:entry>
<oasis:entry colname="5">0.168
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>23</bold>
</oasis:entry>
<oasis:entry colname="2">−160.7
</oasis:entry>
<oasis:entry colname="3">−91.9
</oasis:entry>
<oasis:entry colname="4">43.4
</oasis:entry>
<oasis:entry colname="5">0.169
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>24</bold>
</oasis:entry>
<oasis:entry colname="2">−172.4
</oasis:entry>
<oasis:entry colname="3">−80.4
</oasis:entry>
<oasis:entry colname="4">33.8
</oasis:entry>
<oasis:entry colname="5">0.177
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>25</bold>
</oasis:entry>
<oasis:entry colname="2">−172.7
</oasis:entry>
<oasis:entry colname="3">−82.2
</oasis:entry>
<oasis:entry colname="4">41.2
</oasis:entry>
<oasis:entry colname="5">0.180
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>26</bold>
</oasis:entry>
<oasis:entry colname="2">−172.2
</oasis:entry>
<oasis:entry colname="3">−84.1
</oasis:entry>
<oasis:entry colname="4">42.3
</oasis:entry>
<oasis:entry colname="5">0.180
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>27</bold>
</oasis:entry>
<oasis:entry colname="2">−172.5
</oasis:entry>
<oasis:entry colname="3">−87.0
</oasis:entry>
<oasis:entry colname="4">50.6
</oasis:entry>
<oasis:entry colname="5">0.189
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>1*</bold>
</oasis:entry>
<oasis:entry colname="2">−172.1
</oasis:entry>
<oasis:entry colname="3">−80.3
</oasis:entry>
<oasis:entry colname="4">29.4
</oasis:entry>
<oasis:entry colname="5">0.186
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>2*</bold>
</oasis:entry>
<oasis:entry colname="2">−168.2
</oasis:entry>
<oasis:entry colname="3">−90.9
</oasis:entry>
<oasis:entry colname="4">27.2
</oasis:entry>
<oasis:entry colname="5">0.174
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>3*</bold>
</oasis:entry>
<oasis:entry colname="2">−172.8
</oasis:entry>
<oasis:entry colname="3">−83.9
</oasis:entry>
<oasis:entry colname="4">30.2
</oasis:entry>
<oasis:entry colname="5">0.178
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>4*</bold>
</oasis:entry>
<oasis:entry colname="2">−170.8
</oasis:entry>
<oasis:entry colname="3">−80.5
</oasis:entry>
<oasis:entry colname="4">34.0
</oasis:entry>
<oasis:entry colname="5">0.172
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>5*</bold>
</oasis:entry>
<oasis:entry colname="2">−172.1
</oasis:entry>
<oasis:entry colname="3">−83.9
</oasis:entry>
<oasis:entry colname="4">42.0
</oasis:entry>
<oasis:entry colname="5">0.182
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>6*</bold>
</oasis:entry>
<oasis:entry colname="2">−169.4
</oasis:entry>
<oasis:entry colname="3">−93.1
</oasis:entry>
<oasis:entry colname="4">53.2
</oasis:entry>
<oasis:entry colname="5">0.189
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>7*</bold>
</oasis:entry>
<oasis:entry colname="2">−164.2
</oasis:entry>
<oasis:entry colname="3">−87.0
</oasis:entry>
<oasis:entry colname="4">42.7
</oasis:entry>
<oasis:entry colname="5">0.175
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>8*</bold>
</oasis:entry>
<oasis:entry colname="2">−173.3
</oasis:entry>
<oasis:entry colname="3">−85.5
</oasis:entry>
<oasis:entry colname="4">43.7
</oasis:entry>
<oasis:entry colname="5">0.181
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>9*</bold>
</oasis:entry>
<oasis:entry colname="2">−172.3
</oasis:entry>
<oasis:entry colname="3">−84.7
</oasis:entry>
<oasis:entry colname="4">44.1
</oasis:entry>
<oasis:entry colname="5">0.180</oasis:entry>
</oasis:row>
</oasis:tbody>
</oasis:tgroup>
</oasis:table>
</table-wrap>
</p>
<p><bold>1.2. Subsite Interactions.</bold>
The open mouth of the
small hydrophobic pocket formed by residues Leu23‘,
Gly48, Gly49, Ile50, Pro81‘, Val82‘, and Ile84‘ of HIVPR
is directly toward the Ar<sub>2</sub>
group and wraps the most
part of the latter (Figure <xref rid="jm0102710f00003"></xref>
). They interact with each
other tightly through hydrophobic interaction. The
outside edge of the Ar<sub>2</sub>
group is almost blocked off by
the hydrogen network formed between Arg8‘ and Asp29.
Interestingly, the two terminal methyl groups of the side
chains of residues Val82‘ and Ile84‘, respectively, interact with the two aromatic rings of the Ar<sub>2</sub>
group of
compound <bold>20</bold>
or the benzyl ring of the other inhibitors
through nonpolar alkane−π interaction<xref rid="jm0102710b00037" ref-type="bibr"></xref>
(Figure <xref rid="jm0102710f00003"></xref>
).
This kind of alkane−π interaction has not yet been
appreciated in inhibitor−enzyme binding. To estimate
the strength of the alkane−π interaction, we performed
a theoretical calculation employing the ab initio quantum chemistry methods of Möler−Plesset second-order
correlation method (MP2)<xref rid="jm0102710b00038" ref-type="bibr"></xref>
at the 6-31G* basis set level,
taking methane−benzene as model systems. The distance between the methyl carbon and the center of
benzene is 3.7 Å, which is in agreement with the
distances of the two methyl carbons to the centers of
the two rings of Ar<sub>2</sub>
(Figure <xref rid="jm0102710f00003"></xref>
). The binding energy of
MP2/6-31G* between methyl and benzene is −1.3 kcal/mol. This indicates that the alkane−π interaction
contributes about 2.6 kcal/mol energy for compound <bold>20</bold>
−HIVPR binding, or at least 1.3 kcal/mol energy for the
other compounds−HIVPR binding, and points out the
importance of the aromaticity of Ar<sub>2</sub>
.
</p>
<p>The Ar<sub>1</sub>
−CONH group binds with the side chains of
residues Ala28, Asp29, Asp30, Val32, Ile47, Gly48, and
Ile84 of HIVPR through not only hydrophobic interaction but also electrostatic interaction to some extent.
The carbonyl group (>CO) of residue Gly48 is in a
position almost perpendicular to the plane of the
aromatic ring of the Ar<sub>1</sub>
group. The distance from the
carbonyl oxygen of Gly48 to the center of the aromatic
ring of the Ar<sub>1</sub>
group is 3.51 Å. So, the residue Gly48
may be one of the important factors determining the
3D positioning of the Ar<sub>1</sub>
group in the binding pocket.
</p>
<p>The NH−tertiary butyl group at the other end of the
AHPBA molecules is surrounded by residues Gly27‘,
Ala28‘, Asp29‘, Ile47‘, Gly48‘, Gly49‘, and Ile50 of
HIVPR. Although the hydrophobic space is not fully
occupied by the tertiary butyl group, they are in good
geometrical match through the side chains of Ala28‘ and
Ile50. The proline−CO group of AHPBAs situates in a
small hydrophobic pocket of the subsite S<sub>1</sub>
‘ and interacts
with the side chains of residues Leu23, Val82, and Ile84
of HIVPR; the chloride points directly to the gap
between Leu23, Val82, and Ile84.
</p>
<p><bold>1.3. Hydrogen-Bonding Interactions.</bold>
Another important characteristic of the interaction between AHPBAs and HIVPR is the hydrogen bonding (Figure <xref rid="jm0102710f00003"></xref>
).
There are several hydrogen bonds formed between the
AHPBAs and the side chains of some residues in
HIVPR. The hydroxyl group at position 4 of AHPBAs
(Table <xref rid="jm0102710t00001"></xref>
) could form hydrogen bonds with O<sup>δ1</sup>
and O<sup>δ2</sup>
atoms of Asp25 or O<sup>δ2</sup>
of Asp25‘, and the >CO group
at position 5 (Table <xref rid="jm0102710t00001"></xref>
) forms a hydrogen bond with the
protonated O<sup>δ1</sup>
of Asp25‘. This network of hydrogen
bonds in the catalytic site of HIVPR must play a vital
role in determining the level of binding affinities for
AHPBAs with HIVPR, and this may be the important
reason why the AHPBAs could inhibit the HIVPR much
more potently. The oxygen atom of the hydroxyl group
at Ar<sub>1</sub>
might be an acceptor to form a hydrogen bond
with the −NH group at the backbone of residue Asp29
on one hand; the hydrogen atom of the hydroxyl group
at Ar<sub>1</sub>
hydrogen bonds with O<sup>δ1</sup>
of the same residue on
the other hand. These hydrogen bonds greatly strengthen
the interaction of the aromatic ring Ar<sub>1</sub>
with the
surrounding hydrophobic field produced by side chains
of residues Ala28, Val32, Ile47, and Ile84 in HIVPR.
Interestingly, the −NH group at position 9 of AHPBAs
also forms a hydrogen bond with the >CO group of
residue Gly48‘ in HIVPR. This hydrogen bonding intensely determines the 3D space position of the tertiary
butyl group in the binding pocket and stabilizes the
hydrophobic interaction of the tertiary butyl group with
the side chains of residues Ala28‘, Ile47‘, and Ile50 in
HIVPR.
</p>
<p>On further inspection of the AHPBA−HIVPR complex
model, the >CO groups at positions 1 and 8 of
AHPBAs are located adjacent to the −NH groups of
Ile50/Ile50‘. The distances between them are within 4
Å, and the conformation of this part in the complex is
symmetric to some extent. There may be a hydrogen
bond network formed between the >CO groups at
positions 1 and 8 of AHPBAs and the −NH groups of
Ile50/Ile50‘ through a water molecule if the complex is
crystallized. This is just like the hydrogen bonding
tetrahedral network and a water molecule named as
Wat301 found in the kni272−HIVPR<sup>28</sup>
and other inhibitor−HIVPR crystal structures.<named-content content-type="bibref-group"><xref rid="jm0102710b00041" ref-type="bibr"></xref>
,<xref rid="jm0102710b00042" ref-type="bibr"></xref>
</named-content>
</p>
<p>As a whole, the AHPBAs interact with HIVPR through
a hydrophobic, hydrogen bonding interaction and a local,
weak electrostatic interaction. The hydroxyl group at
position 4 of AHPBAs is located at the center of the
electrostatic field produced by the negatively charged
side chains of an active catalytic triad of HIVPR. The
binding of the AHPBAs may introduce significant influence on the conformation of those regions that define
the binding site of HIVPR, and the different ionization
states of the catalytic aspartyl groups of Asp25 and
Asp25‘. The presence of the inhibitor makes the dimeric
structure of HIVPR stabilized, especially the flap region
that becomes conformationally closed.<named-content content-type="bibref-group"><xref rid="jm0102710b00043" ref-type="bibr"></xref>
,<xref rid="jm0102710b00044" ref-type="bibr"></xref>
</named-content>
</p>
<p><bold>2. Correlation between Binding Free Energy
and Inhibitory Activity. </bold>
Table <xref rid="jm0102710t00003"></xref>
lists the predicted
binding free energy of AHPBAs with HIVPR. Satisfied
that the 3D structures of the AHPBA−HIVPR complexes were practically reasonable, the multiple regression analysis<sup>45</sup>
was performed to explore whether the
inhibitory potencies of AHPBAs could be correlated with
the energetic information. The regression equation was
obtained for the inhibitory potencies, −logIC<sub>50</sub>
s, using
the total binding free energies, Δ<italic toggle="yes">G</italic>
, as the sole descriptor
variable. A good correlation was found between the
inhibitory potencies and the predicted binding free
energies (eq 2), and this relationship is also graphically
shown in Figure <xref rid="jm0102710f00004"></xref>
.<xref rid="jm0102710e00002"></xref>
<disp-formula content-type="pre-labeled" id="jm0102710e00002"><!--%@md;sys;6q@%log%@mh;1q@%IC%@sb@%50%@sbx@%%@mh;2q@%=%@mh;2q@%−2.968%@mh;2q@%−%@mh;2q@%0.763%@mh;2q@%×%@mh;2q@%&Dgr;%@ital@%G%@rsf@%%@/mh;%lnwidth?9q:0@%%@fn;(;vis;full;auto@%%@ital@%n%@mh;2q@%%@rsf@%=%@mh;2q@%27,%@mh;2q@%%@ital@%r%@mh;2q@%%@rsf@%=%@mh;2q@%0.927,%@mh;2q@%[S_EL2;quad]\
%@bf@%%@ital@%r%@rsf@%%@ex@%2%@exx@%%@mh;2q@%=%@mh;2q@%0.860,%@mh;2q@%%@ital@%F%@rsf@%%@sb@%1,25%@sbx@%%@mh;2q@%=%@mh;2q@%162.240,%@mh;2q@%%@ital@%s%@mh;2q@%%@rsf@%=%@mh;2q@%0.188%@fnx;);vis;full@%%@id;reqid;2@%%@mx@%[S_EL2;quad]
--><graphic xlink:href="jm0102710e00002.gif" position="anchor" orientation="portrait"></graphic>
</disp-formula>
<fig id="jm0102710f00004" position="float" orientation="portrait"><label>4</label>
<caption><p>Correlation between the binding free energy (Δ<italic toggle="yes">G</italic>
,
kcal/mol, <italic toggle="yes">T </italic>
= 298.15 K) of AHPBAs (·, compounds of the
training set; ▴, compounds of the testing set) with the HIVPR
and the experimental inhibitory potencies (−logIC<sub>50</sub>
).</p>
</caption>
<graphic xlink:href="jm0102710f00004.tif" position="float" orientation="portrait"></graphic>
</fig>
<table-wrap id="jm0102710t00003" position="float" orientation="portrait"><label>3</label>
<caption><p>Predicted Binding Free Energy (kcal/mol) vs the Experimental Activity (−logIC<sub>50</sub>
) of AHPBAs and kni272</p>
</caption>
<oasis:table colsep="2" rowsep="2"><oasis:tgroup cols="6"><oasis:colspec colnum="1" colname="1"></oasis:colspec>
<oasis:colspec colnum="2" colname="2"></oasis:colspec>
<oasis:colspec colnum="3" colname="3"></oasis:colspec>
<oasis:colspec colnum="4" colname="4"></oasis:colspec>
<oasis:colspec colnum="5" colname="5"></oasis:colspec>
<oasis:colspec colnum="6" colname="6"></oasis:colspec>
<oasis:tbody><oasis:row><oasis:entry namest="1" nameend="1">compd</oasis:entry>
<oasis:entry namest="2" nameend="2">−logIC<sub>50</sub>
</oasis:entry>
<oasis:entry namest="3" nameend="3">Δ<italic toggle="yes">G
</italic>
(kcal/mol)</oasis:entry>
<oasis:entry namest="4" nameend="4">compd</oasis:entry>
<oasis:entry namest="5" nameend="5">−logIC<sub>50</sub>
</oasis:entry>
<oasis:entry namest="6" nameend="6">Δ<italic toggle="yes">G</italic>
(kcal/mol)
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>1</bold>
</oasis:entry>
<oasis:entry colname="2">8.10
</oasis:entry>
<oasis:entry colname="3">−14.81
</oasis:entry>
<oasis:entry colname="4"><bold>19</bold>
</oasis:entry>
<oasis:entry colname="5">8.49
</oasis:entry>
<oasis:entry colname="6">−15.02
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>2</bold>
</oasis:entry>
<oasis:entry colname="2">8.89
</oasis:entry>
<oasis:entry colname="3">−15.31
</oasis:entry>
<oasis:entry colname="4"><bold>20</bold>
</oasis:entry>
<oasis:entry colname="5">9.10
</oasis:entry>
<oasis:entry colname="6">−16.02
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>3</bold>
</oasis:entry>
<oasis:entry colname="2">8.77
</oasis:entry>
<oasis:entry colname="3">−15.48
</oasis:entry>
<oasis:entry colname="4"><bold>21</bold>
</oasis:entry>
<oasis:entry colname="5">8.55
</oasis:entry>
<oasis:entry colname="6">−14.96
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>4</bold>
</oasis:entry>
<oasis:entry colname="2">8.60
</oasis:entry>
<oasis:entry colname="3">−15.01
</oasis:entry>
<oasis:entry colname="4"><bold>22</bold>
</oasis:entry>
<oasis:entry colname="5">8.92
</oasis:entry>
<oasis:entry colname="6">−15.26
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>5</bold>
</oasis:entry>
<oasis:entry colname="2">8.46
</oasis:entry>
<oasis:entry colname="3">−15.25
</oasis:entry>
<oasis:entry colname="4"><bold>23</bold>
</oasis:entry>
<oasis:entry colname="5">9.10
</oasis:entry>
<oasis:entry colname="6">−15.05
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>6</bold>
</oasis:entry>
<oasis:entry colname="2">8.72
</oasis:entry>
<oasis:entry colname="3">−15.28
</oasis:entry>
<oasis:entry colname="4"><bold>24</bold>
</oasis:entry>
<oasis:entry colname="5">7.59
</oasis:entry>
<oasis:entry colname="6">−14.05
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>7</bold>
</oasis:entry>
<oasis:entry colname="2">8.68
</oasis:entry>
<oasis:entry colname="3">−15.15
</oasis:entry>
<oasis:entry colname="4"><bold>25</bold>
</oasis:entry>
<oasis:entry colname="5">7.96
</oasis:entry>
<oasis:entry colname="6">−14.15
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>8</bold>
</oasis:entry>
<oasis:entry colname="2">8.34
</oasis:entry>
<oasis:entry colname="3">−15.03
</oasis:entry>
<oasis:entry colname="4"><bold>26</bold>
</oasis:entry>
<oasis:entry colname="5">7.92
</oasis:entry>
<oasis:entry colname="6">−13.91
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>9</bold>
</oasis:entry>
<oasis:entry colname="2">8.20
</oasis:entry>
<oasis:entry colname="3">−14.90
</oasis:entry>
<oasis:entry colname="4"><bold>27</bold>
</oasis:entry>
<oasis:entry colname="5">8.44
</oasis:entry>
<oasis:entry colname="6">−14.92
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>10</bold>
</oasis:entry>
<oasis:entry colname="2">8.41
</oasis:entry>
<oasis:entry colname="3">−14.98
</oasis:entry>
<oasis:entry colname="4"><bold>1*</bold>
</oasis:entry>
<oasis:entry colname="5">6.00
</oasis:entry>
<oasis:entry colname="6">−11.18
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>11</bold>
</oasis:entry>
<oasis:entry colname="2">8.60
</oasis:entry>
<oasis:entry colname="3">−15.18
</oasis:entry>
<oasis:entry colname="4"><bold>2*</bold>
</oasis:entry>
<oasis:entry colname="5">6.00
</oasis:entry>
<oasis:entry colname="6">−11.29
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>12</bold>
</oasis:entry>
<oasis:entry colname="2">8.89
</oasis:entry>
<oasis:entry colname="3">−15.66
</oasis:entry>
<oasis:entry colname="4"><bold>3*</bold>
</oasis:entry>
<oasis:entry colname="5">7.41
</oasis:entry>
<oasis:entry colname="6">−13.31
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>13</bold>
</oasis:entry>
<oasis:entry colname="2">7.50
</oasis:entry>
<oasis:entry colname="3">−13.60
</oasis:entry>
<oasis:entry colname="4"><bold>4*</bold>
</oasis:entry>
<oasis:entry colname="5">8.05
</oasis:entry>
<oasis:entry colname="6">−14.42
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>14</bold>
</oasis:entry>
<oasis:entry colname="2">8.10
</oasis:entry>
<oasis:entry colname="3">−14.76
</oasis:entry>
<oasis:entry colname="4"><bold>5*</bold>
</oasis:entry>
<oasis:entry colname="5">8.82
</oasis:entry>
<oasis:entry colname="6">−15.08
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>15</bold>
</oasis:entry>
<oasis:entry colname="2">8.44
</oasis:entry>
<oasis:entry colname="3">−14.93
</oasis:entry>
<oasis:entry colname="4"><bold>6*</bold>
</oasis:entry>
<oasis:entry colname="5">8.47
</oasis:entry>
<oasis:entry colname="6">−15.06
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>16</bold>
</oasis:entry>
<oasis:entry colname="2">7.30
</oasis:entry>
<oasis:entry colname="3">−13.67
</oasis:entry>
<oasis:entry colname="4"><bold>7*</bold>
</oasis:entry>
<oasis:entry colname="5">8.89
</oasis:entry>
<oasis:entry colname="6">−15.40
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>17</bold>
</oasis:entry>
<oasis:entry colname="2">7.46
</oasis:entry>
<oasis:entry colname="3">−13.86
</oasis:entry>
<oasis:entry colname="4"><bold>8*</bold>
</oasis:entry>
<oasis:entry colname="5">8.27
</oasis:entry>
<oasis:entry colname="6">−14.78
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>18</bold>
</oasis:entry>
<oasis:entry colname="2">8.92
</oasis:entry>
<oasis:entry colname="3">−15.50
</oasis:entry>
<oasis:entry colname="4"><bold>9*</bold>
</oasis:entry>
<oasis:entry colname="5">7.85
</oasis:entry>
<oasis:entry colname="6">−13.89</oasis:entry>
</oasis:row>
</oasis:tbody>
</oasis:tgroup>
</oasis:table>
</table-wrap>
</p>
<p>It is obvious that there would be nearly 1.4 kcal/mol
difference in binding free energy if there is one order
numerical difference in the inhibitory potency (IC<sub>50</sub>
). As
listed in Table <xref rid="jm0102710t00004"></xref>
, the decreasing amount in binding free
energy caused by substitution from the meta to para
position relative to the hydroxyl group at Ar<sub>1</sub>
is greater
than that of substitution from the meta to ortho position. The methyl substitution at the meta position of
the Ar<sub>2</sub>
group may increase the binding affinity as
compared with that at the para position as judged from
the amount of binding free energy, which is in agreement with the data of the inhibitory potency (Table <xref rid="jm0102710t00004"></xref>
).
<table-wrap id="jm0102710t00004" position="float" orientation="portrait"><label>4</label>
<caption><p>Statistical Indexes of CoMFA, CoMSIA, and HQSAR Models Based on AHPBA Binding Conformers</p>
</caption>
<oasis:table colsep="2" rowsep="2"><oasis:tgroup cols="6"><oasis:colspec colnum="1" colname="1"></oasis:colspec>
<oasis:colspec colnum="2" colname="2"></oasis:colspec>
<oasis:colspec colnum="3" colname="3"></oasis:colspec>
<oasis:colspec colnum="4" colname="4"></oasis:colspec>
<oasis:colspec colnum="5" colname="5"></oasis:colspec>
<oasis:colspec colnum="6" colname="6"></oasis:colspec>
<oasis:tbody><oasis:row><oasis:entry colname="1"></oasis:entry>
<oasis:entry namest="2" nameend="3">cross-validated</oasis:entry>
<oasis:entry namest="4" nameend="6">conventional</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry namest="1" nameend="1"></oasis:entry>
<oasis:entry namest="2" nameend="2"><italic toggle="yes">r</italic>
<sub>cross</sub>
<sup>2</sup>
</oasis:entry>
<oasis:entry namest="3" nameend="3">optimal comp</oasis:entry>
<oasis:entry namest="4" nameend="4"><italic toggle="yes">r</italic>
<sup>2</sup>
</oasis:entry>
<oasis:entry namest="5" nameend="5">s</oasis:entry>
<oasis:entry namest="6" nameend="6"><italic toggle="yes">F</italic>
<sub>6,20</sub>
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">CoMFA
</oasis:entry>
<oasis:entry colname="2">0.613
</oasis:entry>
<oasis:entry colname="3">5
</oasis:entry>
<oasis:entry colname="4">0.978
</oasis:entry>
<oasis:entry colname="5">0.085
</oasis:entry>
<oasis:entry colname="6">149.159
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">CoMSIA
</oasis:entry>
<oasis:entry colname="2">0.530
</oasis:entry>
<oasis:entry colname="3">6
</oasis:entry>
<oasis:entry colname="4">0.970
</oasis:entry>
<oasis:entry colname="5">0.100
</oasis:entry>
<oasis:entry colname="6">106.709
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">steric (S)
</oasis:entry>
<oasis:entry colname="2">0.349
</oasis:entry>
<oasis:entry colname="3">6
</oasis:entry>
<oasis:entry colname="4">0.951
</oasis:entry>
<oasis:entry colname="5">0.127
</oasis:entry>
<oasis:entry colname="6">65.344
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">electrostatic (E)
</oasis:entry>
<oasis:entry colname="2">0.366
</oasis:entry>
<oasis:entry colname="3">3
</oasis:entry>
<oasis:entry colname="4">0.825
</oasis:entry>
<oasis:entry colname="5">0.241
</oasis:entry>
<oasis:entry colname="6">15.682
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">hydrophobic (H)
</oasis:entry>
<oasis:entry colname="2">0.422
</oasis:entry>
<oasis:entry colname="3">6
</oasis:entry>
<oasis:entry colname="4">0.949
</oasis:entry>
<oasis:entry colname="5">0.130
</oasis:entry>
<oasis:entry colname="6">61.861
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">HB acceptor
</oasis:entry>
<oasis:entry colname="2">0.453
</oasis:entry>
<oasis:entry colname="3">5
</oasis:entry>
<oasis:entry colname="4">0.818
</oasis:entry>
<oasis:entry colname="5">0.246
</oasis:entry>
<oasis:entry colname="6">14.966
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">HB donor
</oasis:entry>
<oasis:entry colname="2">0.373
</oasis:entry>
<oasis:entry colname="3">2
</oasis:entry>
<oasis:entry colname="4">0.782
</oasis:entry>
<oasis:entry colname="5">0.269
</oasis:entry>
<oasis:entry colname="6">11.960
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">HQSAR
</oasis:entry>
<oasis:entry colname="2">0.717
</oasis:entry>
<oasis:entry colname="3">5
</oasis:entry>
<oasis:entry colname="4">0.950
</oasis:entry>
<oasis:entry colname="5">0.128
</oasis:entry>
<oasis:entry colname="6">307 (BL)<italic toggle="yes"><sup>a</sup>
</italic>
<sup></sup>
</oasis:entry>
</oasis:row>
</oasis:tbody>
</oasis:tgroup>
</oasis:table>
<table-wrap-foot><p><italic toggle="yes"><sup>a</sup>
</italic>
<sup></sup>
Best length in the HQSAR model.</p>
</table-wrap-foot>
</table-wrap>
</p>
<p>The above relationship together with the interacting
mode of AHPBAs with HIVPR can enhance and complement the comprehension for the binding−inhibitory
potency relations deduced from experimental data.<named-content content-type="bibref-group"><xref rid="jm0102710b00010" ref-type="bibr"></xref>
,<xref rid="jm0102710b00046" ref-type="bibr"></xref>
−<xref rid="jm0102710b00047" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00048" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00049" ref-type="bibr"></xref>
</named-content>
The structure-based thermodynamic analyses, using the
isothermal titration calorimetry and other biological
assays,<named-content content-type="bibref-group"><xref rid="jm0102710b00010" ref-type="bibr"></xref>
,<xref rid="jm0102710b00047" ref-type="bibr"></xref>
−<xref rid="jm0102710b00048" ref-type="bibr"></xref>
</named-content>
had demonstrated the linkage between
the binding energetics of inhibitors and the structural
stability of HIVPR. The dissection of the thermodynamic
forces<sup>49</sup>
indicated that the high binding affinity of an
inhibitor with HIVPR came from the favorable binding
free energy. The structural and energetic explanation
herein is consistent with the viewpoints from these
experimental results. The values of the predicted binding free energies for AHPBAs (Table <xref rid="jm0102710t00003"></xref>
and Figure <xref rid="jm0102710f00004"></xref>
)
are at the same level with the experimental data.<named-content content-type="bibref-group"><xref rid="jm0102710b00047" ref-type="bibr"></xref>
−<xref rid="jm0102710b00048" specific-use="suppress-in-print" ref-type="bibr"></xref>
<xref rid="jm0102710b00049" ref-type="bibr"></xref>
</named-content>
Beyond the experimental studies, it is clearly illustrated
for the positional contribution of the substitution groups
to the binding of AHPBAs with HIVPR and the resulting
inhibitory potency against HIVPR.
</p>
<p>The sophisticated method for the calculation of binding free energy is the free energy perturbation (FEP)
approach.<named-content content-type="bibref-group"><xref rid="jm0102710b00050" ref-type="bibr"></xref>
,<xref rid="jm0102710b00051" ref-type="bibr"></xref>
</named-content>
However, the FEP approach is time-consuming; thus, it cannot be extended to predict the
binding affinities for a large set of molecules. Dominy
et al.<xref rid="jm0102710b00011" ref-type="bibr"></xref>
developed an empirical protocol for binding free
energy prediction based on the generation of protein−ligand complex ensembles and applied this method in
protein−ligand binding simulation of the HIV/FIV protease system. As compared with the FEP approach,<named-content content-type="bibref-group"><xref rid="jm0102710b00050" ref-type="bibr"></xref>
,<xref rid="jm0102710b00051" ref-type="bibr"></xref>
</named-content>
this empirical method saves a lot of computational
expense. It is still time-consuming if one uses this
method in predicting the binding affinities of a series
of molecules, for each ligand has to be docked into the
conformational ensembles derived from an amount of
X-ray crystal structures of the protein−ligand complex
or from the molecular dynamics simulations. Automated
molecular docking can identify the binding conformation
and predict the binding affinity very quickly; therefore,
it can be applied in constructing the prediction model
for a series of molecules in a tolerable time, as indicated
above that the inhibitory potency correlates well with
the AutoDock predicted binding free energy (eq 2 and
Figure <xref rid="jm0102710f00004"></xref>
). This relationship suggests that those potential HIVPR inhibitors exhibiting stronger binding free
energies using this paradigm would therefore be expected to have greater efficacy toward inhibitory action.
</p>
<p><bold>3. 3D-QSAR Models. 3.1. CoMFA. </bold>
Although CoMFA
is not able to appropriately describe all of the binding
force, being based principally on standard steric and
electrostatic molecular fields to model substrate−enzyme interactions, it is still a widely used tool for the
study of QSAR at the 3D level. The major objective of
CoMFA analysis about AHPBAs is to find the best
predictive model within the system. PLS analysis
results based on a least-squares fit are listed in Table
<xref rid="jm0102710t00004"></xref>
, which shows that all of the statistical indexes are
reasonably high. Table <xref rid="jm0102710t00005"></xref>
is compiled with the predicted
activities of these 27 AHPBAs by the 3D-QSAR model
vs their experimental inhibitory potencies (−logIC<sub>50</sub>
s).
As listed in Table <xref rid="jm0102710t00004"></xref>
, for a CoMFA model with a <italic toggle="yes">r</italic>
<sub>cv</sub>
<sup>2</sup>
value
of 0.613 for five components, a conventional <italic toggle="yes">r</italic>
<sup>2</sup>
of 0.978
is obtained based on the binding conformations and
their alignment in the active site of HIVPR. The linear
relationship shown in Figure <xref rid="jm0102710f00005"></xref>
indicates that the fitting
power is rational potent and the predictive ability is
satisfactory.
<fig id="jm0102710f00005" position="float" orientation="portrait"><label>5</label>
<caption><p>Correlation between the predicted activities (PA) by CoMFA (A), CoMSIA (B), and HQSAR (C) models and the experimental inhibitory potencies (−logIC<sub>50</sub>
) (·, compounds
of the training set; ▴, compounds of the testing set; ▪,
kni272).<named-content content-type="bibref-group"><xref rid="jm0102710b00028" ref-type="bibr"></xref>
,<xref rid="jm0102710b00046" ref-type="bibr"></xref>
</named-content>
</p>
</caption>
<graphic xlink:href="jm0102710f00005.tif" position="float" orientation="portrait"></graphic>
</fig>
<table-wrap id="jm0102710t00005" position="float" orientation="portrait"><label>5</label>
<caption><p>Predicted Activities (PA) vs Experimental Activities (EA, −logIC<sub>50</sub>
) and Residues (δ) by CoMFA, CoMSIA, and
HQSAR</p>
</caption>
<oasis:table colsep="2" rowsep="2"><oasis:tgroup cols="8"><oasis:colspec colnum="1" colname="1"></oasis:colspec>
<oasis:colspec colnum="2" colname="2"></oasis:colspec>
<oasis:colspec colnum="3" colname="3"></oasis:colspec>
<oasis:colspec colnum="4" colname="4"></oasis:colspec>
<oasis:colspec colnum="5" colname="5"></oasis:colspec>
<oasis:colspec colnum="6" colname="6"></oasis:colspec>
<oasis:colspec colnum="7" colname="7"></oasis:colspec>
<oasis:colspec colnum="8" colname="8"></oasis:colspec>
<oasis:tbody><oasis:row><oasis:entry colname="1"></oasis:entry>
<oasis:entry colname="2"></oasis:entry>
<oasis:entry namest="3" nameend="4">CoMFA</oasis:entry>
<oasis:entry namest="5" nameend="6">CoMSIA</oasis:entry>
<oasis:entry namest="7" nameend="8">HQSAR</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry namest="1" nameend="1">compd</oasis:entry>
<oasis:entry namest="2" nameend="2">EA</oasis:entry>
<oasis:entry namest="3" nameend="3">PA</oasis:entry>
<oasis:entry namest="4" nameend="4">δ</oasis:entry>
<oasis:entry namest="5" nameend="5">PA</oasis:entry>
<oasis:entry namest="6" nameend="6">δ</oasis:entry>
<oasis:entry namest="7" nameend="7">PA</oasis:entry>
<oasis:entry namest="8" nameend="8">δ
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>1</bold>
</oasis:entry>
<oasis:entry colname="2">8.10
</oasis:entry>
<oasis:entry colname="3">8.18
</oasis:entry>
<oasis:entry colname="4">−0.08
</oasis:entry>
<oasis:entry colname="5">8.20
</oasis:entry>
<oasis:entry colname="6">−0.10
</oasis:entry>
<oasis:entry colname="7">7.99
</oasis:entry>
<oasis:entry colname="8">0.11
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>2</bold>
</oasis:entry>
<oasis:entry colname="2">8.89
</oasis:entry>
<oasis:entry colname="3">8.98
</oasis:entry>
<oasis:entry colname="4">0.09
</oasis:entry>
<oasis:entry colname="5">8.79
</oasis:entry>
<oasis:entry colname="6">0.10
</oasis:entry>
<oasis:entry colname="7">8.93
</oasis:entry>
<oasis:entry colname="8">−0.04
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>3</bold>
</oasis:entry>
<oasis:entry colname="2">8.77
</oasis:entry>
<oasis:entry colname="3">8.84
</oasis:entry>
<oasis:entry colname="4">−0.07
</oasis:entry>
<oasis:entry colname="5">8.92
</oasis:entry>
<oasis:entry colname="6">−0.15
</oasis:entry>
<oasis:entry colname="7">8.88
</oasis:entry>
<oasis:entry colname="8">−0.11
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>4</bold>
</oasis:entry>
<oasis:entry colname="2">8.60
</oasis:entry>
<oasis:entry colname="3">8.66
</oasis:entry>
<oasis:entry colname="4">−0.06
</oasis:entry>
<oasis:entry colname="5">8.64
</oasis:entry>
<oasis:entry colname="6">−0.04
</oasis:entry>
<oasis:entry colname="7">8.65
</oasis:entry>
<oasis:entry colname="8">−0.05
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>5</bold>
</oasis:entry>
<oasis:entry colname="2">8.46
</oasis:entry>
<oasis:entry colname="3">8.34
</oasis:entry>
<oasis:entry colname="4">0.12
</oasis:entry>
<oasis:entry colname="5">8.31
</oasis:entry>
<oasis:entry colname="6">0.15
</oasis:entry>
<oasis:entry colname="7">8.41
</oasis:entry>
<oasis:entry colname="8">0.05
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>6</bold>
</oasis:entry>
<oasis:entry colname="2">8.72
</oasis:entry>
<oasis:entry colname="3">8.79
</oasis:entry>
<oasis:entry colname="4">−0.07
</oasis:entry>
<oasis:entry colname="5">8.68
</oasis:entry>
<oasis:entry colname="6">0.04
</oasis:entry>
<oasis:entry colname="7">8.78
</oasis:entry>
<oasis:entry colname="8">−0.06
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>7</bold>
</oasis:entry>
<oasis:entry colname="2">8.68
</oasis:entry>
<oasis:entry colname="3">8.70
</oasis:entry>
<oasis:entry colname="4">−0.02
</oasis:entry>
<oasis:entry colname="5">8.68
</oasis:entry>
<oasis:entry colname="6">0.00
</oasis:entry>
<oasis:entry colname="7">8.69
</oasis:entry>
<oasis:entry colname="8">−0.01
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>8</bold>
</oasis:entry>
<oasis:entry colname="2">8.34
</oasis:entry>
<oasis:entry colname="3">8.37
</oasis:entry>
<oasis:entry colname="4">−0.03
</oasis:entry>
<oasis:entry colname="5">8.40
</oasis:entry>
<oasis:entry colname="6">−0.06
</oasis:entry>
<oasis:entry colname="7">8.45
</oasis:entry>
<oasis:entry colname="8">−0.11
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>9</bold>
</oasis:entry>
<oasis:entry colname="2">8.20
</oasis:entry>
<oasis:entry colname="3">8.20
</oasis:entry>
<oasis:entry colname="4">0.00
</oasis:entry>
<oasis:entry colname="5">8.18
</oasis:entry>
<oasis:entry colname="6">0.02
</oasis:entry>
<oasis:entry colname="7">8.26
</oasis:entry>
<oasis:entry colname="8">−0.06
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>10</bold>
</oasis:entry>
<oasis:entry colname="2">8.41
</oasis:entry>
<oasis:entry colname="3">8.36
</oasis:entry>
<oasis:entry colname="4">0.05
</oasis:entry>
<oasis:entry colname="5">8.39
</oasis:entry>
<oasis:entry colname="6">0.02
</oasis:entry>
<oasis:entry colname="7">8.40
</oasis:entry>
<oasis:entry colname="8">0.01
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>11</bold>
</oasis:entry>
<oasis:entry colname="2">8.60
</oasis:entry>
<oasis:entry colname="3">8.62
</oasis:entry>
<oasis:entry colname="4">−0.02
</oasis:entry>
<oasis:entry colname="5">8.64
</oasis:entry>
<oasis:entry colname="6">−0.04
</oasis:entry>
<oasis:entry colname="7">8.44
</oasis:entry>
<oasis:entry colname="8">0.16
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>12</bold>
</oasis:entry>
<oasis:entry colname="2">8.89
</oasis:entry>
<oasis:entry colname="3">8.98
</oasis:entry>
<oasis:entry colname="4">−0.09
</oasis:entry>
<oasis:entry colname="5">8.96
</oasis:entry>
<oasis:entry colname="6">−0.07
</oasis:entry>
<oasis:entry colname="7">8.81
</oasis:entry>
<oasis:entry colname="8">0.08
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>13</bold>
</oasis:entry>
<oasis:entry colname="2">7.50
</oasis:entry>
<oasis:entry colname="3">7.45
</oasis:entry>
<oasis:entry colname="4">0.05
</oasis:entry>
<oasis:entry colname="5">7.42
</oasis:entry>
<oasis:entry colname="6">0.08
</oasis:entry>
<oasis:entry colname="7">7.50
</oasis:entry>
<oasis:entry colname="8">0.00
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>14</bold>
</oasis:entry>
<oasis:entry colname="2">8.10
</oasis:entry>
<oasis:entry colname="3">8.12
</oasis:entry>
<oasis:entry colname="4">−0.02
</oasis:entry>
<oasis:entry colname="5">8.14
</oasis:entry>
<oasis:entry colname="6">−0.04
</oasis:entry>
<oasis:entry colname="7">8.24
</oasis:entry>
<oasis:entry colname="8">−0.14
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>15</bold>
</oasis:entry>
<oasis:entry colname="2">8.44
</oasis:entry>
<oasis:entry colname="3">8.39
</oasis:entry>
<oasis:entry colname="4">0.05
</oasis:entry>
<oasis:entry colname="5">8.45
</oasis:entry>
<oasis:entry colname="6">−0.01
</oasis:entry>
<oasis:entry colname="7">8.34
</oasis:entry>
<oasis:entry colname="8">0.10
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>16</bold>
</oasis:entry>
<oasis:entry colname="2">7.30
</oasis:entry>
<oasis:entry colname="3">7.38
</oasis:entry>
<oasis:entry colname="4">−0.08
</oasis:entry>
<oasis:entry colname="5">7.29
</oasis:entry>
<oasis:entry colname="6">0.01
</oasis:entry>
<oasis:entry colname="7">7.35
</oasis:entry>
<oasis:entry colname="8">−0.05
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>17</bold>
</oasis:entry>
<oasis:entry colname="2">7.46
</oasis:entry>
<oasis:entry colname="3">7.38
</oasis:entry>
<oasis:entry colname="4">0.08
</oasis:entry>
<oasis:entry colname="5">7.42
</oasis:entry>
<oasis:entry colname="6">0.04
</oasis:entry>
<oasis:entry colname="7">7.44
</oasis:entry>
<oasis:entry colname="8">0.02
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>18</bold>
</oasis:entry>
<oasis:entry colname="2">8.92
</oasis:entry>
<oasis:entry colname="3">8.94
</oasis:entry>
<oasis:entry colname="4">−0.02
</oasis:entry>
<oasis:entry colname="5">8.95
</oasis:entry>
<oasis:entry colname="6">−0.03
</oasis:entry>
<oasis:entry colname="7">8.98
</oasis:entry>
<oasis:entry colname="8">−0.06
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>19</bold>
</oasis:entry>
<oasis:entry colname="2">8.49
</oasis:entry>
<oasis:entry colname="3">8.50
</oasis:entry>
<oasis:entry colname="4">−0.01
</oasis:entry>
<oasis:entry colname="5">8.52
</oasis:entry>
<oasis:entry colname="6">−0.03
</oasis:entry>
<oasis:entry colname="7">8.58
</oasis:entry>
<oasis:entry colname="8">−0.09
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>20</bold>
</oasis:entry>
<oasis:entry colname="2">9.10
</oasis:entry>
<oasis:entry colname="3">9.07
</oasis:entry>
<oasis:entry colname="4">0.03
</oasis:entry>
<oasis:entry colname="5">9.04
</oasis:entry>
<oasis:entry colname="6">0.06
</oasis:entry>
<oasis:entry colname="7">8.96
</oasis:entry>
<oasis:entry colname="8">0.14
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>21</bold>
</oasis:entry>
<oasis:entry colname="2">8.55
</oasis:entry>
<oasis:entry colname="3">8.54
</oasis:entry>
<oasis:entry colname="4">0.01
</oasis:entry>
<oasis:entry colname="5">8.56
</oasis:entry>
<oasis:entry colname="6">−0.01
</oasis:entry>
<oasis:entry colname="7">8.62
</oasis:entry>
<oasis:entry colname="8">−0.07
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>22</bold>
</oasis:entry>
<oasis:entry colname="2">8.92
</oasis:entry>
<oasis:entry colname="3">8.81
</oasis:entry>
<oasis:entry colname="4">0.11
</oasis:entry>
<oasis:entry colname="5">8.80
</oasis:entry>
<oasis:entry colname="6">0.12
</oasis:entry>
<oasis:entry colname="7">8.90
</oasis:entry>
<oasis:entry colname="8">0.02
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>23</bold>
</oasis:entry>
<oasis:entry colname="2">9.10
</oasis:entry>
<oasis:entry colname="3">9.01
</oasis:entry>
<oasis:entry colname="4">0.09
</oasis:entry>
<oasis:entry colname="5">8.99
</oasis:entry>
<oasis:entry colname="6">0.11
</oasis:entry>
<oasis:entry colname="7">8.95
</oasis:entry>
<oasis:entry colname="8">0.15
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>24</bold>
</oasis:entry>
<oasis:entry colname="2">7.59
</oasis:entry>
<oasis:entry colname="3">7.71
</oasis:entry>
<oasis:entry colname="4">−0.12
</oasis:entry>
<oasis:entry colname="5">7.70
</oasis:entry>
<oasis:entry colname="6">−0.11
</oasis:entry>
<oasis:entry colname="7">7.70
</oasis:entry>
<oasis:entry colname="8">−0.11
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>25</bold>
</oasis:entry>
<oasis:entry colname="2">7.96
</oasis:entry>
<oasis:entry colname="3">7.86
</oasis:entry>
<oasis:entry colname="4">0.10
</oasis:entry>
<oasis:entry colname="5">7.87
</oasis:entry>
<oasis:entry colname="6">0.09
</oasis:entry>
<oasis:entry colname="7">7.87
</oasis:entry>
<oasis:entry colname="8">0.09
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>26</bold>
</oasis:entry>
<oasis:entry colname="2">7.92
</oasis:entry>
<oasis:entry colname="3">7.90
</oasis:entry>
<oasis:entry colname="4">0.02
</oasis:entry>
<oasis:entry colname="5">7.94
</oasis:entry>
<oasis:entry colname="6">−0.02
</oasis:entry>
<oasis:entry colname="7">7.85
</oasis:entry>
<oasis:entry colname="8">0.07
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>27</bold>
</oasis:entry>
<oasis:entry colname="2">8.44
</oasis:entry>
<oasis:entry colname="3">8.43
</oasis:entry>
<oasis:entry colname="4">0.01
</oasis:entry>
<oasis:entry colname="5">8.42
</oasis:entry>
<oasis:entry colname="6">0.02
</oasis:entry>
<oasis:entry colname="7">8.54
</oasis:entry>
<oasis:entry colname="8">−0.10
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>1*</bold>
</oasis:entry>
<oasis:entry colname="2">6.00
</oasis:entry>
<oasis:entry colname="3">6.18
</oasis:entry>
<oasis:entry colname="4">−0.18
</oasis:entry>
<oasis:entry colname="5">5.96
</oasis:entry>
<oasis:entry colname="6">0.04
</oasis:entry>
<oasis:entry colname="7">6.21
</oasis:entry>
<oasis:entry colname="8">−0.21
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>2*</bold>
</oasis:entry>
<oasis:entry colname="2">6.00
</oasis:entry>
<oasis:entry colname="3">6.08
</oasis:entry>
<oasis:entry colname="4">−0.08
</oasis:entry>
<oasis:entry colname="5">5.93
</oasis:entry>
<oasis:entry colname="6">0.07
</oasis:entry>
<oasis:entry colname="7">5.91
</oasis:entry>
<oasis:entry colname="8">0.09
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>3*</bold>
</oasis:entry>
<oasis:entry colname="2">7.41
</oasis:entry>
<oasis:entry colname="3">7.21
</oasis:entry>
<oasis:entry colname="4">0.20
</oasis:entry>
<oasis:entry colname="5">7.39
</oasis:entry>
<oasis:entry colname="6">0.02
</oasis:entry>
<oasis:entry colname="7">7.43
</oasis:entry>
<oasis:entry colname="8">−0.02
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>4*</bold>
</oasis:entry>
<oasis:entry colname="2">8.05
</oasis:entry>
<oasis:entry colname="3">8.08
</oasis:entry>
<oasis:entry colname="4">−0.03
</oasis:entry>
<oasis:entry colname="5">8.15
</oasis:entry>
<oasis:entry colname="6">−0.10
</oasis:entry>
<oasis:entry colname="7">8.06
</oasis:entry>
<oasis:entry colname="8">−0.01
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>5*</bold>
</oasis:entry>
<oasis:entry colname="2">8.82
</oasis:entry>
<oasis:entry colname="3">8.72
</oasis:entry>
<oasis:entry colname="4">0.10
</oasis:entry>
<oasis:entry colname="5">8.68
</oasis:entry>
<oasis:entry colname="6">0.14
</oasis:entry>
<oasis:entry colname="7">8.90
</oasis:entry>
<oasis:entry colname="8">−0.08
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>6*</bold>
</oasis:entry>
<oasis:entry colname="2">8.47
</oasis:entry>
<oasis:entry colname="3">8.41
</oasis:entry>
<oasis:entry colname="4">0.06
</oasis:entry>
<oasis:entry colname="5">8.57
</oasis:entry>
<oasis:entry colname="6">0.10
</oasis:entry>
<oasis:entry colname="7">8.49
</oasis:entry>
<oasis:entry colname="8">−0.02
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>7*</bold>
</oasis:entry>
<oasis:entry colname="2">8.89
</oasis:entry>
<oasis:entry colname="3">8.95
</oasis:entry>
<oasis:entry colname="4">−0.06
</oasis:entry>
<oasis:entry colname="5">8.94
</oasis:entry>
<oasis:entry colname="6">−0.05
</oasis:entry>
<oasis:entry colname="7">8.79
</oasis:entry>
<oasis:entry colname="8">0.10
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>8*</bold>
</oasis:entry>
<oasis:entry colname="2">8.27
</oasis:entry>
<oasis:entry colname="3">8.28
</oasis:entry>
<oasis:entry colname="4">−0.01
</oasis:entry>
<oasis:entry colname="5">8.33
</oasis:entry>
<oasis:entry colname="6">−0.06
</oasis:entry>
<oasis:entry colname="7">8.27
</oasis:entry>
<oasis:entry colname="8">0.00
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1"><bold>9*</bold>
</oasis:entry>
<oasis:entry colname="2">7.85
</oasis:entry>
<oasis:entry colname="3">7.84
</oasis:entry>
<oasis:entry colname="4">0.01
</oasis:entry>
<oasis:entry colname="5">7.93
</oasis:entry>
<oasis:entry colname="6">−0.08
</oasis:entry>
<oasis:entry colname="7">7.89
</oasis:entry>
<oasis:entry colname="8">−0.04
</oasis:entry>
</oasis:row>
<oasis:row><oasis:entry colname="1">kni272*
</oasis:entry>
<oasis:entry colname="2">8.20<sup>46</sup>
</oasis:entry>
<oasis:entry colname="3">8.07
</oasis:entry>
<oasis:entry colname="4">0.13
</oasis:entry>
<oasis:entry colname="5">8.17
</oasis:entry>
<oasis:entry colname="6">0.03
</oasis:entry>
<oasis:entry colname="7">8.14
</oasis:entry>
<oasis:entry colname="8">0.06</oasis:entry>
</oasis:row>
</oasis:tbody>
</oasis:tgroup>
</oasis:table>
<table-wrap-foot><p>* Compounds that were not included in the construction of the
3D-QSAR models.</p>
</table-wrap-foot>
</table-wrap>
</p>
<p><bold>3.2. CoMSIA.</bold>
CoMSIA analysis results are also
summarized in Table <xref rid="jm0102710t00004"></xref>
. A CoMSIA model with an <italic toggle="yes">r</italic>
<sub>cross</sub>
<sup>2</sup>
value of 0.530 for six components and a conventional <italic toggle="yes">r</italic>
<sup>2</sup>
of 0.970 is obtained. These data demonstrate that the
CoMSIA model is also fairly predictive, and the predicted inhibitory potencies of AHPBA are listed in Table
<xref rid="jm0102710t00005"></xref>
and also shown in Figure <xref rid="jm0102710f00005"></xref>
. The highly conventional
<italic toggle="yes">r</italic>
<sup>2</sup>
results relating to five different descriptor variables
(steric, electrostatic, hydrophobic, and hydrogen bond
donor and acceptor) (Table <xref rid="jm0102710t00004"></xref>
) illustrate that these
variables are necessary not only to fully describe the
field properties around the AHPBA molecules but also
to fully describe the interaction mode of AHPBAs with
HIVPR.
</p>
<p><bold>3.3. HQSAR. </bold>
Table <xref rid="jm0102710t00004"></xref>
also shows a summary of the
HQSAR calculation results. These data show that the
least standard error occurs at a cross-validated <italic toggle="yes">r</italic>
<sup>2</sup>
(<italic toggle="yes">q</italic>
<sup>2</sup>
)
of 0.717 with five optimal components. The hologram
that gives the lowest standard error has a length of 307.
The PLS analysis yields a conventional <italic toggle="yes">r</italic>
<sup>2</sup>
of 0.950 for
the studied compounds. The predicted inhibitory potencies of AHPBAs against HIVPR are also listed in Table
<xref rid="jm0102710t00005"></xref>
, and their correlation is shown in Figure <xref rid="jm0102710f00005"></xref>
. It is
important to have a QSAR technique that offers not only
a consistent and reproducible prediction but also a fast
and convenient procedure. The HQSAR model in the
study appears well-suited for such application.
</p>
<p><bold>3.4. Testing of 3D-QSAR Models.</bold>
To test the
stability and predictive ability of the 3D-QSAR results
of AHPBAs, nine analogous compounds<sup>14-17</sup>
together
with compound kni272,<xref rid="jm0102710b00028" ref-type="bibr"></xref>
which was not included in the
construction of CoMFA, CoMSIA, and HQSAR models,
were selected as a set of testing for validation. The
results are simultaneously shown in Table <xref rid="jm0102710t00005"></xref>
(star-labeled compound numbers) and Figure <xref rid="jm0102710f00005"></xref>
(in triangle
and square pattern-labeled symbols), and the predicted
−logIC<sub>50</sub>
values are in good agreement with the experimental data in a statistically tolerable error range. To
investigate structural differences of binding mode between the testing set of compounds and the training set,
automated molecular docking was performed for the
testing set using the same method as that of the training
set. The geometrical parameters and the predicted
binding free energies for these compounds were also
compiled in Tables <xref rid="jm0102710t00002"></xref>
and <xref rid="jm0102710t00003"></xref>
and graphically shown in
Figures <xref rid="jm0102710f00002"></xref>
C and 4, respectively. As listed in Table <xref rid="jm0102710t00002"></xref>
and
shown in Figure <xref rid="jm0102710f00002"></xref>
C, the three torsion angles and the
conformational RMSD values as compared with kni272<sup>28</sup>
are in the same levels as that of the training set. The
torsion angle τ<sub>3</sub>
for compounds <bold>1*</bold>
−<bold>3*</bold>
, which indicates
the relative position of the aromatic ring in the Ar<sub>1</sub>
group and the adjacent carbonyl amide backbone, is
almost 30 degrees less than that of all others. This
means that the energy consumed for the conformational
change from the coplanar to out-of-planar state (binding
conformation) of these three compounds is much less
than that of the 3-OH's of the Ar<sub>1</sub>
compound. In other
words, the binding energies for compounds <bold>1*</bold>
−<bold>3*</bold>
must
be much lower. Inspecting the feature of the binding
conformation of compounds <bold>1*</bold>
−<bold>3*</bold>
, one intramolecular
hydrogen bond is formed between the −OH or the −NH<sub>2</sub>
of the Ar<sub>1</sub>
group and the oxygen atom of the adjacent
amide carbonyl group. Meanwhile, the typical hydrogen
bond between the −OH of the Ar<sub>1</sub>
group of AHPBAs and
the O<sup>δ1</sup>
of the Asp29 of HIVPR could not be formed. This
may be the structural and energetic source for the great
decrease of binding affinities and therefore the lower
inhibitory potencies for compounds <bold>1*</bold>
−<bold>3*</bold>
. The much
higher level of predicted binding free energies shown
in Table <xref rid="jm0102710t00003"></xref>
and Figure <xref rid="jm0102710f00004"></xref>
is the direct reflection and
testimony of the difference in the binding mode for
compounds <bold>1*</bold>
−<bold>3*</bold>
as compared with other inhibitors.
</p>
<p><bold>4. CoMFA Contour Map and Comparison with
HIVPR Topology. </bold>
The 3D “contour plots” produced by
CoMFA are shown in Figure <xref rid="jm0102710f00006"></xref>
. Colored polyhedras in
the map show these areas in 3D space where changes
in the field values for AHPBAs correlate strongly with
concomitant changes in inhibitory potencies. Detrimental and beneficial steric interactions are respectively
displayed in yellow and green contours, while blue and
red contours illustrate the regions of desirable positive
and negative electrostatic interactions. Some large
regions of green contour around the outside edge of the
Ar<sub>2</sub>
group suggest that more bulky substituents in these
positions will significantly improve the inhibitory potencies. The yellow polyhedral near the inside edge of the
para position of the above aromatic ring indicates that
more steric bulk is unfavorable for the inhibitory
potencies. The blue contours near the Ar<sub>1</sub>
and Ar<sub>2</sub>
group
suggest that positively charged substituents might
increase the biological activity. The small red polyhedral
around the Ar<sub>2</sub>
group indicates that high electron
density might play a favorable role in inhibitory potencies.
<fig id="jm0102710f00006" position="float" orientation="portrait"><label>6</label>
<caption><p>CoMFA contour maps as compared with the structural topology of the binding site in the AHPBA−HIVPR complex; only the residues within 5 Å around the inhibitor (compound<bold>20</bold>
) are shown in the stick style.</p>
</caption>
<graphic xlink:href="jm0102710f00006.tif" position="float" orientation="portrait"></graphic>
</fig>
</p>
<p>Combining the CoMFA contour map with the topology
of the HIVPR 3D structural binding site for AHPBAs,
several insights into the binding of AHPBAs with
HIVPR, which is described in the “interacting mode”
section, can also readily be observed from the CoMFA
map. The field property not only coincides well with the
environmental characteristics of the binding pocket but
also indicates that some further structural modification
of AHPBAs could be found. Most of the amino acids
around the AHPBAs in the binding pocket are hydrophobic in nature (Figure <xref rid="jm0102710f00006"></xref>
); this is consistent with the
CoMFA results about the relative field attribute. The
colored polyhedras of CoMFA located in the cavity of
the binding pocket are a direct index for the kinds and
magnitudes of the substituents selection in the process
of AHPBA analogues synthesis.
</p>
<p>Furthermore, some SARs of AHPBAs could highlight
the consistency between the 3D-QSAR results and the
complementary features of AHPBAs with the binding
site of HIVPR. Introducing a hydrophobic substituent
to the meta position of the hydroxyl group at Ar<sub>1</sub>
significantly increases the binding affinity of AHPBAs
with HIVPR.<xref rid="jm0102710b00017" ref-type="bibr"></xref>
The green polyhedral around the hydroxyl group of Ar<sub>1</sub>
coincides with the hydrophobic
pocket enwrapping the Ar<sub>1</sub>
group. The meta substituent
could be enlarged to some extent in order to intensify
the interaction between this part of Ar<sub>1</sub>
and the side
chains of residues Val32, Ile47, and Ile84 of HIVPR.
This may be the reason why the inhibitory activities of
compounds <bold>2</bold>
, <bold>3</bold>
, <bold>6</bold>
, <bold>7</bold>
, <bold>12</bold>
, <bold>18</bold>
, <bold>20</bold>
, and <bold>22</bold>
are higher than
other compounds that do not contain such substituents.
The meta substitution of a methyl group instead of
fluorine at Ar<sub>1</sub>
is more suitable because of the more
hydrophobic than electrostatic interaction requirement
of this subsite; thus, the inhibitory potencies of compounds have the order of <bold>2 </bold>
> <bold>3</bold>
and <bold>6 </bold>
> <bold>7</bold>
. The methyl
group at the ortho position of −OH in Ar<sub>1</sub>
(Table <xref rid="jm0102710t00001"></xref>
)
interacts with the aromatic ring of Ar<sub>2</sub>
in a mode of
alkane−π interaction<sup>37</sup>
(Figures <xref rid="jm0102710f00001"></xref>
, <xref rid="jm0102710f00003"></xref>
, and 6). This kind
of intramolecular interaction takes a symmetrical 3D
position with the alkane−π interaction between the
aromatic ring of Ar<sub>2</sub>
and the side chains of Val82‘ and
Ile84‘ in HIVPR (Figure <xref rid="jm0102710f00003"></xref>
). These alkane−π interactions
make the molecular energy of AHPBA lower, and it is
beneficial to the AHPBA−HIVPR complex formation.
</p>
<p>As one can see from Figure <xref rid="jm0102710f00006"></xref>
, the local hydrophobic
pocket at the S<sub>1</sub>
subsite is large enough to enwrap a
relatively large volume group. The more bulky aromatic
substitution could interact better with the side chains
of residues Leu23‘, Ile50, Pro81‘, Val82‘, and Ile84‘ of
HIVPR and therefore increase the inhibitory potencies
of AHPBAs. The two large green polyhedras situated
around the Ar<sub>2</sub>
group could demonstrate this point of
view, and the meta and/or para substitutions are the
best choice to intensify this local hydrophobic interaction. Therefore, it is natural that the inhibitory activities
of the compounds in Table <xref rid="jm0102710t00001"></xref>
have the order <bold>19 </bold>
> <bold>1</bold>
, <bold>20
</bold>
> <bold>2</bold>
, <bold>22 </bold>
> <bold>7</bold>
, <bold>11 </bold>
> <bold>9</bold>
, <bold>12 </bold>
> <bold>6</bold>
, and <bold>14 </bold>
> <bold>16</bold>
.
</p>
</sec>
<sec id="d7e2903"><title>Conclusion</title>
<p>We have obtained not only the probable binding
conformations but also the reasonable prediction of
binding free energies of AHPBAs with HIVPR employing the LGA algorithm of the AutoDock 3.0 program.<xref rid="jm0102710b00030" ref-type="bibr"></xref>
Modeling results indicate that the binding free energies
of AHPBAs calculated by this method correlate very well
with the reported inhibitory potencies against HIVPR<sup>14-17</sup>
and provide a structural and energetic explanation for
the differences in the binding affinities of AHPBAs with
HIVPR. On the basis of the binding conformations of
AHPBAs, we have developed stable and predictive 3D-QSAR models with acceptable <italic toggle="yes">r</italic>
<sub>cross</sub>
<sup>2</sup>
values by undertaking CoMFA, CoMSIA, and HQSAR techniques, and
these models could be mapped back to the structural
topology of the active site in HIVPR. This leads to a
better understanding of important AHPBA−HIVPR
interactions and thus provides guidelines for the structural modifications of the inhibitors and a predictive
model for scoring novel synthetic candidates.
</p>
<p>Typically, structure-based design is focused on the
elucidation of enzyme−substrate interactions but does
not always lead to predictive models. On the other hand,
3D-QSAR models do not necessarily reflect topological
features of the protein structure. These models are
generally constructed using alignment rules, which are
not always consistent with the characteristics of the
binding conformations. In this study, we successfully
combined these two approaches. The 3D-QSAR results
allow focus on those regions, where electrostatic, steric,
or hydrophobic effects have a dominant role in AHPBA−HIVPR interactions. The predictive ability testing for
the models has validated their robustness, so the
application of these models for quantitative prediction
of inhibitory potencies against HIVPR is possible within
a structurally limited range. Hence, for new candidates
as potential HIVPR inhibitors, reliable inhibitory activities can be computed by “interpolation”, and less reliable
IC<sub>50</sub>
's by “extrapolation” might be obtained for candidates with lower structural similarity to the training
set molecules.
</p>
</sec>
</body>
<back><ack><title>Acknowledgments</title>
<p>The authors are grateful for the
financial support from the National Natural Science
Foundation of China (Grant 29725203) and the State
Key Program of Basic Research of China (Grant
1998051115). We also acknowledge Prof. Arthur J.
Olson of the Scripps Research Institute in La Jolla, CA
for his provision of the AutoDock 3.0 program.
</p>
</ack>
<ref-list><title>References</title>
<ref id="jm0102710b00001"><element-citation publication-type="journal"><name name-style="western"><surname>Pearl</surname>
<given-names>L. H.</given-names>
</name>
<name name-style="western"><surname>Taylor</surname>
<given-names>W. R</given-names>
</name>
<article-title>A structural model for the retroviral proteases</article-title>
<source>Nature</source>
<year>1987</year>
<volume>329</volume>
<fpage>351</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1038/329351a0</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00002"><element-citation publication-type="journal"><name name-style="western"><surname>Ratner</surname>
<given-names>L.</given-names>
</name>
<name name-style="western"><surname>Haseltine</surname>
<given-names>W.</given-names>
</name>
<name name-style="western"><surname>Patarca</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Livak</surname>
<given-names>K. J.</given-names>
</name>
<name name-style="western"><surname>Starcich</surname>
<given-names>B.</given-names>
</name>
<name name-style="western"><surname>Josephs</surname>
<given-names>S. F.</given-names>
</name>
<name name-style="western"><surname>Doran</surname>
<given-names>E. R.</given-names>
</name>
<name name-style="western"><surname>Rafalski</surname>
<given-names>J. A.</given-names>
</name>
<name name-style="western"><surname>Whitehorn</surname>
<given-names>E. A.</given-names>
</name>
<name name-style="western"><surname>Baumeister</surname>
<given-names>K</given-names>
</name>
<article-title>Complete nucleotide sequence of the AIDS virus, HTLV-III</article-title>
<source>Nature</source>
<year>1985</year>
<volume>313</volume>
<fpage>277</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1038/313277a0</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00003"><element-citation publication-type="journal"><name name-style="western"><surname>Seelmeier</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Schmidt</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Turk</surname>
<given-names>V.</given-names>
</name>
<name name-style="western"><surname>von der Helm</surname>
<given-names>K</given-names>
</name>
<article-title>Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>1988</year>
<volume>85</volume>
<issue>18</issue>
<fpage>6612</fpage>
<lpage>6616</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.85.18.6612</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00004"><element-citation publication-type="journal"><name name-style="western"><surname>Appett</surname>
<given-names>K</given-names>
</name>
<article-title>Crystal structures of HIV-1 protease-inhibitors complexes</article-title>
<source>Perspect. Drug Discovery Des.</source>
<year>1993</year>
<volume>1</volume>
<fpage>23</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1007/BF02171654</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00005"><element-citation publication-type="journal"><name name-style="western"><surname>Kohl</surname>
<given-names>N. E.</given-names>
</name>
<name name-style="western"><surname>Emini</surname>
<given-names>E. A.</given-names>
</name>
<name name-style="western"><surname>Schleif</surname>
<given-names>W. A.</given-names>
</name>
<name name-style="western"><surname>Davis</surname>
<given-names>L. J.</given-names>
</name>
<name name-style="western"><surname>Heimbach</surname>
<given-names>J. C.</given-names>
</name>
<name name-style="western"><surname>Dixon</surname>
<given-names>R. A.</given-names>
</name>
<name name-style="western"><surname>Scolnick</surname>
<given-names>E. M.</given-names>
</name>
<name name-style="western"><surname>Sigal</surname>
<given-names>I. S</given-names>
</name>
<article-title>Active human immunodeficiency virus protease is required for viral infectivity</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>1988</year>
<volume>85</volume>
<fpage>4686</fpage>
<lpage>4690</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.85.13.4686</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00006"><element-citation publication-type="journal"><name name-style="western"><surname>McQuade</surname>
<given-names>T. J.</given-names>
</name>
<name name-style="western"><surname>Tomasselli</surname>
<given-names>A. G.</given-names>
</name>
<name name-style="western"><surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name name-style="western"><surname>Karacostas</surname>
<given-names>V.</given-names>
</name>
<name name-style="western"><surname>Moss</surname>
<given-names>B.</given-names>
</name>
<name name-style="western"><surname>Sawyer</surname>
<given-names>T. K.</given-names>
</name>
<name name-style="western"><surname>Heinrikson</surname>
<given-names>R. L.</given-names>
</name>
<name name-style="western"><surname>Tarpley</surname>
<given-names>W. G</given-names>
</name>
<article-title>A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation</article-title>
<source>Science</source>
<year>1990</year>
<volume>247</volume>
<fpage>454</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="doi">10.1126/science.2405486</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00007"><element-citation publication-type="journal"><name name-style="western"><surname>Pyring</surname>
<given-names>D.</given-names>
</name>
<name name-style="western"><surname>Lindberg</surname>
<given-names>J.</given-names>
</name>
<name name-style="western"><surname>Rosenquist</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Zuccarello</surname>
<given-names>G.</given-names>
</name>
<name name-style="western"><surname>Kvarnstrom</surname>
<given-names>I.</given-names>
</name>
<name name-style="western"><surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Vrang</surname>
<given-names>L.</given-names>
</name>
<name name-style="western"><surname>Unge</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Classon</surname>
<given-names>B.</given-names>
</name>
<name name-style="western"><surname>Hallberg</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Samuelsson</surname>
<given-names>B</given-names>
</name>
<article-title>Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution</article-title>
<source>J. Med. Chem.</source>
<year>2001</year>
<volume>44</volume>
<issue>19</issue>
<fpage>3083</fpage>
<lpage>3091</lpage>
<pub-id pub-id-type="doi">10.1021/jm001134q</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00008"><element-citation publication-type="journal"><name name-style="western"><surname>Rozzelle</surname>
<given-names>J. E.</given-names>
</name>
<name name-style="western"><surname>Dauber</surname>
<given-names>D. S.</given-names>
</name>
<name name-style="western"><surname>Todd</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Kelle</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Craik</surname>
<given-names>C. S</given-names>
</name>
<article-title>Macromolecular inhibitors of HIV-1 protease</article-title>
<source>J. Biol. Chem.</source>
<year>2000</year>
<volume>275</volume>
<fpage>7080</fpage>
<lpage>7086</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.275.10.7080</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00009"><element-citation publication-type="journal"><name name-style="western"><surname>Lee</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Laco</surname>
<given-names>G. S.</given-names>
</name>
<name name-style="western"><surname>Torbett</surname>
<given-names>B. E.</given-names>
</name>
<name name-style="western"><surname>Fox</surname>
<given-names>H. S.</given-names>
</name>
<name name-style="western"><surname>Lerner</surname>
<given-names>D. L.</given-names>
</name>
<name name-style="western"><surname>Elder</surname>
<given-names>J. H.</given-names>
</name>
<name name-style="western"><surname>Wong</surname>
<given-names>C. H</given-names>
</name>
<article-title>Analysis of the s3 and s3‘ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitors efficacious against FIV, SIV, and HIV in vitro and ex vivo</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>1998</year>
<volume>95</volume>
<fpage>934</fpage>
<lpage>944</lpage>
</element-citation>
</ref>
<ref id="jm0102710b00010"><element-citation publication-type="journal"><name name-style="western"><surname>Todd</surname>
<given-names>J. M.</given-names>
</name>
<name name-style="western"><surname>Freire</surname>
<given-names>E</given-names>
</name>
<article-title>The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease</article-title>
<source>Proteins: Struct., Funct., Genet.</source>
<year>1999</year>
<volume>36</volume>
<fpage>147</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1097-0134(19990801)36:2%3C147::AID-PROT2%3E3.0.CO;2-3</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00011"><element-citation publication-type="journal"><name name-style="western"><surname>Dominy</surname>
<given-names>B. N.</given-names>
</name>
<name name-style="western"><surname>Brooks</surname>
<given-names>C. L., </given-names>
<suffix>I</suffix>
</name>
<article-title>Methodology for protein-ligand binding studies: appilication to a model for drug resistance, the HIV/FIV protease system</article-title>
<source>Proteins: Struct., Funct., Genet.</source>
<year>1999</year>
<volume>36</volume>
<fpage>318</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1097-0134(19990815)36:3%3C318::AID-PROT6%3E3.0.CO;2-K</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00012"><mixed-citation><name name-style="western"><surname>Hagen</surname>
<given-names>S. E.</given-names>
</name>
; <name name-style="western"><surname>Domagala</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Gajda</surname>
<given-names>C.</given-names>
</name>
; <name name-style="western"><surname>Lovdahl</surname>
<given-names>M.</given-names>
</name>
; <name name-style="western"><surname>Tait</surname>
<given-names>B. D.</given-names>
</name>
; <name name-style="western"><surname>Wise</surname>
<given-names>E.</given-names>
</name>
; <name name-style="western"><surname>Holler</surname>
<given-names>T.</given-names>
</name>
; <name name-style="western"><surname>Hupe</surname>
<given-names>D.</given-names>
</name>
; <name name-style="western"><surname>Nouhan</surname>
<given-names>C.</given-names>
</name>
; <name name-style="western"><surname>Urumov</surname>
<given-names>A.</given-names>
</name>
; <name name-style="western"><surname>Zeikus</surname>
<given-names>G.</given-names>
</name>
; <name name-style="western"><surname>Zeikus</surname>
<given-names>E.</given-names>
</name>
; <name name-style="western"><surname>Lunney</surname>
<given-names>E. A.</given-names>
</name>
; <name name-style="western"><surname>Pavlovsky</surname>
<given-names>A.</given-names>
</name>
; <name name-style="western"><surname>Gracheck</surname>
<given-names>S. J.</given-names>
</name>
; <name name-style="western"><surname>Saunders</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>VanderRoest</surname>
<given-names>S.</given-names>
</name>
; <name name-style="western"><surname>Brodfuehrer</surname>
<given-names>J.</given-names>
</name>
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. <italic toggle="yes"> J. Med. Chem.</italic>
<bold>2001</bold>
, <italic toggle="yes">44 </italic>
(14), 2319−2332.<pub-id pub-id-type="doi">10.1021/jm0003844</pub-id>
</mixed-citation>
</ref>
<ref id="jm0102710b00013"><element-citation publication-type="journal"><name name-style="western"><surname>Hong</surname>
<given-names>L.</given-names>
</name>
<name name-style="western"><surname>Zhang</surname>
<given-names>X. J.</given-names>
</name>
<name name-style="western"><surname>Foundling</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Hartsuck</surname>
<given-names>J. A.</given-names>
</name>
<name name-style="western"><surname>Tang</surname>
<given-names>J</given-names>
</name>
<article-title>Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs</article-title>
<source>FEBS Lett.</source>
<year>1997</year>
<volume>420</volume>
<fpage>11</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(97)01477-4</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00014"><element-citation publication-type="journal"><name name-style="western"><surname>Sakurai</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Higashida</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Sugano</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Komai</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Yagi</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Ozawa</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Handa</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Nishigaki</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Yabe</surname>
<given-names>Y</given-names>
</name>
<article-title>Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA</article-title>
<source>Bioorg. Med. Chem.</source>
<year>1994</year>
<volume>2</volume>
<fpage>807</fpage>
<lpage>825</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0896(00)82181-1</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00015"><element-citation publication-type="journal"><name name-style="western"><surname>Komai</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Higashida</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Sakurai</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Nitta</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Kasuya</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Miyamaoto</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Yagi</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Ozawa</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Handa</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Mohri</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Yasuoka</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Oka</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Nishigaki</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Kimura</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name name-style="western"><surname>Yabe</surname>
<given-names>Y</given-names>
</name>
<article-title>Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA?II. Modification of pyrrolidine ring at P1‘ proline</article-title>
<source>Bioorg. Med. Chem.</source>
<year>1996</year>
<volume>4</volume>
<fpage>1365</fpage>
<lpage>1377</lpage>
<pub-id pub-id-type="doi">10.1016/0968-0896(96)00130-7</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00016"><element-citation publication-type="journal"><name name-style="western"><surname>Takashiro</surname>
<given-names>E.</given-names>
</name>
<name name-style="western"><surname>Watanabe</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Nitta</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Kasuya</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Miyamoto</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Ozawa</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Yagi</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Nishigaki</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Shibayama</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Nakagawa</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Iwamoto</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Yabe</surname>
<given-names>Y</given-names>
</name>
<article-title>Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site</article-title>
<source>Bioorg. Med. Chem.</source>
<year>1998</year>
<volume>6</volume>
<fpage>595</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0896(98)00004-2</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00017"><element-citation publication-type="journal"><name name-style="western"><surname>Takashiro</surname>
<given-names>E.</given-names>
</name>
<name name-style="western"><surname>Hayakawa</surname>
<given-names>I.</given-names>
</name>
<name name-style="western"><surname>Nitta</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Kasuya</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Miyamoto</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Ozawa</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Yagi</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Yamamoto</surname>
<given-names>I.</given-names>
</name>
<name name-style="western"><surname>Shibayama</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Nakagawa</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Yabe</surname>
<given-names>Y</given-names>
</name>
<article-title>Structure-activity relationship of HIV-1 protease inhibitors containing α-hydroxy-β-amino acids. Detailed study of P1 site</article-title>
<source>Bioorg. Med. Chem.</source>
<year>1999</year>
<volume>7</volume>
<fpage>2063</fpage>
<lpage>2072</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0896(99)00127-3</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00018"><mixed-citation><name name-style="western"><surname>Kaldor</surname>
<given-names>S. W.</given-names>
</name>
; <name name-style="western"><surname>Kalish</surname>
<given-names>V. J.</given-names>
</name>
; <name name-style="western"><surname>Davies</surname>
<given-names>J. F.</given-names>
</name>
; <name name-style="western"><surname>Shetty</surname>
<given-names>B. V.</given-names>
</name>
; <name name-style="western"><surname>Fritz</surname>
<given-names>J. E.</given-names>
</name>
; <name name-style="western"><surname>Appelt</surname>
<given-names>K.</given-names>
</name>
; <name name-style="western"><surname>Burgess</surname>
<given-names>J. A.</given-names>
</name>
; <name name-style="western"><surname>Campanale</surname>
<given-names>K. M.</given-names>
</name>
; <name name-style="western"><surname>Chirgadze</surname>
<given-names>N. Y.</given-names>
</name>
; <name name-style="western"><surname>Clawson</surname>
<given-names>D. K.</given-names>
</name>
; <name name-style="western"><surname>Dressman</surname>
<given-names>B. A.</given-names>
</name>
; <name name-style="western"><surname>Hatch</surname>
<given-names>S. D.</given-names>
</name>
; <name name-style="western"><surname>Khalil</surname>
<given-names>D. A.</given-names>
</name>
; <name name-style="western"><surname>Kosa</surname>
<given-names>M. B.</given-names>
</name>
; <name name-style="western"><surname>Lubbehusen</surname>
<given-names>P. P.</given-names>
</name>
; <name name-style="western"><surname>Muesing</surname>
<given-names>M. A.</given-names>
</name>
; <name name-style="western"><surname>Patick</surname>
<given-names>A. K.</given-names>
</name>
; <name name-style="western"><surname>Reich</surname>
<given-names>S. H.</given-names>
</name>
; <name name-style="western"><surname>Su</surname>
<given-names>K. S.</given-names>
</name>
; <name name-style="western"><surname>Tatlock</surname>
<given-names>J. H.</given-names>
</name>
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. <italic toggle="yes"> J. Med. Chem.</italic>
<bold>1997</bold>
, <italic toggle="yes">40</italic>
, 3979−3985.<pub-id pub-id-type="doi">10.1021/jm9704098</pub-id>
</mixed-citation>
</ref>
<ref id="jm0102710b00019"><element-citation publication-type="journal"><name name-style="western"><surname>Ringhofer</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Kallen</surname>
<given-names>J.</given-names>
</name>
<name name-style="western"><surname>Dutzler</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Billoch</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Visser</surname>
<given-names>A. J. W. G.</given-names>
</name>
<name name-style="western"><surname>Scholz</surname>
<given-names>D.</given-names>
</name>
<name name-style="western"><surname>Steinhauser</surname>
<given-names>O.</given-names>
</name>
<name name-style="western"><surname>Schreiber</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Auer</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Kungl</surname>
<given-names>A. J</given-names>
</name>
<article-title>X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor sdz283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations</article-title>
<source>J. Mol. Biol.</source>
<year>1999</year>
<volume>286</volume>
<fpage>1147</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.1006/jmbi.1998.2533</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00020"><element-citation publication-type="journal"><name name-style="western"><surname>Gupta</surname>
<given-names>S. P.</given-names>
</name>
<name name-style="western"><surname>Babu</surname>
<given-names>M. S</given-names>
</name>
<article-title>Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors</article-title>
<source>Bioorg. Med. Chem.</source>
<year>1999</year>
<volume>7</volume>
<fpage>2549</fpage>
<lpage>2553</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0896(99)00175-3</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00021"><element-citation publication-type="journal"><name name-style="western"><surname>Jiang</surname>
<given-names>H. L.</given-names>
</name>
<name name-style="western"><surname>Chen</surname>
<given-names>K. X.</given-names>
</name>
<name name-style="western"><surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Chen</surname>
<given-names>J. Z.</given-names>
</name>
<name name-style="western"><surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name name-style="western"><surname>Wang</surname>
<given-names>Q. M.</given-names>
</name>
<name name-style="western"><surname>Ji</surname>
<given-names>R. Y</given-names>
</name>
<article-title>Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human a-thrombin</article-title>
<source>J. Med. Chem.</source>
<year>1997</year>
<volume>40</volume>
<fpage>3085</fpage>
<lpage>3090</lpage>
<pub-id pub-id-type="doi">10.1021/jm960309m</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00022"><element-citation publication-type="journal"><name name-style="western"><surname>Cramer</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Cramer</surname>
<given-names>R. D.</given-names>
<suffix>III</suffix>
</name>
<name name-style="western"><surname>Jones</surname>
<given-names>D. M</given-names>
</name>
<article-title>Comparative molecular field analysis. 1. Effect of shape on binding of steroids to carrier proteins</article-title>
<source>J. Am. Chem. Soc.</source>
<year>1988</year>
<volume>110</volume>
<fpage>5959</fpage>
<lpage>5967</lpage>
<pub-id pub-id-type="doi">10.1021/ja00226a005</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00023"><element-citation publication-type="journal"><name name-style="western"><surname>Klebe</surname>
<given-names>G.</given-names>
</name>
<name name-style="western"><surname>Abraham</surname>
<given-names>U.</given-names>
</name>
<name name-style="western"><surname>Mietzner</surname>
<given-names>T</given-names>
</name>
<article-title>Molecular similarity indices in a comparative analysis(CoMSIA) of drug molecules to correlate and predict their biological activity</article-title>
<source>J. Med. Chem.</source>
<year>1994</year>
<volume>37</volume>
<fpage>4130</fpage>
<lpage>4146</lpage>
<pub-id pub-id-type="doi">10.1021/jm00050a010</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00024"><element-citation publication-type="journal"><name name-style="western"><surname>Tong</surname>
<given-names>W.</given-names>
</name>
<name name-style="western"><surname>Lowis</surname>
<given-names>D. R.</given-names>
</name>
<name name-style="western"><surname>Perkins</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Welsh</surname>
<given-names>W. J.</given-names>
</name>
<name name-style="western"><surname>Goddette</surname>
<given-names>D. W.</given-names>
</name>
<name name-style="western"><surname>Heritage</surname>
<given-names>T. W.</given-names>
</name>
<name name-style="western"><surname>Sheehan</surname>
<given-names>D. M</given-names>
</name>
<article-title>Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor</article-title>
<source>J. Chem. Inf. Comput. Sci.</source>
<year>1998</year>
<volume>38</volume>
<fpage>669</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1021/ci980008g</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00025"><mixed-citation><italic toggle="yes">Sybyl</italic>
, version 6.5; Tripos Associates: St. Louis, MO, 1998.</mixed-citation>
</ref>
<ref id="jm0102710b00026"><mixed-citation><name name-style="western"><surname>Frisch</surname>
<given-names>M. J.</given-names>
</name>
; <name name-style="western"><surname>Trucks</surname>
<given-names>G. W.</given-names>
</name>
; <name name-style="western"><surname>Schlegel</surname>
<given-names>H. B.</given-names>
</name>
; <name name-style="western"><surname>Scuseria</surname>
<given-names>G. E.</given-names>
</name>
; <name name-style="western"><surname>Robb</surname>
<given-names>M. A.</given-names>
</name>
; <name name-style="western"><surname>Cheeseman</surname>
<given-names>J. R.</given-names>
</name>
; <name name-style="western"><surname>Zakrzewski</surname>
<given-names>V. G.</given-names>
</name>
; <name name-style="western"><surname>Montgomery</surname>
<given-names>J. A.</given-names>
<suffix>Jr.</suffix>
</name>
; <name name-style="western"><surname>Stratmann</surname>
<given-names>R. E.</given-names>
</name>
; <name name-style="western"><surname>Burant</surname>
<given-names>J. C.</given-names>
</name>
; <name name-style="western"><surname>Dapprich</surname>
<given-names>S.</given-names>
</name>
; <name name-style="western"><surname>Millam</surname>
<given-names>J. M.</given-names>
</name>
; <name name-style="western"><surname>Daniels</surname>
<given-names>A. D.</given-names>
</name>
; <name name-style="western"><surname>Kudin</surname>
<given-names>K. N.</given-names>
</name>
; <name name-style="western"><surname>Strain</surname>
<given-names>M. C.</given-names>
</name>
; <name name-style="western"><surname>Farkas</surname>
<given-names>O.</given-names>
</name>
; <name name-style="western"><surname>Tomasi</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Barone</surname>
<given-names>V.</given-names>
</name>
; <name name-style="western"><surname>Cossi</surname>
<given-names>M.</given-names>
</name>
; <name name-style="western"><surname>Cammi</surname>
<given-names>R.</given-names>
</name>
; <name name-style="western"><surname>Mennucci</surname>
<given-names>B.</given-names>
</name>
; <name name-style="western"><surname>Pomelli</surname>
<given-names>C.</given-names>
</name>
; <name name-style="western"><surname>Adamo</surname>
<given-names>C.</given-names>
</name>
; <name name-style="western"><surname>Clifford</surname>
<given-names>S.</given-names>
</name>
; <name name-style="western"><surname>Ochterski</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Petersson</surname>
<given-names>G. A.</given-names>
</name>
; <name name-style="western"><surname>Ayala</surname>
<given-names>P. Y.</given-names>
</name>
; <name name-style="western"><surname>Cui</surname>
<given-names>Q.</given-names>
</name>
; <name name-style="western"><surname>Morokuma</surname>
<given-names>K.</given-names>
</name>
; <name name-style="western"><surname>Malick</surname>
<given-names>D. K.</given-names>
</name>
; <name name-style="western"><surname>Rabuck</surname>
<given-names>A. D.</given-names>
</name>
; <name name-style="western"><surname>Raghavachari</surname>
<given-names>K.</given-names>
</name>
; <name name-style="western"><surname>Foresman</surname>
<given-names>J. B.</given-names>
</name>
; <name name-style="western"><surname>Cioslowski</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Ortiz</surname>
<given-names>J. V.</given-names>
</name>
; <name name-style="western"><surname>Stefanov</surname>
<given-names>B. B.</given-names>
</name>
; <name name-style="western"><surname>Liu</surname>
<given-names>G.</given-names>
</name>
; <name name-style="western"><surname>Liashenko</surname>
<given-names>A.</given-names>
</name>
; <name name-style="western"><surname>Piskorz</surname>
<given-names>P.</given-names>
</name>
; <name name-style="western"><surname>Komaromi</surname>
<given-names>I.</given-names>
</name>
; <name name-style="western"><surname>Gomperts</surname>
<given-names>R.</given-names>
</name>
; <name name-style="western"><surname>Martin</surname>
<given-names>R. L.</given-names>
</name>
; <name name-style="western"><surname>Fox</surname>
<given-names>D. J.</given-names>
</name>
; <name name-style="western"><surname>Keith</surname>
<given-names>T.</given-names>
</name>
; <name name-style="western"><surname>Al-Laham</surname>
<given-names>M. A.</given-names>
</name>
; <name name-style="western"><surname>Peng</surname>
<given-names>C. Y.</given-names>
</name>
; <name name-style="western"><surname>Nanayakkara</surname>
<given-names>A.</given-names>
</name>
; <name name-style="western"><surname>Gonzalez</surname>
<given-names>C.</given-names>
</name>
; <name name-style="western"><surname>Challacombe</surname>
<given-names>M.</given-names>
</name>
; <name name-style="western"><surname>Gill</surname>
<given-names>P. M. W.</given-names>
</name>
; <name name-style="western"><surname>Johnson</surname>
<given-names>B. G.</given-names>
</name>
; <name name-style="western"><surname>Chen</surname>
<given-names>W.</given-names>
</name>
; <name name-style="western"><surname>Wong</surname>
<given-names>M. W.</given-names>
</name>
; <name name-style="western"><surname>Andres</surname>
<given-names>J. L.</given-names>
</name>
; <name name-style="western"><surname>Head-Gordon</surname>
<given-names>M.</given-names>
</name>
; <name name-style="western"><surname>Replogle</surname>
<given-names>E. S.</given-names>
</name>
; <name name-style="western"><surname>Pople</surname>
<given-names>J.</given-names>
</name>
A.<italic toggle="yes"> Gaussian 98</italic>
; Gaussian, Inc.: Pittsburgh, PA, 1998.</mixed-citation>
</ref>
<ref id="jm0102710b00027"><element-citation publication-type="journal"><name name-style="western"><surname>Purcel</surname>
<given-names>W. P.</given-names>
</name>
<name name-style="western"><surname>Singer</surname>
<given-names>J. A.</given-names>
</name>
<source>J. Chem. Eng. Data</source>
<year>1967</year>
<volume>12</volume>
<fpage>235</fpage>
<lpage>246</lpage>
<comment>. Details of the implementation are given in Sybyl 6.5 Theory Manual; Tripos: St. Louis, MO, 1998; p 69. </comment>
<pub-id pub-id-type="doi">10.1021/je60033a020</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00028"><element-citation publication-type="journal"><name name-style="western"><surname>Baldwin</surname>
<given-names>E. T.</given-names>
</name>
<name name-style="western"><surname>Bhat</surname>
<given-names>T. N.</given-names>
</name>
<name name-style="western"><surname>Gulnik</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name name-style="western"><surname>Topol</surname>
<given-names>I. A.</given-names>
</name>
<name name-style="western"><surname>Kiso</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Mimoto</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Mitsuya</surname>
<given-names>H.</given-names>
</name>
<name name-style="western"><surname>Erickson</surname>
<given-names>J. W</given-names>
</name>
<article-title>Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analogue containing allophenylnorstatine</article-title>
<source>Structure</source>
<year>1995</year>
<volume>3</volume>
<issue>6</issue>
<fpage>581</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1016/S0969-2126(01)00192-7</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00029"><mixed-citation><italic toggle="yes">InsightII</italic>
, version 98; Molecular Simulation Inc.: California, 1998.</mixed-citation>
</ref>
<ref id="jm0102710b00030"><element-citation publication-type="journal"><name name-style="western"><surname>Morris</surname>
<given-names>G. M.</given-names>
</name>
<name name-style="western"><surname>Goodsell</surname>
<given-names>D. S.</given-names>
</name>
<name name-style="western"><surname>Halliday</surname>
<given-names>R. S.</given-names>
</name>
<name name-style="western"><surname>Huey</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Hart</surname>
<given-names>W. E.</given-names>
</name>
<name name-style="western"><surname>Belew</surname>
<given-names>R. K.</given-names>
</name>
<name name-style="western"><surname>Olson</surname>
<given-names>A. J</given-names>
</name>
<article-title>Automated docking using Lamarckian genetic algorithm and empirical binding free energy function</article-title>
<source>J. Comput. Chem.</source>
<year>1998</year>
<volume>19</volume>
<fpage>1639</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-987X(19981115)19:14%3C1639::AID-JCC10%3E3.0.CO;2-B</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00031"><element-citation publication-type="journal"><name name-style="western"><surname>Solis</surname>
<given-names>F. J.</given-names>
</name>
<name name-style="western"><surname>Wets</surname>
<given-names>R. J. B</given-names>
</name>
<article-title>Minimization by random search techniques</article-title>
<source>Maths Opera. Res.</source>
<year>1981</year>
<volume>6</volume>
<fpage>19</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1287/moor.6.1.19</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00032"><element-citation publication-type="journal"><name name-style="western"><surname>Weiner</surname>
<given-names>S. J.</given-names>
</name>
<name name-style="western"><surname>Kollman</surname>
<given-names>P. A.</given-names>
</name>
<name name-style="western"><surname>Case</surname>
<given-names>D. A.</given-names>
</name>
<name name-style="western"><surname>Singh</surname>
<given-names>C.</given-names>
</name>
<name name-style="western"><surname>Ghio</surname>
<given-names>G.</given-names>
</name>
<name name-style="western"><surname>Alagona</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Profeta</surname>
<given-names>P.</given-names>
</name>
<name name-style="western"><surname>Weiner</surname>
<given-names>P.</given-names>
</name>
<source>J. Am. Chem. Soc.</source>
<year>1984</year>
<volume>106</volume>
<fpage>765</fpage>
<lpage>784</lpage>
<comment>. Details of the implementation are given in Sybyl 6.5 Theory Manual; Tripos: St. Louis, MO, 1998; p 441. </comment>
<pub-id pub-id-type="doi">10.1021/ja00315a051</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00033"><element-citation publication-type="journal"><name name-style="western"><surname>Morris</surname>
<given-names>G. M.</given-names>
</name>
<name name-style="western"><surname>Goodsell</surname>
<given-names>D. S.</given-names>
</name>
<name name-style="western"><surname>Huey</surname>
<given-names>R.</given-names>
</name>
<name name-style="western"><surname>Olson</surname>
<given-names>A. J</given-names>
</name>
<article-title>Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4</article-title>
<source>J. Comput.-Aided Mol. Des.</source>
<year>1996</year>
<volume>10</volume>
<fpage>293</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1007/BF00124499</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00034"><element-citation publication-type="journal"><name name-style="western"><surname>Ghose</surname>
<given-names>A. K.</given-names>
</name>
<name name-style="western"><surname>Viswanadhan</surname>
<given-names>V. N.</given-names>
</name>
<name name-style="western"><surname>Wendoloski</surname>
<given-names>J. J</given-names>
</name>
<article-title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</article-title>
<source>J. Comb. Chem.</source>
<year>1999</year>
<volume>1</volume>
<fpage>55</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1021/cc9800071</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00035"><element-citation publication-type="journal"><name name-style="western"><surname>Thompson</surname>
<given-names>W. J.</given-names>
</name>
<name name-style="western"><surname>Fitzgerald</surname>
<given-names>P. M.</given-names>
</name>
<name name-style="western"><surname>Holloway</surname>
<given-names>M. K.</given-names>
</name>
<name name-style="western"><surname>Emini</surname>
<given-names>E. A.</given-names>
</name>
<name name-style="western"><surname>Darke</surname>
<given-names>P. L.</given-names>
</name>
<name name-style="western"><surname>McKeever</surname>
<given-names>B. M.</given-names>
</name>
<name name-style="western"><surname>Schleif</surname>
<given-names>W. A.</given-names>
</name>
<name name-style="western"><surname>Quintero</surname>
<given-names>J. C.</given-names>
</name>
<name name-style="western"><surname>Zugay</surname>
<given-names>J. A.</given-names>
</name>
<name name-style="western"><surname>Tucker</surname>
<given-names>T. J.</given-names>
</name>
<name name-style="western"><surname>Schwering</surname>
<given-names>J. E.</given-names>
</name>
<name name-style="western"><surname>Homnick</surname>
<given-names>C. F.</given-names>
</name>
<name name-style="western"><surname>Nunberg</surname>
<given-names>J.</given-names>
</name>
<name name-style="western"><surname>Springer</surname>
<given-names>J. P.</given-names>
</name>
<name name-style="western"><surname>Juff</surname>
<given-names>J. R</given-names>
</name>
<article-title>Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1‘ phenyl substituents: X-ray crystal structure assisted design</article-title>
<source>J. Med. Chem.</source>
<year>1992</year>
<volume>35</volume>
<fpage>1685</fpage>
<lpage>1701</lpage>
<pub-id pub-id-type="doi">10.1021/jm00088a003</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00036"><element-citation publication-type="journal"><name name-style="western"><surname>Thanki</surname>
<given-names>N.</given-names>
</name>
<name name-style="western"><surname>Rao</surname>
<given-names>J. K.</given-names>
</name>
<name name-style="western"><surname>Foundling</surname>
<given-names>S. I.</given-names>
</name>
<name name-style="western"><surname>Howe</surname>
<given-names>W. J.</given-names>
</name>
<name name-style="western"><surname>Moon</surname>
<given-names>J. B.</given-names>
</name>
<name name-style="western"><surname>Hui</surname>
<given-names>J. O.</given-names>
</name>
<name name-style="western"><surname>Tomasselli</surname>
<given-names>A. G.</given-names>
</name>
<name name-style="western"><surname>Heinrikson</surname>
<given-names>R. L.</given-names>
</name>
<name name-style="western"><surname>Thaisrivongs</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Wlodawer</surname>
<given-names>A</given-names>
</name>
<article-title>Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling</article-title>
<source>Protein Sci.</source>
<year>1992</year>
<volume>1</volume>
<fpage>1061</fpage>
<lpage>1072</lpage>
<pub-id pub-id-type="doi">10.1002/pro.5560010811</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00037"><element-citation publication-type="journal"><name name-style="western"><surname>Kim</surname>
<given-names>K. S.</given-names>
</name>
<name name-style="western"><surname>Tarakeshwar</surname>
<given-names>P.</given-names>
</name>
<name name-style="western"><surname>Lee</surname>
<given-names>J. Y</given-names>
</name>
<article-title>Molecular clusters of π-systems: theoretical studies of structures, spectra, and origin of interaction energies</article-title>
<source>Chem. Rev.</source>
<year>2000</year>
<volume>100</volume>
<fpage>4145</fpage>
<lpage>4185</lpage>
<pub-id pub-id-type="doi">10.1021/cr990051i</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00038"><element-citation publication-type="journal"><name name-style="western"><surname>Head-Gordon</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Pople</surname>
<given-names>J. A</given-names>
</name>
<article-title>A Method for two-electron Gaussian integral and integral derivative evaluation using recurrence relations</article-title>
<source>J. Chem. Phys.</source>
<year>1988</year>
<volume>89</volume>
<fpage>5777</fpage>
<pub-id pub-id-type="doi">10.1063/1.455553</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00039"><mixed-citation>POV-ray-Team; <italic toggle="yes"> POV-ray</italic>
, version 3; 1999 (www.povray.org).</mixed-citation>
</ref>
<ref id="jm0102710b00040"><element-citation publication-type="journal"><name name-style="western"><surname>Wallace</surname>
<given-names>A. C.</given-names>
</name>
<name name-style="western"><surname>Laskowski</surname>
<given-names>R. A.</given-names>
</name>
<name name-style="western"><surname>Thornton</surname>
<given-names>J. M. LIGPLOT</given-names>
</name>
<article-title>A program to generate schematic diagrams of protein-ligand interactions</article-title>
<source>Protein Eng.</source>
<year>1995</year>
<volume>8</volume>
<fpage>127</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1093/protein/8.2.127</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00041"><mixed-citation><name name-style="western"><surname>Erickson</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Neidhart</surname>
<given-names>D. J.</given-names>
</name>
; <name name-style="western"><surname>VanDrie</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Kempf</surname>
<given-names>D. J.</given-names>
</name>
; <name name-style="western"><surname>Wang</surname>
<given-names>X. C.</given-names>
</name>
; <name name-style="western"><surname>Norbeck</surname>
<given-names>D. W.</given-names>
</name>
; <name name-style="western"><surname>Plattner</surname>
<given-names>J. J.</given-names>
</name>
; <name name-style="western"><surname>Rittenhouse</surname>
<given-names>J. W.</given-names>
</name>
; <name name-style="western"><surname>Turon</surname>
<given-names>M.</given-names>
</name>
; <name name-style="western"><surname>Wideburg</surname>
<given-names>N.</given-names>
</name>
; <name name-style="western"><surname>Kohlbrenner</surname>
<given-names>W. E.</given-names>
</name>
; <name name-style="western"><surname>Simmer</surname>
<given-names>R.</given-names>
</name>
; <name name-style="western"><surname>Helfrich</surname>
<given-names>R.</given-names>
</name>
; <name name-style="western"><surname>Paul</surname>
<given-names>D. A.</given-names>
</name>
; <name name-style="western"><surname>Knigge</surname>
<given-names>M.</given-names>
</name>
Design, activity, and 2.8 A crystal structure of a <italic toggle="yes">C</italic>
<italic toggle="yes"><sub>2</sub>
</italic>
symmetric inhibitor complexed to HIV-1 protease. <italic toggle="yes"> Science</italic>
<bold>1990</bold>
, 527−533.<pub-id pub-id-type="doi">10.1126/science.2200122</pub-id>
</mixed-citation>
</ref>
<ref id="jm0102710b00042"><element-citation publication-type="journal"><name name-style="western"><surname>Rosin</surname>
<given-names>C. D.</given-names>
</name>
<name name-style="western"><surname>Belew</surname>
<given-names>R. K.</given-names>
</name>
<name name-style="western"><surname>Walker</surname>
<given-names>W. L.</given-names>
</name>
<name name-style="western"><surname>Morris</surname>
<given-names>G. M.</given-names>
</name>
<name name-style="western"><surname>Olson</surname>
<given-names>A. J.</given-names>
</name>
<name name-style="western"><surname>Goodsell</surname>
<given-names>D. S</given-names>
</name>
<article-title>Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors</article-title>
<source>J. Mol. Biol.</source>
<year>1999</year>
<volume>287</volume>
<fpage>77</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1006/jmbi.1998.2579</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00043"><element-citation publication-type="journal"><name name-style="western"><surname>Nicholson</surname>
<given-names>L. K.</given-names>
</name>
<name name-style="western"><surname>Yamazaki</surname>
<given-names>T.</given-names>
</name>
<name name-style="western"><surname>Torchia</surname>
<given-names>D. A.</given-names>
</name>
<name name-style="western"><surname>Grzesiek</surname>
<given-names>S.</given-names>
</name>
<name name-style="western"><surname>Bax</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Stahl</surname>
<given-names>S. J.</given-names>
</name>
<name name-style="western"><surname>Kaufman</surname>
<given-names>J. D.</given-names>
</name>
<name name-style="western"><surname>Wingfield</surname>
<given-names>P. T.</given-names>
</name>
<name name-style="western"><surname>Lam</surname>
<given-names>P. Y.</given-names>
</name>
<name name-style="western"><surname>Jadhav</surname>
<given-names>P. K</given-names>
</name>
<article-title>Flexibility and function in HIV-1 protease</article-title>
<source>Nat. Struct. Biol.</source>
<year>1995</year>
<volume>2</volume>
<fpage>274</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1038/nsb0495-274</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00044"><element-citation publication-type="journal"><name name-style="western"><surname>Rosin</surname>
<given-names>C. D.</given-names>
</name>
<name name-style="western"><surname>Belew</surname>
<given-names>R. K.</given-names>
</name>
<name name-style="western"><surname>Morris</surname>
<given-names>G. M.</given-names>
</name>
<name name-style="western"><surname>Olson</surname>
<given-names>A. J.</given-names>
</name>
<name name-style="western"><surname>Goodsell</surname>
<given-names>D. S</given-names>
</name>
<article-title>Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>1999</year>
<volume>96</volume>
<fpage>1369</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.4.1369</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00045"><element-citation publication-type="journal"><name name-style="western"><surname>Stahle</surname>
<given-names>L.</given-names>
</name>
<name name-style="western"><surname>Wold</surname>
<given-names>S</given-names>
</name>
<article-title>Multivariate data analysis and experimental design in biomedical research</article-title>
<source>Prog. Med. Chem.</source>
<year>1988</year>
<volume>25</volume>
<fpage>291</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1016/S0079-6468(08)70281-9</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00046"><mixed-citation><name name-style="western"><surname>Mimoto</surname>
<given-names>T.</given-names>
</name>
; <name name-style="western"><surname>Imai</surname>
<given-names>J.</given-names>
</name>
; <name name-style="western"><surname>Kisanuki</surname>
<given-names>S.</given-names>
</name>
; <name name-style="western"><surname>Enomoto</surname>
<given-names>H.</given-names>
</name>
; <name name-style="western"><surname>Hattori</surname>
<given-names>N.</given-names>
</name>
; <name name-style="western"><surname>Akaji</surname>
<given-names>K.</given-names>
</name>
; <name name-style="western"><surname>Kiso</surname>
<given-names>Y.</given-names>
</name>
Kynostatin (kni)-227 and −272, highly potent anti-HIV agents: conformationally constrained inhiboitors of HIV protease containing allophenorstatine. <italic toggle="yes"> Chem. Pharm. Bull.</italic>
<bold>1992</bold>
, <italic toggle="yes">40</italic>
(8), 2251−2253.</mixed-citation>
</ref>
<ref id="jm0102710b00047"><element-citation publication-type="journal"><name name-style="western"><surname>Rick</surname>
<given-names>S. W.</given-names>
</name>
<name name-style="western"><surname>Topol</surname>
<given-names>I. A.</given-names>
</name>
<name name-style="western"><surname>Erickson</surname>
<given-names>J. W.</given-names>
</name>
<name name-style="western"><surname>Burt</surname>
<given-names>S. K</given-names>
</name>
<article-title>Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease</article-title>
<source>Protein Sci.</source>
<year>1998</year>
<volume>7</volume>
<issue>8</issue>
<fpage>1750</fpage>
<lpage>1756</lpage>
<pub-id pub-id-type="doi">10.1002/pro.5560070809</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00048"><element-citation publication-type="journal"><name name-style="western"><surname>Trylska</surname>
<given-names>J.</given-names>
</name>
<name name-style="western"><surname>Antosiewicz</surname>
<given-names>J.</given-names>
</name>
<name name-style="western"><surname>Geller</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Hodge</surname>
<given-names>C. N.</given-names>
</name>
<name name-style="western"><surname>Klabe</surname>
<given-names>R. M.</given-names>
</name>
<name name-style="western"><surname>Head</surname>
<given-names>M. S.</given-names>
</name>
<name name-style="western"><surname>Gilson</surname>
<given-names>M. K</given-names>
</name>
<article-title>Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease</article-title>
<source>Protein Sci.</source>
<year>1999</year>
<volume>8</volume>
<issue>1</issue>
<fpage>180</fpage>
<lpage>195</lpage>
</element-citation>
</ref>
<ref id="jm0102710b00049"><element-citation publication-type="journal"><name name-style="western"><surname>Velazquez-Campoy</surname>
<given-names>A.</given-names>
</name>
<name name-style="western"><surname>Luque</surname>
<given-names>I.</given-names>
</name>
<name name-style="western"><surname>Todd</surname>
<given-names>M. J.</given-names>
</name>
<name name-style="western"><surname>Milutinovich</surname>
<given-names>M.</given-names>
</name>
<name name-style="western"><surname>Kiso</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Freire</surname>
<given-names>E</given-names>
</name>
<article-title>Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor</article-title>
<source>Protein Sci.</source>
<year>2000</year>
<volume>9</volume>
<issue>9</issue>
<fpage>1801</fpage>
<lpage>1809</lpage>
<pub-id pub-id-type="doi">10.1110/ps.9.9.1801</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00050"><element-citation publication-type="journal"><name name-style="western"><surname>Kollman</surname>
<given-names>P</given-names>
</name>
<article-title>Free energy calculations: applications to chemical and biochemical phenomena</article-title>
<source>Chem. Rev.</source>
<year>1993</year>
<volume>93</volume>
<fpage>3</fpage>
<comment> (7), 2395-2417. </comment>
<pub-id pub-id-type="doi">10.1021/cr00023a004</pub-id>
</element-citation>
</ref>
<ref id="jm0102710b00051"><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name name-style="western"><surname>Duan</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western"><surname>Stouten</surname>
<given-names>P.</given-names>
</name>
<name name-style="western"><surname>De Lucca</surname>
<given-names>G. V.</given-names>
</name>
<name name-style="western"><surname>Klabe</surname>
<given-names>R. M.</given-names>
</name>
<name name-style="western"><surname>Kollman</surname>
<given-names>P</given-names>
</name>
<article-title>Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations</article-title>
<source>J. Comput.-Aided Mol. Des.</source>
<year>2001</year>
<volume>15</volume>
<issue>2</issue>
<fpage>145</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1023/A:1008156222963</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models</title>
</titleInfo>
<name type="personal"><namePart type="family">HUANG</namePart>
<namePart type="given">Xaioqin</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</affiliation>
<affiliation> Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="family">XU</namePart>
<namePart type="given">Liaosa</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Fudan University.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="family">LUO</namePart>
<namePart type="given">Xiaomin</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="family">FAN</namePart>
<namePart type="given">Kangnian</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Fudan University.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="family">JI</namePart>
<namePart type="given">Ruyun</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal" displayLabel="corresp"><namePart type="family">PEI</namePart>
<namePart type="given">Gang</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Shanghai Institute of Biochemistry and Cell Biology, ShanghaiInstitutes for Biological Sciences, Chinese Academy of Sciences.</affiliation>
<affiliation> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="family">CHEN</namePart>
<namePart type="given">Kaixian</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal" displayLabel="corresp"><namePart type="family">JIANG</namePart>
<namePart type="given">Hualiang</namePart>
<affiliation>Center for Drug Design and Discovery, State Key Laboratory of Drug Research, Shanghai Institute ofMateria Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 294 Taiyuan Road,Shanghai 200031, People's Republic of China, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200032, People's Republic of China, andDepartment of Chemistry, Fudan University, Shanghai 2000437, People's Republic of China</affiliation>
<affiliation> Shanghai Institute of Materia Medica, Shanghai Institutes forBiological Sciences, Chinese Academy of Sciences.</affiliation>
<affiliation> To whom correspondence should be addressed. Tel: +86-21-64311833 ext. 222. Fax: +86-21-64370269. E-mail: H.J., hljiang@mail.shcnc.ac.cn, jiang@iris3.simm.ac.cn; G.P., gpei@sibs.ac.cn.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>American Chemical Society</publisher>
<dateCreated encoding="w3cdtf">2001-12-08</dateCreated>
<dateIssued encoding="w3cdtf">2002-01-17</dateIssued>
<copyrightDate encoding="w3cdtf">2002</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<abstract>The Lamarckian genetic algorithm of AutoDock 3.0 has been used to dock 27 3(S)-amino-2(S)-hydroxyl-4-phenylbutanoic acids (AHPBAs) into the active site of HIV-1 protease (HIVPR). The binding mode was demonstrated in the aspects of the inhibitor's conformation, subsite interaction, and hydrogen bonding. The data of geometrical parameters (τ1, τ2, and τ3 listed in Table ) and root mean square deviation values as compared with the known inhibitor, kni272, show that both kinds of inhibitors interact with HIVPR in a very similar way. The r2 value of 0.860 indicates that the calculated binding free energies correlate well with the inhibitory activities. The structural and energetic differences in inhibitory potencies of AHPBAs were reasonably explored. Using the binding conformations of AHPBAs, consistent and highly predictive 3D-QSAR models were developed by performing CoMFA, CoMSIA, and HQSAR analyses. The reasonable rcorss2 values were 0.613, 0.530, and 0.717 for CoMFA, CoMSIA, and HQSAR models, respectively. The predictive ability of these models was validated by kni272 and a set of nine compounds that were not included in the training set. Mapping these models back to the topology of the active site of HIVPR leads to a better understanding of vital AHPBA−HIVPR interactions. Structural-based investigations and the final 3D-QSAR results provide clear guidelines and accurate activity predictions for novel HIVPR inhibitors.</abstract>
<relatedItem type="host"><titleInfo><title>Journal of Medicinal Chemistry</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J. Med. Chem.</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0022-2623</identifier>
<identifier type="eISSN">1520-4804</identifier>
<identifier type="acspubs">jm</identifier>
<identifier type="coden">JMCMAR</identifier>
<identifier type="uri">pubs.acs.org/jmc</identifier>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>45</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>333</start>
<end>343</end>
</extent>
</part>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00001" displayLabel="bibjm0102710b00001"><titleInfo><title>A structural model for the retroviral proteases</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>A structural model for the retroviral proteases</title>
</titleInfo>
<name type="personal"><namePart type="family">PEARL</namePart>
<namePart type="given">L. H.</namePart>
</name>
<name type="personal"><namePart type="family">TAYLOR</namePart>
<namePart type="given">W. R</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Nature</title>
</titleInfo>
<genre>journal</genre>
<part><date>1987</date>
<detail type="volume"><caption>vol.</caption>
<number>329</number>
</detail>
<extent unit="pages"><start>351</start>
<end>354</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00002" displayLabel="bibjm0102710b00002"><titleInfo><title>Complete nucleotide sequence of the AIDS virus, HTLV-III</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Complete nucleotide sequence of the AIDS virus, HTLV-III</title>
</titleInfo>
<name type="personal"><namePart type="family">RATNER</namePart>
<namePart type="given">L.</namePart>
</name>
<name type="personal"><namePart type="family">HASELTINE</namePart>
<namePart type="given">W.</namePart>
</name>
<name type="personal"><namePart type="family">PATARCA</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">LIVAK</namePart>
<namePart type="given">K. J.</namePart>
</name>
<name type="personal"><namePart type="family">STARCICH</namePart>
<namePart type="given">B.</namePart>
</name>
<name type="personal"><namePart type="family">JOSEPHS</namePart>
<namePart type="given">S. F.</namePart>
</name>
<name type="personal"><namePart type="family">DORAN</namePart>
<namePart type="given">E. R.</namePart>
</name>
<name type="personal"><namePart type="family">RAFALSKI</namePart>
<namePart type="given">J. A.</namePart>
</name>
<name type="personal"><namePart type="family">WHITEHORN</namePart>
<namePart type="given">E. A.</namePart>
</name>
<name type="personal"><namePart type="family">BAUMEISTER</namePart>
<namePart type="given">K</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Nature</title>
</titleInfo>
<genre>journal</genre>
<part><date>1985</date>
<detail type="volume"><caption>vol.</caption>
<number>313</number>
</detail>
<extent unit="pages"><start>277</start>
<end>284</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00003" displayLabel="bibjm0102710b00003"><titleInfo><title>Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A</title>
</titleInfo>
<name type="personal"><namePart type="family">SEELMEIER</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">SCHMIDT</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">TURK</namePart>
<namePart type="given">V.</namePart>
</name>
<name type="personal"><namePart type="family">VON DER HELM</namePart>
<namePart type="given">K</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U.S.A.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1988</date>
<detail type="volume"><caption>vol.</caption>
<number>85</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>18</number>
</detail>
<extent unit="pages"><start>6612</start>
<end>6616</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00004" displayLabel="bibjm0102710b00004"><titleInfo><title>Crystal structures of HIV-1 protease-inhibitors complexes</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Crystal structures of HIV-1 protease-inhibitors complexes</title>
</titleInfo>
<name type="personal"><namePart type="family">APPETT</namePart>
<namePart type="given">K</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Perspect. Drug Discovery Des.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1993</date>
<detail type="volume"><caption>vol.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>23</start>
<end>48</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00005" displayLabel="bibjm0102710b00005"><titleInfo><title>Active human immunodeficiency virus protease is required for viral infectivity</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Active human immunodeficiency virus protease is required for viral infectivity</title>
</titleInfo>
<name type="personal"><namePart type="family">KOHL</namePart>
<namePart type="given">N. E.</namePart>
</name>
<name type="personal"><namePart type="family">EMINI</namePart>
<namePart type="given">E. A.</namePart>
</name>
<name type="personal"><namePart type="family">SCHLEIF</namePart>
<namePart type="given">W. A.</namePart>
</name>
<name type="personal"><namePart type="family">DAVIS</namePart>
<namePart type="given">L. J.</namePart>
</name>
<name type="personal"><namePart type="family">HEIMBACH</namePart>
<namePart type="given">J. C.</namePart>
</name>
<name type="personal"><namePart type="family">DIXON</namePart>
<namePart type="given">R. A.</namePart>
</name>
<name type="personal"><namePart type="family">SCOLNICK</namePart>
<namePart type="given">E. M.</namePart>
</name>
<name type="personal"><namePart type="family">SIGAL</namePart>
<namePart type="given">I. S</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U.S.A.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1988</date>
<detail type="volume"><caption>vol.</caption>
<number>85</number>
</detail>
<extent unit="pages"><start>4686</start>
<end>4690</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00006" displayLabel="bibjm0102710b00006"><titleInfo><title>A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation</title>
</titleInfo>
<name type="personal"><namePart type="family">MCQUADE</namePart>
<namePart type="given">T. J.</namePart>
</name>
<name type="personal"><namePart type="family">TOMASSELLI</namePart>
<namePart type="given">A. G.</namePart>
</name>
<name type="personal"><namePart type="family">LIU</namePart>
<namePart type="given">L.</namePart>
</name>
<name type="personal"><namePart type="family">KARACOSTAS</namePart>
<namePart type="given">V.</namePart>
</name>
<name type="personal"><namePart type="family">MOSS</namePart>
<namePart type="given">B.</namePart>
</name>
<name type="personal"><namePart type="family">SAWYER</namePart>
<namePart type="given">T. K.</namePart>
</name>
<name type="personal"><namePart type="family">HEINRIKSON</namePart>
<namePart type="given">R. L.</namePart>
</name>
<name type="personal"><namePart type="family">TARPLEY</namePart>
<namePart type="given">W. G</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Science</title>
</titleInfo>
<genre>journal</genre>
<part><date>1990</date>
<detail type="volume"><caption>vol.</caption>
<number>247</number>
</detail>
<extent unit="pages"><start>454</start>
<end>456</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00007" displayLabel="bibjm0102710b00007"><titleInfo><title>Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution</title>
</titleInfo>
<name type="personal"><namePart type="family">PYRING</namePart>
<namePart type="given">D.</namePart>
</name>
<name type="personal"><namePart type="family">LINDBERG</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">ROSENQUIST</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">ZUCCARELLO</namePart>
<namePart type="given">G.</namePart>
</name>
<name type="personal"><namePart type="family">KVARNSTROM</namePart>
<namePart type="given">I.</namePart>
</name>
<name type="personal"><namePart type="family">ZHANG</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">VRANG</namePart>
<namePart type="given">L.</namePart>
</name>
<name type="personal"><namePart type="family">UNGE</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">CLASSON</namePart>
<namePart type="given">B.</namePart>
</name>
<name type="personal"><namePart type="family">HALLBERG</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">SAMUELSSON</namePart>
<namePart type="given">B</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>44</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>19</number>
</detail>
<extent unit="pages"><start>3083</start>
<end>3091</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00008" displayLabel="bibjm0102710b00008"><titleInfo><title>Macromolecular inhibitors of HIV-1 protease</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Macromolecular inhibitors of HIV-1 protease</title>
</titleInfo>
<name type="personal"><namePart type="family">ROZZELLE</namePart>
<namePart type="given">J. E.</namePart>
</name>
<name type="personal"><namePart type="family">DAUBER</namePart>
<namePart type="given">D. S.</namePart>
</name>
<name type="personal"><namePart type="family">TODD</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">KELLE</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">CRAIK</namePart>
<namePart type="given">C. S</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Biol. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>275</number>
</detail>
<extent unit="pages"><start>7080</start>
<end>7086</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00009" displayLabel="bibjm0102710b00009"><titleInfo><title>Analysis of the s3 and s3‘ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitors efficacious against FIV, SIV, and HIV in vitro and ex vivo</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Analysis of the s3 and s3‘ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitors efficacious against FIV, SIV, and HIV in vitro and ex vivo</title>
</titleInfo>
<name type="personal"><namePart type="family">LEE</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">LACO</namePart>
<namePart type="given">G. S.</namePart>
</name>
<name type="personal"><namePart type="family">TORBETT</namePart>
<namePart type="given">B. E.</namePart>
</name>
<name type="personal"><namePart type="family">FOX</namePart>
<namePart type="given">H. S.</namePart>
</name>
<name type="personal"><namePart type="family">LERNER</namePart>
<namePart type="given">D. L.</namePart>
</name>
<name type="personal"><namePart type="family">ELDER</namePart>
<namePart type="given">J. H.</namePart>
</name>
<name type="personal"><namePart type="family">WONG</namePart>
<namePart type="given">C. H</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U.S.A.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>95</number>
</detail>
<extent unit="pages"><start>934</start>
<end>944</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00010" displayLabel="bibjm0102710b00010"><titleInfo><title>The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease</title>
</titleInfo>
<name type="personal"><namePart type="family">TODD</namePart>
<namePart type="given">J. M.</namePart>
</name>
<name type="personal"><namePart type="family">FREIRE</namePart>
<namePart type="given">E</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Proteins: Struct., Funct., Genet.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>147</start>
<end>156</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00011" displayLabel="bibjm0102710b00011"><titleInfo><title>Methodology for protein-ligand binding studies: appilication to a model for drug resistance, the HIV/FIV protease system</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Methodology for protein-ligand binding studies: appilication to a model for drug resistance, the HIV/FIV protease system</title>
</titleInfo>
<name type="personal"><namePart type="family">DOMINY</namePart>
<namePart type="given">B. N.</namePart>
</name>
<name type="personal"><namePart type="family">BROOKS</namePart>
<namePart type="given">C. L.,</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Proteins: Struct., Funct., Genet.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>318</start>
<end>331</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00012" displayLabel="bibjm0102710b00012"><name type="personal"><namePart type="family">HAGEN</namePart>
<namePart type="given">S. E.</namePart>
</name>
<name type="personal"><namePart type="family">DOMAGALA</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">GAJDA</namePart>
<namePart type="given">C.</namePart>
</name>
<name type="personal"><namePart type="family">LOVDAHL</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">TAIT</namePart>
<namePart type="given">B. D.</namePart>
</name>
<name type="personal"><namePart type="family">WISE</namePart>
<namePart type="given">E.</namePart>
</name>
<name type="personal"><namePart type="family">HOLLER</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">HUPE</namePart>
<namePart type="given">D.</namePart>
</name>
<name type="personal"><namePart type="family">NOUHAN</namePart>
<namePart type="given">C.</namePart>
</name>
<name type="personal"><namePart type="family">URUMOV</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">ZEIKUS</namePart>
<namePart type="given">G.</namePart>
</name>
<name type="personal"><namePart type="family">ZEIKUS</namePart>
<namePart type="given">E.</namePart>
</name>
<name type="personal"><namePart type="family">LUNNEY</namePart>
<namePart type="given">E. A.</namePart>
</name>
<name type="personal"><namePart type="family">PAVLOVSKY</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">GRACHECK</namePart>
<namePart type="given">S. J.</namePart>
</name>
<name type="personal"><namePart type="family">SAUNDERS</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">VANDERROEST</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">BRODFUEHRER</namePart>
<namePart type="given">J.</namePart>
</name>
<titleInfo><title> J. Med. Chem.</title>
</titleInfo>
<note type="content-in-line">HagenS. E.; DomagalaJ.; GajdaC.; LovdahlM.; TaitB. D.; WiseE.; HollerT.; HupeD.; NouhanC.; UrumovA.; ZeikusG.; ZeikusE.; LunneyE. A.; PavlovskyA.; GracheckS. J.; SaundersJ.; VanderRoestS.; BrodfuehrerJ. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J. Med. Chem. 2001, 44 (14), 2319−2332.10.1021/jm0003844</note>
<identifier type="doi">10.1021/jm0003844</identifier>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00013" displayLabel="bibjm0102710b00013"><titleInfo><title>Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs</title>
</titleInfo>
<name type="personal"><namePart type="family">HONG</namePart>
<namePart type="given">L.</namePart>
</name>
<name type="personal"><namePart type="family">ZHANG</namePart>
<namePart type="given">X. J.</namePart>
</name>
<name type="personal"><namePart type="family">FOUNDLING</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">HARTSUCK</namePart>
<namePart type="given">J. A.</namePart>
</name>
<name type="personal"><namePart type="family">TANG</namePart>
<namePart type="given">J</namePart>
</name>
<relatedItem type="host"><titleInfo><title>FEBS Lett.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>420</number>
</detail>
<extent unit="pages"><start>11</start>
<end>16</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00014" displayLabel="bibjm0102710b00014"><titleInfo><title>Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA</title>
</titleInfo>
<name type="personal"><namePart type="family">SAKURAI</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">HIGASHIDA</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">SUGANO</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">KOMAI</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">YAGI</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">OZAWA</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">HANDA</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">NISHIGAKI</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">YABE</namePart>
<namePart type="given">Y</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Bioorg. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>807</start>
<end>825</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00015" displayLabel="bibjm0102710b00015"><titleInfo><title>Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA?II. Modification of pyrrolidine ring at P1‘ proline</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA?II. Modification of pyrrolidine ring at P1‘ proline</title>
</titleInfo>
<name type="personal"><namePart type="family">KOMAI</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">HIGASHIDA</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">SAKURAI</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">NITTA</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">KASUYA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">MIYAMAOTO</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">YAGI</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">OZAWA</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">HANDA</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">MOHRI</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">YASUOKA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">OKA</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">NISHIGAKI</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">KIMURA</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">SHIMADA</namePart>
<namePart type="given">K.</namePart>
</name>
<name type="personal"><namePart type="family">YABE</namePart>
<namePart type="given">Y</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Bioorg. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>4</number>
</detail>
<extent unit="pages"><start>1365</start>
<end>1377</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00016" displayLabel="bibjm0102710b00016"><titleInfo><title>Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site</title>
</titleInfo>
<name type="personal"><namePart type="family">TAKASHIRO</namePart>
<namePart type="given">E.</namePart>
</name>
<name type="personal"><namePart type="family">WATANABE</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">NITTA</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">KASUYA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">MIYAMOTO</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">OZAWA</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">YAGI</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">NISHIGAKI</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">SHIBAYAMA</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">NAKAGAWA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">IWAMOTO</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">YABE</namePart>
<namePart type="given">Y</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Bioorg. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>595</start>
<end>604</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00017" displayLabel="bibjm0102710b00017"><titleInfo><title>Structure-activity relationship of HIV-1 protease inhibitors containing α-hydroxy-β-amino acids. Detailed study of P1 site</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Structure-activity relationship of HIV-1 protease inhibitors containing α-hydroxy-β-amino acids. Detailed study of P1 site</title>
</titleInfo>
<name type="personal"><namePart type="family">TAKASHIRO</namePart>
<namePart type="given">E.</namePart>
</name>
<name type="personal"><namePart type="family">HAYAKAWA</namePart>
<namePart type="given">I.</namePart>
</name>
<name type="personal"><namePart type="family">NITTA</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">KASUYA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">MIYAMOTO</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">OZAWA</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">YAGI</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">YAMAMOTO</namePart>
<namePart type="given">I.</namePart>
</name>
<name type="personal"><namePart type="family">SHIBAYAMA</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">NAKAGAWA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">YABE</namePart>
<namePart type="given">Y</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Bioorg. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>7</number>
</detail>
<extent unit="pages"><start>2063</start>
<end>2072</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00018" displayLabel="bibjm0102710b00018"><name type="personal"><namePart type="family">KALDOR</namePart>
<namePart type="given">S. W.</namePart>
</name>
<name type="personal"><namePart type="family">KALISH</namePart>
<namePart type="given">V. J.</namePart>
</name>
<name type="personal"><namePart type="family">DAVIES</namePart>
<namePart type="given">J. F.</namePart>
</name>
<name type="personal"><namePart type="family">SHETTY</namePart>
<namePart type="given">B. V.</namePart>
</name>
<name type="personal"><namePart type="family">FRITZ</namePart>
<namePart type="given">J. E.</namePart>
</name>
<name type="personal"><namePart type="family">APPELT</namePart>
<namePart type="given">K.</namePart>
</name>
<name type="personal"><namePart type="family">BURGESS</namePart>
<namePart type="given">J. A.</namePart>
</name>
<name type="personal"><namePart type="family">CAMPANALE</namePart>
<namePart type="given">K. M.</namePart>
</name>
<name type="personal"><namePart type="family">CHIRGADZE</namePart>
<namePart type="given">N. Y.</namePart>
</name>
<name type="personal"><namePart type="family">CLAWSON</namePart>
<namePart type="given">D. K.</namePart>
</name>
<name type="personal"><namePart type="family">DRESSMAN</namePart>
<namePart type="given">B. A.</namePart>
</name>
<name type="personal"><namePart type="family">HATCH</namePart>
<namePart type="given">S. D.</namePart>
</name>
<name type="personal"><namePart type="family">KHALIL</namePart>
<namePart type="given">D. A.</namePart>
</name>
<name type="personal"><namePart type="family">KOSA</namePart>
<namePart type="given">M. B.</namePart>
</name>
<name type="personal"><namePart type="family">LUBBEHUSEN</namePart>
<namePart type="given">P. P.</namePart>
</name>
<name type="personal"><namePart type="family">MUESING</namePart>
<namePart type="given">M. A.</namePart>
</name>
<name type="personal"><namePart type="family">PATICK</namePart>
<namePart type="given">A. K.</namePart>
</name>
<name type="personal"><namePart type="family">REICH</namePart>
<namePart type="given">S. H.</namePart>
</name>
<name type="personal"><namePart type="family">SU</namePart>
<namePart type="given">K. S.</namePart>
</name>
<name type="personal"><namePart type="family">TATLOCK</namePart>
<namePart type="given">J. H.</namePart>
</name>
<titleInfo><title> J. Med. Chem.</title>
</titleInfo>
<note type="content-in-line">KaldorS. W.; KalishV. J.; DaviesJ. F.; ShettyB. V.; FritzJ. E.; AppeltK.; BurgessJ. A.; CampanaleK. M.; ChirgadzeN. Y.; ClawsonD. K.; DressmanB. A.; HatchS. D.; KhalilD. A.; KosaM. B.; LubbehusenP. P.; MuesingM. A.; PatickA. K.; ReichS. H.; SuK. S.; TatlockJ. H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979−3985.10.1021/jm9704098</note>
<identifier type="doi">10.1021/jm9704098</identifier>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00019" displayLabel="bibjm0102710b00019"><titleInfo><title>X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor sdz283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor sdz283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations</title>
</titleInfo>
<name type="personal"><namePart type="family">RINGHOFER</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">KALLEN</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">DUTZLER</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">BILLOCH</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">VISSER</namePart>
<namePart type="given">A. J. W. G.</namePart>
</name>
<name type="personal"><namePart type="family">SCHOLZ</namePart>
<namePart type="given">D.</namePart>
</name>
<name type="personal"><namePart type="family">STEINHAUSER</namePart>
<namePart type="given">O.</namePart>
</name>
<name type="personal"><namePart type="family">SCHREIBER</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">AUER</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">KUNGL</namePart>
<namePart type="given">A. J</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Mol. Biol.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>286</number>
</detail>
<extent unit="pages"><start>1147</start>
<end>1159</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00020" displayLabel="bibjm0102710b00020"><titleInfo><title>Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors</title>
</titleInfo>
<name type="personal"><namePart type="family">GUPTA</namePart>
<namePart type="given">S. P.</namePart>
</name>
<name type="personal"><namePart type="family">BABU</namePart>
<namePart type="given">M. S</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Bioorg. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>7</number>
</detail>
<extent unit="pages"><start>2549</start>
<end>2553</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00021" displayLabel="bibjm0102710b00021"><titleInfo><title>Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human a-thrombin</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human a-thrombin</title>
</titleInfo>
<name type="personal"><namePart type="family">JIANG</namePart>
<namePart type="given">H. L.</namePart>
</name>
<name type="personal"><namePart type="family">CHEN</namePart>
<namePart type="given">K. X.</namePart>
</name>
<name type="personal"><namePart type="family">TANG</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">CHEN</namePart>
<namePart type="given">J. Z.</namePart>
</name>
<name type="personal"><namePart type="family">LI</namePart>
<namePart type="given">Q.</namePart>
</name>
<name type="personal"><namePart type="family">WANG</namePart>
<namePart type="given">Q. M.</namePart>
</name>
<name type="personal"><namePart type="family">JI</namePart>
<namePart type="given">R. Y</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>40</number>
</detail>
<extent unit="pages"><start>3085</start>
<end>3090</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00022" displayLabel="bibjm0102710b00022"><titleInfo><title>Comparative molecular field analysis. 1. Effect of shape on binding of steroids to carrier proteins</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Comparative molecular field analysis. 1. Effect of shape on binding of steroids to carrier proteins</title>
</titleInfo>
<name type="personal"><namePart type="family">CRAMER</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">CRAMER</namePart>
<namePart type="given">R. D.</namePart>
</name>
<name type="personal"><namePart type="family">JONES</namePart>
<namePart type="given">D. M</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Am. Chem. Soc.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1988</date>
<detail type="volume"><caption>vol.</caption>
<number>110</number>
</detail>
<extent unit="pages"><start>5959</start>
<end>5967</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00023" displayLabel="bibjm0102710b00023"><titleInfo><title>Molecular similarity indices in a comparative analysis(CoMSIA) of drug molecules to correlate and predict their biological activity</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Molecular similarity indices in a comparative analysis(CoMSIA) of drug molecules to correlate and predict their biological activity</title>
</titleInfo>
<name type="personal"><namePart type="family">KLEBE</namePart>
<namePart type="given">G.</namePart>
</name>
<name type="personal"><namePart type="family">ABRAHAM</namePart>
<namePart type="given">U.</namePart>
</name>
<name type="personal"><namePart type="family">MIETZNER</namePart>
<namePart type="given">T</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>37</number>
</detail>
<extent unit="pages"><start>4130</start>
<end>4146</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00024" displayLabel="bibjm0102710b00024"><titleInfo><title>Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor</title>
</titleInfo>
<name type="personal"><namePart type="family">TONG</namePart>
<namePart type="given">W.</namePart>
</name>
<name type="personal"><namePart type="family">LOWIS</namePart>
<namePart type="given">D. R.</namePart>
</name>
<name type="personal"><namePart type="family">PERKINS</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">CHEN</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">WELSH</namePart>
<namePart type="given">W. J.</namePart>
</name>
<name type="personal"><namePart type="family">GODDETTE</namePart>
<namePart type="given">D. W.</namePart>
</name>
<name type="personal"><namePart type="family">HERITAGE</namePart>
<namePart type="given">T. W.</namePart>
</name>
<name type="personal"><namePart type="family">SHEEHAN</namePart>
<namePart type="given">D. M</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Chem. Inf. Comput. Sci.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>38</number>
</detail>
<extent unit="pages"><start>669</start>
<end>677</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00025" displayLabel="bibjm0102710b00025"><titleInfo><title>Sybyl</title>
</titleInfo>
<note type="content-in-line">Sybyl, version 6.5; Tripos Associates: St. Louis, MO, 1998.</note>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00026" displayLabel="bibjm0102710b00026"><name type="personal"><namePart type="family">FRISCH</namePart>
<namePart type="given">M. J.</namePart>
</name>
<name type="personal"><namePart type="family">TRUCKS</namePart>
<namePart type="given">G. W.</namePart>
</name>
<name type="personal"><namePart type="family">SCHLEGEL</namePart>
<namePart type="given">H. B.</namePart>
</name>
<name type="personal"><namePart type="family">SCUSERIA</namePart>
<namePart type="given">G. E.</namePart>
</name>
<name type="personal"><namePart type="family">ROBB</namePart>
<namePart type="given">M. A.</namePart>
</name>
<name type="personal"><namePart type="family">CHEESEMAN</namePart>
<namePart type="given">J. R.</namePart>
</name>
<name type="personal"><namePart type="family">ZAKRZEWSKI</namePart>
<namePart type="given">V. G.</namePart>
</name>
<name type="personal"><namePart type="family">MONTGOMERY</namePart>
<namePart type="given">J. A.</namePart>
</name>
<name type="personal"><namePart type="family">STRATMANN</namePart>
<namePart type="given">R. E.</namePart>
</name>
<name type="personal"><namePart type="family">BURANT</namePart>
<namePart type="given">J. C.</namePart>
</name>
<name type="personal"><namePart type="family">DAPPRICH</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">MILLAM</namePart>
<namePart type="given">J. M.</namePart>
</name>
<name type="personal"><namePart type="family">DANIELS</namePart>
<namePart type="given">A. D.</namePart>
</name>
<name type="personal"><namePart type="family">KUDIN</namePart>
<namePart type="given">K. N.</namePart>
</name>
<name type="personal"><namePart type="family">STRAIN</namePart>
<namePart type="given">M. C.</namePart>
</name>
<name type="personal"><namePart type="family">FARKAS</namePart>
<namePart type="given">O.</namePart>
</name>
<name type="personal"><namePart type="family">TOMASI</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">BARONE</namePart>
<namePart type="given">V.</namePart>
</name>
<name type="personal"><namePart type="family">COSSI</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">CAMMI</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">MENNUCCI</namePart>
<namePart type="given">B.</namePart>
</name>
<name type="personal"><namePart type="family">POMELLI</namePart>
<namePart type="given">C.</namePart>
</name>
<name type="personal"><namePart type="family">ADAMO</namePart>
<namePart type="given">C.</namePart>
</name>
<name type="personal"><namePart type="family">CLIFFORD</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">OCHTERSKI</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">PETERSSON</namePart>
<namePart type="given">G. A.</namePart>
</name>
<name type="personal"><namePart type="family">AYALA</namePart>
<namePart type="given">P. Y.</namePart>
</name>
<name type="personal"><namePart type="family">CUI</namePart>
<namePart type="given">Q.</namePart>
</name>
<name type="personal"><namePart type="family">MOROKUMA</namePart>
<namePart type="given">K.</namePart>
</name>
<name type="personal"><namePart type="family">MALICK</namePart>
<namePart type="given">D. K.</namePart>
</name>
<name type="personal"><namePart type="family">RABUCK</namePart>
<namePart type="given">A. D.</namePart>
</name>
<name type="personal"><namePart type="family">RAGHAVACHARI</namePart>
<namePart type="given">K.</namePart>
</name>
<name type="personal"><namePart type="family">FORESMAN</namePart>
<namePart type="given">J. B.</namePart>
</name>
<name type="personal"><namePart type="family">CIOSLOWSKI</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">ORTIZ</namePart>
<namePart type="given">J. V.</namePart>
</name>
<name type="personal"><namePart type="family">STEFANOV</namePart>
<namePart type="given">B. B.</namePart>
</name>
<name type="personal"><namePart type="family">LIU</namePart>
<namePart type="given">G.</namePart>
</name>
<name type="personal"><namePart type="family">LIASHENKO</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">PISKORZ</namePart>
<namePart type="given">P.</namePart>
</name>
<name type="personal"><namePart type="family">KOMAROMI</namePart>
<namePart type="given">I.</namePart>
</name>
<name type="personal"><namePart type="family">GOMPERTS</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">MARTIN</namePart>
<namePart type="given">R. L.</namePart>
</name>
<name type="personal"><namePart type="family">FOX</namePart>
<namePart type="given">D. J.</namePart>
</name>
<name type="personal"><namePart type="family">KEITH</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">AL-LAHAM</namePart>
<namePart type="given">M. A.</namePart>
</name>
<name type="personal"><namePart type="family">PENG</namePart>
<namePart type="given">C. Y.</namePart>
</name>
<name type="personal"><namePart type="family">NANAYAKKARA</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">GONZALEZ</namePart>
<namePart type="given">C.</namePart>
</name>
<name type="personal"><namePart type="family">CHALLACOMBE</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">GILL</namePart>
<namePart type="given">P. M. W.</namePart>
</name>
<name type="personal"><namePart type="family">JOHNSON</namePart>
<namePart type="given">B. G.</namePart>
</name>
<name type="personal"><namePart type="family">CHEN</namePart>
<namePart type="given">W.</namePart>
</name>
<name type="personal"><namePart type="family">WONG</namePart>
<namePart type="given">M. W.</namePart>
</name>
<name type="personal"><namePart type="family">ANDRES</namePart>
<namePart type="given">J. L.</namePart>
</name>
<name type="personal"><namePart type="family">HEAD-GORDON</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">REPLOGLE</namePart>
<namePart type="given">E. S.</namePart>
</name>
<name type="personal"><namePart type="family">POPLE</namePart>
<namePart type="given">J.</namePart>
</name>
<titleInfo><title> Gaussian 98</title>
</titleInfo>
<note type="content-in-line">FrischM. J.; TrucksG. W.; SchlegelH. B.; ScuseriaG. E.; RobbM. A.; CheesemanJ. R.; ZakrzewskiV. G.; MontgomeryJ. A.Jr.; StratmannR. E.; BurantJ. C.; DapprichS.; MillamJ. M.; DanielsA. D.; KudinK. N.; StrainM. C.; FarkasO.; TomasiJ.; BaroneV.; CossiM.; CammiR.; MennucciB.; PomelliC.; AdamoC.; CliffordS.; OchterskiJ.; PeterssonG. A.; AyalaP. Y.; CuiQ.; MorokumaK.; MalickD. K.; RabuckA. D.; RaghavachariK.; ForesmanJ. B.; CioslowskiJ.; OrtizJ. V.; StefanovB. B.; LiuG.; LiashenkoA.; PiskorzP.; KomaromiI.; GompertsR.; MartinR. L.; FoxD. J.; KeithT.; Al-LahamM. A.; PengC. Y.; NanayakkaraA.; GonzalezC.; ChallacombeM.; GillP. M. W.; JohnsonB. G.; ChenW.; WongM. W.; AndresJ. L.; Head-GordonM.; ReplogleE. S.; PopleJ. A. Gaussian 98; Gaussian, Inc.: Pittsburgh, PA, 1998.</note>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00027" displayLabel="bibjm0102710b00027"><name type="personal"><namePart type="family">PURCEL</namePart>
<namePart type="given">W. P.</namePart>
</name>
<name type="personal"><namePart type="family">SINGER</namePart>
<namePart type="given">J. A.</namePart>
</name>
<titleInfo><title>J. Chem. Eng. Data</title>
</titleInfo>
<genre type="journal">journal</genre>
<note type="content-in-line">Purcel W. P. Singer J. A. J. Chem. Eng. Data 1967 12 235 246 . Details of the implementation are given in Sybyl 6.5 Theory Manual; Tripos: St. Louis, MO, 1998; p 69. 10.1021/je60033a020</note>
<identifier type="doi">10.1021/je60033a020</identifier>
<part><date>1967</date>
<detail type="volume"><caption>vol.</caption>
<number>12</number>
</detail>
<extent unit="pages"><start>235</start>
<end>246</end>
</extent>
</part>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00028" displayLabel="bibjm0102710b00028"><titleInfo><title>Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analogue containing allophenylnorstatine</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analogue containing allophenylnorstatine</title>
</titleInfo>
<name type="personal"><namePart type="family">BALDWIN</namePart>
<namePart type="given">E. T.</namePart>
</name>
<name type="personal"><namePart type="family">BHAT</namePart>
<namePart type="given">T. N.</namePart>
</name>
<name type="personal"><namePart type="family">GULNIK</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">LIU</namePart>
<namePart type="given">B.</namePart>
</name>
<name type="personal"><namePart type="family">TOPOL</namePart>
<namePart type="given">I. A.</namePart>
</name>
<name type="personal"><namePart type="family">KISO</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">MIMOTO</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">MITSUYA</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">ERICKSON</namePart>
<namePart type="given">J. W</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Structure</title>
</titleInfo>
<genre>journal</genre>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>3</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>581</start>
<end>590</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00029" displayLabel="bibjm0102710b00029"><titleInfo><title>InsightII</title>
</titleInfo>
<note type="content-in-line">InsightII, version 98; Molecular Simulation Inc.: California, 1998.</note>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00030" displayLabel="bibjm0102710b00030"><titleInfo><title>Automated docking using Lamarckian genetic algorithm and empirical binding free energy function</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Automated docking using Lamarckian genetic algorithm and empirical binding free energy function</title>
</titleInfo>
<name type="personal"><namePart type="family">MORRIS</namePart>
<namePart type="given">G. M.</namePart>
</name>
<name type="personal"><namePart type="family">GOODSELL</namePart>
<namePart type="given">D. S.</namePart>
</name>
<name type="personal"><namePart type="family">HALLIDAY</namePart>
<namePart type="given">R. S.</namePart>
</name>
<name type="personal"><namePart type="family">HUEY</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">HART</namePart>
<namePart type="given">W. E.</namePart>
</name>
<name type="personal"><namePart type="family">BELEW</namePart>
<namePart type="given">R. K.</namePart>
</name>
<name type="personal"><namePart type="family">OLSON</namePart>
<namePart type="given">A. J</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Comput. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>19</number>
</detail>
<extent unit="pages"><start>1639</start>
<end>1662</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00031" displayLabel="bibjm0102710b00031"><titleInfo><title>Minimization by random search techniques</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Minimization by random search techniques</title>
</titleInfo>
<name type="personal"><namePart type="family">SOLIS</namePart>
<namePart type="given">F. J.</namePart>
</name>
<name type="personal"><namePart type="family">WETS</namePart>
<namePart type="given">R. J. B</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Maths Opera. Res.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1981</date>
<detail type="volume"><caption>vol.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>19</start>
<end>30</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00032" displayLabel="bibjm0102710b00032"><name type="personal"><namePart type="family">WEINER</namePart>
<namePart type="given">S. J.</namePart>
</name>
<name type="personal"><namePart type="family">KOLLMAN</namePart>
<namePart type="given">P. A.</namePart>
</name>
<name type="personal"><namePart type="family">CASE</namePart>
<namePart type="given">D. A.</namePart>
</name>
<name type="personal"><namePart type="family">SINGH</namePart>
<namePart type="given">C.</namePart>
</name>
<name type="personal"><namePart type="family">GHIO</namePart>
<namePart type="given">G.</namePart>
</name>
<name type="personal"><namePart type="family">ALAGONA</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">PROFETA</namePart>
<namePart type="given">P.</namePart>
</name>
<name type="personal"><namePart type="family">WEINER</namePart>
<namePart type="given">P.</namePart>
</name>
<titleInfo><title>J. Am. Chem. Soc.</title>
</titleInfo>
<genre type="journal">journal</genre>
<note type="content-in-line">Weiner S. J. Kollman P. A. Case D. A. Singh C. Ghio G. Alagona S. Profeta P. Weiner P. J. Am. Chem. Soc. 1984 106 765 784 . Details of the implementation are given in Sybyl 6.5 Theory Manual; Tripos: St. Louis, MO, 1998; p 441. 10.1021/ja00315a051</note>
<identifier type="doi">10.1021/ja00315a051</identifier>
<part><date>1984</date>
<detail type="volume"><caption>vol.</caption>
<number>106</number>
</detail>
<extent unit="pages"><start>765</start>
<end>784</end>
</extent>
</part>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00033" displayLabel="bibjm0102710b00033"><titleInfo><title>Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4</title>
</titleInfo>
<name type="personal"><namePart type="family">MORRIS</namePart>
<namePart type="given">G. M.</namePart>
</name>
<name type="personal"><namePart type="family">GOODSELL</namePart>
<namePart type="given">D. S.</namePart>
</name>
<name type="personal"><namePart type="family">HUEY</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">OLSON</namePart>
<namePart type="given">A. J</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Comput.-Aided Mol. Des.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>10</number>
</detail>
<extent unit="pages"><start>293</start>
<end>304</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00034" displayLabel="bibjm0102710b00034"><titleInfo><title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</title>
</titleInfo>
<name type="personal"><namePart type="family">GHOSE</namePart>
<namePart type="given">A. K.</namePart>
</name>
<name type="personal"><namePart type="family">VISWANADHAN</namePart>
<namePart type="given">V. N.</namePart>
</name>
<name type="personal"><namePart type="family">WENDOLOSKI</namePart>
<namePart type="given">J. J</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Comb. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>55</start>
<end>68</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00035" displayLabel="bibjm0102710b00035"><titleInfo><title>Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1‘ phenyl substituents: X-ray crystal structure assisted design</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1‘ phenyl substituents: X-ray crystal structure assisted design</title>
</titleInfo>
<name type="personal"><namePart type="family">THOMPSON</namePart>
<namePart type="given">W. J.</namePart>
</name>
<name type="personal"><namePart type="family">FITZGERALD</namePart>
<namePart type="given">P. M.</namePart>
</name>
<name type="personal"><namePart type="family">HOLLOWAY</namePart>
<namePart type="given">M. K.</namePart>
</name>
<name type="personal"><namePart type="family">EMINI</namePart>
<namePart type="given">E. A.</namePart>
</name>
<name type="personal"><namePart type="family">DARKE</namePart>
<namePart type="given">P. L.</namePart>
</name>
<name type="personal"><namePart type="family">MCKEEVER</namePart>
<namePart type="given">B. M.</namePart>
</name>
<name type="personal"><namePart type="family">SCHLEIF</namePart>
<namePart type="given">W. A.</namePart>
</name>
<name type="personal"><namePart type="family">QUINTERO</namePart>
<namePart type="given">J. C.</namePart>
</name>
<name type="personal"><namePart type="family">ZUGAY</namePart>
<namePart type="given">J. A.</namePart>
</name>
<name type="personal"><namePart type="family">TUCKER</namePart>
<namePart type="given">T. J.</namePart>
</name>
<name type="personal"><namePart type="family">SCHWERING</namePart>
<namePart type="given">J. E.</namePart>
</name>
<name type="personal"><namePart type="family">HOMNICK</namePart>
<namePart type="given">C. F.</namePart>
</name>
<name type="personal"><namePart type="family">NUNBERG</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">SPRINGER</namePart>
<namePart type="given">J. P.</namePart>
</name>
<name type="personal"><namePart type="family">JUFF</namePart>
<namePart type="given">J. R</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1992</date>
<detail type="volume"><caption>vol.</caption>
<number>35</number>
</detail>
<extent unit="pages"><start>1685</start>
<end>1701</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00036" displayLabel="bibjm0102710b00036"><titleInfo><title>Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling</title>
</titleInfo>
<name type="personal"><namePart type="family">THANKI</namePart>
<namePart type="given">N.</namePart>
</name>
<name type="personal"><namePart type="family">RAO</namePart>
<namePart type="given">J. K.</namePart>
</name>
<name type="personal"><namePart type="family">FOUNDLING</namePart>
<namePart type="given">S. I.</namePart>
</name>
<name type="personal"><namePart type="family">HOWE</namePart>
<namePart type="given">W. J.</namePart>
</name>
<name type="personal"><namePart type="family">MOON</namePart>
<namePart type="given">J. B.</namePart>
</name>
<name type="personal"><namePart type="family">HUI</namePart>
<namePart type="given">J. O.</namePart>
</name>
<name type="personal"><namePart type="family">TOMASSELLI</namePart>
<namePart type="given">A. G.</namePart>
</name>
<name type="personal"><namePart type="family">HEINRIKSON</namePart>
<namePart type="given">R. L.</namePart>
</name>
<name type="personal"><namePart type="family">THAISRIVONGS</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">WLODAWER</namePart>
<namePart type="given">A</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Protein Sci.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1992</date>
<detail type="volume"><caption>vol.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>1061</start>
<end>1072</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00037" displayLabel="bibjm0102710b00037"><titleInfo><title>Molecular clusters of π-systems: theoretical studies of structures, spectra, and origin of interaction energies</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Molecular clusters of π-systems: theoretical studies of structures, spectra, and origin of interaction energies</title>
</titleInfo>
<name type="personal"><namePart type="family">KIM</namePart>
<namePart type="given">K. S.</namePart>
</name>
<name type="personal"><namePart type="family">TARAKESHWAR</namePart>
<namePart type="given">P.</namePart>
</name>
<name type="personal"><namePart type="family">LEE</namePart>
<namePart type="given">J. Y</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Chem. Rev.</title>
</titleInfo>
<genre>journal</genre>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>100</number>
</detail>
<extent unit="pages"><start>4145</start>
<end>4185</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00038" displayLabel="bibjm0102710b00038"><titleInfo><title>A Method for two-electron Gaussian integral and integral derivative evaluation using recurrence relations</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>A Method for two-electron Gaussian integral and integral derivative evaluation using recurrence relations</title>
</titleInfo>
<name type="personal"><namePart type="family">HEAD-GORDON</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">POPLE</namePart>
<namePart type="given">J. A</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Chem. Phys.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1988</date>
<detail type="volume"><caption>vol.</caption>
<number>89</number>
</detail>
<extent unit="pages"><start>5777</start>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00039" displayLabel="bibjm0102710b00039"><titleInfo><title> POV-ray</title>
</titleInfo>
<note type="content-in-line">POV-ray-Team; POV-ray, version 3; 1999 (www.povray.org).</note>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00040" displayLabel="bibjm0102710b00040"><titleInfo><title>A program to generate schematic diagrams of protein-ligand interactions</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>A program to generate schematic diagrams of protein-ligand interactions</title>
</titleInfo>
<name type="personal"><namePart type="family">WALLACE</namePart>
<namePart type="given">A. C.</namePart>
</name>
<name type="personal"><namePart type="family">LASKOWSKI</namePart>
<namePart type="given">R. A.</namePart>
</name>
<name type="personal"><namePart type="family">THORNTON</namePart>
<namePart type="given">J. M. LIGPLOT</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Protein Eng.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>8</number>
</detail>
<extent unit="pages"><start>127</start>
<end>134</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00041" displayLabel="bibjm0102710b00041"><name type="personal"><namePart type="family">ERICKSON</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">NEIDHART</namePart>
<namePart type="given">D. J.</namePart>
</name>
<name type="personal"><namePart type="family">VANDRIE</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">KEMPF</namePart>
<namePart type="given">D. J.</namePart>
</name>
<name type="personal"><namePart type="family">WANG</namePart>
<namePart type="given">X. C.</namePart>
</name>
<name type="personal"><namePart type="family">NORBECK</namePart>
<namePart type="given">D. W.</namePart>
</name>
<name type="personal"><namePart type="family">PLATTNER</namePart>
<namePart type="given">J. J.</namePart>
</name>
<name type="personal"><namePart type="family">RITTENHOUSE</namePart>
<namePart type="given">J. W.</namePart>
</name>
<name type="personal"><namePart type="family">TURON</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">WIDEBURG</namePart>
<namePart type="given">N.</namePart>
</name>
<name type="personal"><namePart type="family">KOHLBRENNER</namePart>
<namePart type="given">W. E.</namePart>
</name>
<name type="personal"><namePart type="family">SIMMER</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">HELFRICH</namePart>
<namePart type="given">R.</namePart>
</name>
<name type="personal"><namePart type="family">PAUL</namePart>
<namePart type="given">D. A.</namePart>
</name>
<name type="personal"><namePart type="family">KNIGGE</namePart>
<namePart type="given">M.</namePart>
</name>
<titleInfo><title>C</title>
</titleInfo>
<note type="content-in-line">EricksonJ.; NeidhartD. J.; VanDrieJ.; KempfD. J.; WangX. C.; NorbeckD. W.; PlattnerJ. J.; RittenhouseJ. W.; TuronM.; WideburgN.; KohlbrennerW. E.; SimmerR.; HelfrichR.; PaulD. A.; KniggeM. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 527−533.10.1126/science.2200122</note>
<identifier type="doi">10.1126/science.2200122</identifier>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00042" displayLabel="bibjm0102710b00042"><titleInfo><title>Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors</title>
</titleInfo>
<name type="personal"><namePart type="family">ROSIN</namePart>
<namePart type="given">C. D.</namePart>
</name>
<name type="personal"><namePart type="family">BELEW</namePart>
<namePart type="given">R. K.</namePart>
</name>
<name type="personal"><namePart type="family">WALKER</namePart>
<namePart type="given">W. L.</namePart>
</name>
<name type="personal"><namePart type="family">MORRIS</namePart>
<namePart type="given">G. M.</namePart>
</name>
<name type="personal"><namePart type="family">OLSON</namePart>
<namePart type="given">A. J.</namePart>
</name>
<name type="personal"><namePart type="family">GOODSELL</namePart>
<namePart type="given">D. S</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Mol. Biol.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>287</number>
</detail>
<extent unit="pages"><start>77</start>
<end>92</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00043" displayLabel="bibjm0102710b00043"><titleInfo><title>Flexibility and function in HIV-1 protease</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Flexibility and function in HIV-1 protease</title>
</titleInfo>
<name type="personal"><namePart type="family">NICHOLSON</namePart>
<namePart type="given">L. K.</namePart>
</name>
<name type="personal"><namePart type="family">YAMAZAKI</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">TORCHIA</namePart>
<namePart type="given">D. A.</namePart>
</name>
<name type="personal"><namePart type="family">GRZESIEK</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">BAX</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">STAHL</namePart>
<namePart type="given">S. J.</namePart>
</name>
<name type="personal"><namePart type="family">KAUFMAN</namePart>
<namePart type="given">J. D.</namePart>
</name>
<name type="personal"><namePart type="family">WINGFIELD</namePart>
<namePart type="given">P. T.</namePart>
</name>
<name type="personal"><namePart type="family">LAM</namePart>
<namePart type="given">P. Y.</namePart>
</name>
<name type="personal"><namePart type="family">JADHAV</namePart>
<namePart type="given">P. K</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Nat. Struct. Biol.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>274</start>
<end>280</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00044" displayLabel="bibjm0102710b00044"><titleInfo><title>Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease</title>
</titleInfo>
<name type="personal"><namePart type="family">ROSIN</namePart>
<namePart type="given">C. D.</namePart>
</name>
<name type="personal"><namePart type="family">BELEW</namePart>
<namePart type="given">R. K.</namePart>
</name>
<name type="personal"><namePart type="family">MORRIS</namePart>
<namePart type="given">G. M.</namePart>
</name>
<name type="personal"><namePart type="family">OLSON</namePart>
<namePart type="given">A. J.</namePart>
</name>
<name type="personal"><namePart type="family">GOODSELL</namePart>
<namePart type="given">D. S</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U.S.A.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>96</number>
</detail>
<extent unit="pages"><start>1369</start>
<end>1374</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00045" displayLabel="bibjm0102710b00045"><titleInfo><title>Multivariate data analysis and experimental design in biomedical research</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Multivariate data analysis and experimental design in biomedical research</title>
</titleInfo>
<name type="personal"><namePart type="family">STAHLE</namePart>
<namePart type="given">L.</namePart>
</name>
<name type="personal"><namePart type="family">WOLD</namePart>
<namePart type="given">S</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Prog. Med. Chem.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1988</date>
<detail type="volume"><caption>vol.</caption>
<number>25</number>
</detail>
<extent unit="pages"><start>291</start>
<end>338</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00046" displayLabel="bibjm0102710b00046"><name type="personal"><namePart type="family">MIMOTO</namePart>
<namePart type="given">T.</namePart>
</name>
<name type="personal"><namePart type="family">IMAI</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">KISANUKI</namePart>
<namePart type="given">S.</namePart>
</name>
<name type="personal"><namePart type="family">ENOMOTO</namePart>
<namePart type="given">H.</namePart>
</name>
<name type="personal"><namePart type="family">HATTORI</namePart>
<namePart type="given">N.</namePart>
</name>
<name type="personal"><namePart type="family">AKAJI</namePart>
<namePart type="given">K.</namePart>
</name>
<name type="personal"><namePart type="family">KISO</namePart>
<namePart type="given">Y.</namePart>
</name>
<titleInfo><title> Chem. Pharm. Bull.</title>
</titleInfo>
<note type="content-in-line">MimotoT.; ImaiJ.; KisanukiS.; EnomotoH.; HattoriN.; AkajiK.; KisoY. Kynostatin (kni)-227 and −272, highly potent anti-HIV agents: conformationally constrained inhiboitors of HIV protease containing allophenorstatine. Chem. Pharm. Bull. 1992, 40 (8), 2251−2253.</note>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00047" displayLabel="bibjm0102710b00047"><titleInfo><title>Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease</title>
</titleInfo>
<name type="personal"><namePart type="family">RICK</namePart>
<namePart type="given">S. W.</namePart>
</name>
<name type="personal"><namePart type="family">TOPOL</namePart>
<namePart type="given">I. A.</namePart>
</name>
<name type="personal"><namePart type="family">ERICKSON</namePart>
<namePart type="given">J. W.</namePart>
</name>
<name type="personal"><namePart type="family">BURT</namePart>
<namePart type="given">S. K</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Protein Sci.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>7</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>8</number>
</detail>
<extent unit="pages"><start>1750</start>
<end>1756</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00048" displayLabel="bibjm0102710b00048"><titleInfo><title>Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease</title>
</titleInfo>
<name type="personal"><namePart type="family">TRYLSKA</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">ANTOSIEWICZ</namePart>
<namePart type="given">J.</namePart>
</name>
<name type="personal"><namePart type="family">GELLER</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">HODGE</namePart>
<namePart type="given">C. N.</namePart>
</name>
<name type="personal"><namePart type="family">KLABE</namePart>
<namePart type="given">R. M.</namePart>
</name>
<name type="personal"><namePart type="family">HEAD</namePart>
<namePart type="given">M. S.</namePart>
</name>
<name type="personal"><namePart type="family">GILSON</namePart>
<namePart type="given">M. K</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Protein Sci.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>8</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>180</start>
<end>195</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00049" displayLabel="bibjm0102710b00049"><titleInfo><title>Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor</title>
</titleInfo>
<name type="personal"><namePart type="family">VELAZQUEZ-CAMPOY</namePart>
<namePart type="given">A.</namePart>
</name>
<name type="personal"><namePart type="family">LUQUE</namePart>
<namePart type="given">I.</namePart>
</name>
<name type="personal"><namePart type="family">TODD</namePart>
<namePart type="given">M. J.</namePart>
</name>
<name type="personal"><namePart type="family">MILUTINOVICH</namePart>
<namePart type="given">M.</namePart>
</name>
<name type="personal"><namePart type="family">KISO</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">FREIRE</namePart>
<namePart type="given">E</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Protein Sci.</title>
</titleInfo>
<genre>journal</genre>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>9</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>9</number>
</detail>
<extent unit="pages"><start>1801</start>
<end>1809</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00050" displayLabel="bibjm0102710b00050"><titleInfo><title>Free energy calculations: applications to chemical and biochemical phenomena</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Free energy calculations: applications to chemical and biochemical phenomena</title>
</titleInfo>
<name type="personal"><namePart type="family">KOLLMAN</namePart>
<namePart type="given">P</namePart>
</name>
<relatedItem type="host"><titleInfo><title>Chem. Rev.</title>
</titleInfo>
<genre>journal</genre>
<part><date>1993</date>
<detail type="volume"><caption>vol.</caption>
<number>93</number>
</detail>
<extent unit="pages"><start>3</start>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" ID="jm0102710b00051" displayLabel="bibjm0102710b00051"><titleInfo><title>Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations</title>
</titleInfo>
<titleInfo contentType="CDATA"><title>Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations</title>
</titleInfo>
<name type="personal"><namePart type="family">WANG</namePart>
<namePart type="given">L.</namePart>
</name>
<name type="personal"><namePart type="family">DUAN</namePart>
<namePart type="given">Y.</namePart>
</name>
<name type="personal"><namePart type="family">STOUTEN</namePart>
<namePart type="given">P.</namePart>
</name>
<name type="personal"><namePart type="family">DE LUCCA</namePart>
<namePart type="given">G. V.</namePart>
</name>
<name type="personal"><namePart type="family">KLABE</namePart>
<namePart type="given">R. M.</namePart>
</name>
<name type="personal"><namePart type="family">KOLLMAN</namePart>
<namePart type="given">P</namePart>
</name>
<relatedItem type="host"><titleInfo><title>J. Comput.-Aided Mol. Des.</title>
</titleInfo>
<genre>journal</genre>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>15</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>145</start>
<end>156</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<identifier type="istex">7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041B</identifier>
<identifier type="ark">ark:/67375/TPS-51T68V2C-W</identifier>
<identifier type="DOI">10.1021/jm0102710</identifier>
<accessCondition type="use and reproduction" contentType="restricted">Copyright © 2002 American Chemical Society</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-X5HBJWF8-J">acs</recordContentSource>
<recordOrigin>Converted from (version 1.2.10) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2020-04-10</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/record.json</uri>
</json:item>
</metadata>
<annexes><json:item><extension>gif</extension>
<original>true</original>
<mimetype>image/gif</mimetype>
<uri>https://api.istex.fr/ark:/67375/TPS-51T68V2C-W/annexes.gif</uri>
</json:item>
<json:item><extension>tiff</extension>
<original>true</original>
<mimetype>image/tiff</mimetype>
<uri>https://api.istex.fr/document/7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041B/annexes/tiff</uri>
</json:item>
</annexes>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:7F4E8EA1FBC49F3DB24BCDE0254B6708FFA6041B |texte= Elucidating the Inhibiting Mode of AHPBA Derivatives against HIV-1 Protease and Building Predictive 3D-QSAR Models }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |